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ABSTRACT 
 
Hyper-coagulability (elevated thrombin) is a feature of T2D. There is an emerging 
evidence of a correlation between the genetic basis of hypercoagulation and T2D. 
We hypothesized that thrombin affects insulin activity and/or exercise responses in 
human skeletal muscle cells which could link the hypercoagulability and insulin 
resistance in T2D. Furthermore, we hypothesized that the metabolic benefits of 
exercise are decreased in cultured muscle cells from T2D patients. 
Cultured human myotubes were used aiming to explore the effects of thrombin on 
insulin signalling and glucose uptake as well as the effect of thrombin on metabolic 
function in the presence and absence of EPS as an in vitro model of exercise. 
Furthermore, to explore the effects of EPS on metabolic function in muscle cell 
cultures derived from T2D and non-diabetic control subjects.  
The findings of the first three chapters of this thesis demonstrated that thrombin 
was shown to have multiple metabolic effects represented by a decrease in insulin 
stimulated IRS1 and Akt activation which was mediated through PKCα, but 
thrombin had no effect on the parallel insulin-stimulated aPKC and AS160 
pathway. Thrombin directly increased glucose uptake through an AMPK mediated 
mechanism. Furthermore, the increase in AMPK activity, elevation of glucose 
uptake and the rise in cytokine release in response to EPS (above basal values) 
that were noted with non-thrombin treated myotubes was lost upon thrombin 
treatment. The key findings of the last chapter there were, AMPK activation and 
glucose uptake increased in response to EPS in control myotubes, and EPS 
enhanced the effect of insulin on glucose uptake and distal insulin signalling 
pathway (AS160). In diabetic myotubes, EPS did not increase AMPK activation 
and glucose uptake, nor enhanced the action of insulin. 
Thus, hypercoagulation associated with diabetes could be involved in multiple 
metabolic effects in skeletal muscle including insulin signalling, exercise signalling, 
proinflammatory pathways, and glucose uptake. There is an intrinsic defect in 
diabetic myotubes represented by defective AMPK, glucose uptake and distal 
insulin signalling in response to EPS that are consistent with the changes 
observed in vivo. 
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CHAPTER 1 : GENERAL INTRODUCTION 
 Diabetes mellitus 1.1
Diabetes is defined as a chronic disease that is associated with abnormally high 
blood glucose levels. It represents a major health problem and a great challenge 
to healthcare provision worldwide. According to the World Health Organization 
(WHO), a diabetic person is characterised by abnormally chronically elevated 
blood sugar with disorders in carbohydrate, lipid and protein metabolism 
(American Diabetes Association, 2015). The chronic increase in blood glucose 
level is associated with a decrease in both life expectancy and quality. 
The condition acquires great attention due to the rapid rise in prevalence 
supported by an increase in obesity and an inactive lifestyle. In an exceptional way 
for a non-infectious disease, in 2007 the Centres for Disease Control and 
Prevention in USA categorised the increase in diabetes incidence as an 
“epidemic” (Home et al., 2008). According to the International Diabetes Federation 
(IDF), disease prevalence is expected to reach 642 million persons in 2040 
compared to 415 million people who have diabetes worldwide in 2015 (Yensen 
and Naylor, 2016).  
This rapidly growing problem of diabetes is causing an economic burden on 
healthcare providing services across the world.  Most countries spend 5-20% of 
their total annual fund allocated for healthcare on diabetes related services (IDF 
Diabetes atlas, 2015). Therefore, every effort should be made in the prevention of 
the disease and improvement of its management.  
Diabetes mellitus as a disease can be diagnosed by polyuria, polydipsia, and 
unexplained weight loss plus one of the following diagnostic criteria adopted by the 
WHO and American Diabetes Association (ADA) as the following; FPG ≥ 7.0 
mmol/l (126 mg/dl) and/or 2-hours post glucose load ≥ 11.1 mmol/l (200 mg/dl) or 
a random venous plasma glucose concentration ≥ 11.1 mmol/l or HbA1c ≥ 6.5 %. 
If the person was asymptomatic, the diagnosis would be confirmed by repeating at 
least one of the above tests. Moreover, the patient is diagnosed as having 
impaired fasting glucose (IFG) if the FPG 6.1–6.9 mmol/l (110 to 125 mg/dl) 
(WHO) or FPG 5.6–6.9 mmol/l (100–125 mg/dl) (ADA). Furthermore, the patient is 
regarded as having impaired glucose tolerance (IGT) if FPG < 7.0 mmol/l (126 
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mg/dl) and 2-hours post glucose load ≥ 7.8 and < 11.1 mmol/l (140 and 200 mg/dl) 
(WHO) or only if the 2-hours post glucose load ≥ 7.8 and < 11.1 mmol/l (140 and 
200 mg/dl) (ADA) (American Diabetes Association, 2015). 
People with IFG and IGT are referred to as having “prediabetes”. This is 
considered an intermediate state between the normal population and clinical 
diabetes and they at relatively high risk of developing future diabetes than normal 
(Gavin Iii et al., 1997; Genuth et al., 2003). Individuals with prediabetes can delay 
the onset or even prevent development of diabetes by interventions that includes 
changing lifestyle (decrease body weight and increase physical activity) and use of 
drugs like metformin or both (Buchanan et al., 2002; Diabetes Prevention Program 
Research, 2002; Parker et al., 2014). 
 
 Classification of diabetes mellitus 1.2
Diabetes mellitus can be classified into either two main types of diabetes or less 
common types. The two main types of diabetes are: 
1.2.1 Type 1 diabetes (T1D) 
Previously known as insulin dependent diabetes, juvenile onset diabetes or 
autoimmune diabetes the exact causes of type 1 diabetes are not fully elucidated, 
but pancreatic beta cell destruction is a final outcome that usually leads to 
absolute deficiency of insulin. Affected people are usually children and young 
adults but any age could be influenced. Due to total insulin deficiency, patients 
with T1D are managed with insulin injection for diabetes control and survival 
(American Diabetes Association, 2016).  
1.2.2 Type 2 diabetes (T2D) 
T2D was previously known as non–insulin-dependent diabetes or adult-onset 
diabetes. Insulin is produced by the pancreatic β-cells but the body becomes 
resistant to insulin and subsequently the insulin produced may become 
insufficient. Insulin resistance is the main prominent feature that leads to a 
decreased response to the secreted insulin in the target tissues, liver and skeletal 
muscle leading to elevated glucose levels. T2D is the most common type of the 
disease and accounts for 90–95% of all diabetes (American Diabetes Association, 
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2016). The affected individuals are usually adults but there are now increasing 
numbers of children and adolescents being diagnosed with T2D. The clinical 
course of T2D is usually gradual and cases undiagnosed for many years are not 
uncommon, as the symptoms are usually not severe enough to be noticed, 
therefore many patients present with complications due to damage to the cells by 
high glucose (IDF Diabetes atlas, 2015).  
Gestational diabetes 
Gestational diabetes is a clinical condition of elevated blood glucose levels above 
the normal values that is firstly recognised during pregnancy. It is established as a 
consequence of hormonal and inflammatory changes of pregnancy that lead to 
insulin resistance (Yensen and Naylor, 2016),  
The normal consequences of gestational diabetes are as follow: 60% of cases of 
gestational diabetes return to normal non-diabetic state after termination of 
pregnancy, 36% develop T2D and only 4% convert to T1D. Therefore, gestational 
diabetes is regarded as an added risk factor for developing diabetes in the future 
(Yensen and Naylor, 2016). 
The less common types of diabetes include: 
 Monogenic diabetes: Examples are; Maturity-Onset Diabetes of the 
Young (MODY) and Neonatal Diabetes Mellitus which occur as a result 
of mutation to genes and accounts for 4% to 13% of diabetes in children 
(Kropff et al., 2011; Fendler et al., 2012). 
 Secondary diabetes: which occur as a complication of treatment of other 
diseases or hormonal imbalances like Cushing’s syndrome or 
acromegaly, or secondary to pancreatic disease (American Diabetes 
Association, 2014). 
 
 Aetiology of T2D 1.3
Insulin resistance and diminished insulin secretion are the main final features of 
patients with T2D. No single cause leads to these metabolic disorders, a complex 
interaction between genetic and environment factors are implicated in the 
development of the disease. 
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1.3.1 Genetics of T2D 
The genetic component in T2D is now well established. Many observations point 
towards the importance of heritability factors as a cause of development of the 
disease. Firstly, T2D is more prevalent in certain ethnic groups. For example, 
people of South Asian origin and African and Africa-Caribbean origin are more 
likely to develop T2D (Oldroyd et al., 2005). The rate of T2D is very low in 
Caucasians in Europe compared to the higher rate, approaching 50%, among 
Pima Indians in the USA (Diamond, 2003). Furthermore, studies show that the 
concordance rate of T2D in monozygotic twins is about 70 % in contrast to that in 
dizygotic twins which is 20-30 % (Medici et al., 1999; Poulsen et al., 1999). In 
addition, the risk of an individual to develop T2D approaches 70 % if both parents 
have diabetes while it is just 40 % if only one of them has the disease compared to 
a population prevalence of 7% (Meigs et al., 2000). 
The advances in genetic studies draw the attention to the new gene candidates 
associated with T2D. Prior to 2007, before the advances of genome-wide 
association studies (GWAS) only few candidate genes had been recognized to be 
linked with T2D based on functional, linkage and candidate gene approaches. The 
most obvious candidate genes discovered in this era include IRS1, PPARG, 
CAPN10 and TCF7L2 (Bonnefond et al., 2010).  
In 2007, multiple results of GWAS started to emerge. One of the earliest studies 
reported in 2007 confirmed the previous genetic associations and revealed two 
new alleles linked to early onset T2D (HHEX and SLC30A8) (Sladek et al., 2007). 
Genome-wide association studies (GWAS) have documented more than 80 loci 
linked to an increase in risk of T2D development (Mohlke and Boehnke, 2015). 
The genes associated with T2D are mostly related to insulin secretion and β-cell 
function rather than genes related to insulin resistance. This could be attributed to 
the insulin resistance phenotype being mostly related to lifestyle factors such as 
overeating and inactivity, and the genetic background is therefore mostly mixed 
with obesity related variants. The following tables list many of the loci and genes 
associated with impaired β-cell function (Table  1-1) and insulin resistance 
(Table  1-2) reported by different gene approaches (linkage analysis, candidate 
gene studies and GWAS). 
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Table ‎1-1:‎β‐cell function related susceptibility genesas identified by candidate 
gene association studies, linkage analysis and GWAS (Bonnefond et al., 2010; 
Qi and Hu, 2012). 
SNP 
gene Chromosome Official Full Name 
rs5219 KCNJ11 11 
potassium voltage-gated channel 
subfamily J member11 
rs7903146 TCF7L2 10 Transcription factor 7‐like 2 
rs10010131 WFS1 4 
wolframin ER transmembrane 
glycoprotein 
rs4402960 IGF2BP2 3 
Insulin‐like growth factor 2 mRNA binding 
protein 2 
rs10946398 CDKAL1 6 
CDK5 regulatory subunit associated 
protein 1‐like 1 
rs13266634 SLC30A8 8 
Solute carrier family 30 (zinc transporter), 
member 8 
rs10811661 CDKN2A/B 9 
Cyclin‐dependent kinase inhibitor 2A/2B 
 
rs1111875 HHEX/IDE 10 
hematopoietically expressed homeobox / 
Insulin‐degrading enzyme 
rs7578597 THADA 2 Thyroid adenoma associated 
rs864745 JAZF1 7 
Juxtaposed with another zinc finger 
protein 1 
rs1277979032 
CDC123‐ 
CAMK1D 
10 
 
Cell division cycle 123 homolog 
(Saccharomyces cerevisiae)‐ Calcium/ 
calmodulin‐dependent protein kinase type 
1D 
rs7961581 
 
TSPAN8‐ 
LGR5 
12 
Tetraspanin 8‐Leucine‐rich repeat‐
containing G protein coupled receptor 5 
rs231362  K KCNQ1 11 
voltage‐gated channel, KQT‐like 
subfamily, member 1 
rs10830963 MTNR1B 11 Melatonin receptor 1B 
rs340874 PROX1 1 Prospero homeobox 1 
rs4607517 GCK 7 Glucokinase (Hexokinase 4) 
rs2191349 7 
DGKB/ 
TMEM195 
7 
Diacylglycerol kinase, β 90 kDa/ 
Transmembrane protein 195 β-cell 
function 
rs1552224 
 
CENTD2 
(ARAP1) 
11 
ArfGAP with RhoGAP domain, ankyrin 
repeat and PH domain 1 
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Table ‎1-2: Insulin resistance related susceptibility genes as identified by 
candidate gene association studies, linkage analysis and GWAS (Brown 
and Walker, 2016). 
 
SNP gene Chromosome Official Full Name 
rs13081389 
PPARG 3 
Peroxisome proliferator‐activated 
receptor‐γ 
rs972283 KLF14 7  Kruppel‐like factor 14 
rs2943641 IRS1 2 Insulin receptor substrate 1 
rs780094‎ GCKR 2 Glucokinase (hexokinase 4) regulator  
rs8050136‎ 
FTO 16 
Fat mass and obesity‐associated 
protein 
rs7903146‎ TCF7L2 10 Transcription factor 7‐like 2 
rs1208‎ NAT2 8 N-acetyltransferase 2 
rs6723108,‎
rs998451 
TMEM163 2 
transmembrane protein 163 
rs35767‎ IGF1 12 insulin like growth factor 1 
rs12970134‎ MC4R 18 melanocortin 4 receptor 
rs17046216‎ SC4MOL 4 sterol-C4-methyl oxidase-like 
rs7077836‎ TCERG1L 10 transcription elongation regulator 1 like 
rs702634‎,‎
rs4311394 
ARL15 12 
ADP ribosylation factor like GTPase 
15 
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1.3.2 Epigenetic Factors related to T2D 
The term “Epigenetic” refers to the study of heritable changes in phenotype that 
does not involve changes in the underlying DNA sequences but can alter gene 
function. Environmental factors, such as nutrition and exercise, could precipitate 
epigenetic effects through different mechanisms such as DNA methylation, histone 
modification or microRNA activation. Knowledge about the epigenetic process and 
its ability to influence the development of T2D is not abundant but epigenetic 
mechanisms have been shown to have a role in the pathogenesis of the disease 
complication. For example, prior hyperglycemia leads to various methylation and 
demethylation events in vascular epithelial cells. These events were shown to 
have effects on gene activity that represented by sustained activation of pro-
inflammatory pathways, which are likely playing a role in the progression of 
diabetic complications (Brasacchio et al., 2009). 
1.3.3  Environmental Factors increase risk of T2D 
The most important environmental factors that increase risk of T2D are nutritional 
factors. Overeating and, as a consequence, positive energy balance leads to 
obesity and fat accumulation. Insulin resistance is a direct result of obesity 
(Samuel and Shulman, 2012). In addition, certain antioxidants and vitamins have a 
protective role against T2D. Studies show that vegetable intake, or dietary 
supplements containing carotenoids, vitamin C and tocopherol have an inverse 
relationship with the development of insulin resistance and T2D (Salonen et al., 
1995; Sargeant et al., 2000; Coyne et al., 2005).  
Other environmental factors are physical factors, such as pollution and chemical 
exposure that could result in increased risk of T2D. Studies show that biological 
pollutants that are used as pesticides or herbicides can induce insulin resistance 
(Porta, 2006; Lee et al., 2011). 
  Glucose homeostasis in normal versus T2D 1.4
Glucose homeostasis in a healthy individual is maintained in a narrow range by 
the effect of hormones. On the one hand is insulin and on the other hand are 
insulin antagonising hormones such as glucagon. The main organs involved in 
glucose regulation are the intestinal tract, pancreas, liver, skeletal muscle and 
adipose tissues. Normal glucose homeostasis is maintained by at least three 
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harmonious mechanisms and include; secretion of insulin from pancreatic β-cells, 
hepatic glucose production, and stimulation of glucose uptake by the liver and 
muscle. 
After a meal, nutrients are absorbed from the gastrointestinal tract into the 
bloodstream via the hepatic portal circulation. Ingested food acts directly on the 
intestinal tract and stimulates its own endocrine cells to secrete groups of 
metabolic hormones known as Incretins. Glucagon-like peptide-1 (GLP-1) and 
gastric inhibitory polypeptide (GIP) are well known examples of incretins. They act 
with the elevated circulatory glucose on pancreatic cells inhibiting alpha cells from 
releasing glucagon and stimulate β-cells to secrete insulin (Kreymann et al., 1987; 
Nauck et al., 2004). 
The pancreatic β-cells secrete insulin in response to the increase in blood glucose 
concentrations. Insulin decreases blood glucose by increasing glucose uptake into 
skeletal muscle and adipose tissue and by lowering glucose production by the 
liver. Pancreatic β-cells produce insulin in two phases. In the first phase, insulin is 
directly secreted after a meal and this rise in insulin is thought to inhibit glucose 
production by the liver. The second phase is released within 1-2 hours (plateau) 
after a meal and is responsible for glucose uptake in insulin sensitive tissues 
(skeletal muscle and adipose tissue) (Moore et al., 1991).  
The liver is the first organ that the absorbed nutrients encounter. It plays an 
essential role in regulating glucose release into the circulation after a meal. 
Hepatic glucose production is inhibited by insulin and stimulated by glucagon. 
During fasting, liver produces glucose from glycogen stores via hepatic 
glycogenolysis until liver glycogen stores are depleted, then it is substituted by 
gluconeogenesis.  
In the early stages of T2D, hepatic insulin resistance develops which means that 
the ability of insulin to suppress hepatic glucose production is reduced (Wei et al., 
2007). As the condition progresses, the balance between insulin and glucagon is 
disturbed leading to further increases in hepatic glucose production (Bagger et al., 
2011). 
In resting muscle and adipose tissue upon insulin stimulation, insulin triggers a 
series of signalling cascades which lead to the translocation of the GLUT4 glucose 
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transporter to the cytoplasmic membrane. This process facilitates glucose uptake 
by facilitated diffusion (Holt et al., 2011). Furthermore, insulin stimulates anabolic 
pathways that include glycogenesis, lipogenesis and protein synthesis. 
Simultaneously, insulin inhibits glycogenolysis, lipolysis. Moreover, insulin 
activates enzymes of glycolysis (glucose metabolism). In T2D, insulin-stimulated 
glucose uptake into the cells is impaired, with impairment in the action of enzymes 
involved in glucose utilisation. Muscle glycogen synthesis rate is also about 50% 
lower than the rate in normal subjects (Shulman et al., 1990). Figure  1-1 shows 
the glucose homeostasis in normal and the possible abnormalities in different 
organs that could be existed in T2D.  
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Figure ‎1-1: Glucose homeostasis in normal versus T2D adapted from (Grayson et 
al., 2013).  
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 Insulin secretion in normal versus in T2D 1.5
The cellular mechanism of insulin secretion from β-cell, as presented in Figure  1-2, 
begins with an influx of glucose into the cell via the glucose transporter, GLUT2. 
Subsequently, glucose is phosphorylated by the enzyme glucokinase to glucose 6-
phosphate (G-6-P) for ATP generation and stimulates a transcription factor PDX1 
for synthesis of new insulin. The ATP generated facilitates closure of ATP-
sensitive potassium channels inhibiting the entry of potassium ions into the cell 
leading to depolarization of the resting membrane potential. As a result, the 
voltage-gated calcium channels in the membrane open and facilitate calcium ion 
entry. The increased intracellular calcium initiates insulin release through 
exocytosis of insulin-containing granules (Hall, 2015). 
 
 
 
Figure ‎1-2:‎Mechanism‎of‎insulin‎secretion‎from‎β-cells. 
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It has been under debate whether insulin resistance or β-cell failure is the primary 
defect in the development of T2D. It was accepted for a long time that β-cell 
dysfunction follows insulin resistance in the progression to T2D. Numerous studies 
suggested that β-cell dysfunction is a result of exhaustion after a long period of a 
compensatory increase in insulin secretion (DeFronzo, 1988; Olefsky and Nolan, 
1995; Reaven, 1995). However, more recently, it has been proposed that β-cell 
dysfunction is the primary defect, based on critical studies that measure β-cell 
function and insulin sensitivity (Polonsky et al., 1996; Kahn, 2001; Pratley and 
Weyer, 2001). Furthermore, studies of first degree relatives of individuals with T2D 
who have no signs of insulin resistance (normal glucose tolerance) show reduced 
insulin secretion responses (Gerich, 1998; van Haeften et al., 2000). Thus, β-cell 
dysfunction seems to be a key early defect that could lead to progression to IGT or 
even T2D if accompanied by insulin resistance. 
When T2D is diagnosed, the degree of β-cell dysfunction becomes quite obvious. 
For example, using the homeostasis model assessment (HOMA), the UK 
Prospective Diabetes Study stated that at time of diagnosis of T2D β-cell activity 
was reduced by 50% and function continues to deteriorate irrespective of therapy 
(1995). 
The secretory function of β-cells is also affected by aging. A decline in β-cell 
secretory function of 0.7 – 1% per year has been observed for both basal and 
glucose stimulated secretion in normal glucose tolerant adult individuals (Szoke et 
al., 2008). In individuals with IGT, the secretory function decline rate is about 
double that of NGT individuals (Szoke et al., 2008), and it is about 6% per year in 
T2D patients (Kahn et al., 2006). 
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 Whole body insulin resistance 1.6
Insulin resistance is described as the inability of target tissues to respond to a 
normal physiological level of insulin. Insulin resistance has detrimental effects on 
glucose homeostasis that can lead to the onset of metabolic abnormalities such as 
T2D. Regarding glucose haemostasis, two essential metabolic defects are 
recognised in insulin resistance. The first is an impairment of the suppression of 
hepatic glucose production in response to insulin and the second is the reduced 
peripheral uptake of glucose.  
There is a substantial body of evidence indicating that insulin resistance is a 
fundamental feature of T2D. Many cross sectional studies have shown that almost 
all patients with T2D are insulin resistant, and many follow up studies have 
suggested that insulin resistance precedes the onset of clinical diabetes by many 
years as reviewed in detail by (Lillioja et al., 1988; DeFronzo et al., 1992).  
Most individuals with insulin resistance are frequently hypertensive with abdominal 
obesity. The cluster of these abnormalities in an individual leads to increased risk 
of developing T2D and cardiovascular complications and is known as metabolic 
syndrome. The table in APPENDIX 1 shows the Definition criteria of diagnosis of 
metabolic syndrome as adopted by different associations. Individuals with 
metabolic syndrome have about a fivefold greater risk of developing T2D. 
Moreover, these individuals have double risk of death from cardiovascular disease 
compared to non-metabolic syndrome people (Alberti et al., 2006). 
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 Skeletal muscle 1.7
1.7.1 Skeletal muscle structure 
Skeletal muscle is composed of numerous muscle fibres that in turn consist of 
multinucleated cells known as myotubes. The myotubes are developed by division 
and fusion of myoblasts. Skeletal muscle cells are covered by three layers. 
Sarcolemma is the term used to describe the plasma membrane of muscle fibres 
and represent the first layer. A number of fibres are organised into bundles 
(fasciculi) that are covered by connective tissue known as the perimysium. Lastly, 
there is a heavier connective tissue layer termed the fascia that sheaths the whole 
muscle (Standring, 2015).  
1.7.2 Skeletal muscle metabolism 
Both glucose and free fatty acids are used as energy sources by skeletal muscle. 
During fasting, muscle glucose uptake is low and the plasma FFA concentrations 
are raised. FFAs act as the principal source for energy production in skeletal 
muscle during fasting. After meals, the plasma glucose concentration is elevated 
leading to stimulation of insulin secretion from the β-cells in the pancreas. The 
resultant increased insulin level will facilitate inhibition of adipose tissue lipolysis 
leading to a decrease in the FFA plasma concentration and consequently, a 
decrease in the rate of lipid utilisation. At the same time, insulin stimulates 
increased glucose uptake into skeletal muscle and activation of key enzymes in 
glucose metabolism leading to a marked increase in muscle glucose oxidation 
(DeFronzo, 1997).  
Glucose provides a source of cellular energy and substrate storage in skeletal 
muscle. Skeletal muscle glucose metabolism occurs through either aerobic or 
anaerobic pathways to produce ATP. The anaerobic pathway of glucose produces 
only a small proportion of ATP and occurs in the cell cytoplasm, and known as 
glycolysis which means splitting of the glucose molecule to form two molecules of 
pyruvic acid. Whereas the aerobic pathway yields the maximum amount of ATP 
production per glucose molecule by entering the tricarboxylic acid cycle within the 
mitochondria (Bouché et al., 2004). 
The first step upon entry of glucose into the cells is its phosphorylation by 
hexokinase to form glucose-6-phosphate. Phosphorylation of glucose is a vital 
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step as it ensures that the glucose is trapped inside the cell and does not diffuse 
back out. In muscle cells this step is irreversible due to the absence of glucose 
phosphatase enzyme that expressed predominantly in liver cells. Therefore, 
skeletal muscle unlike liver cells, cannot produced glucose into circulation during 
fasting or in absence of insulin (van Schaftingen and Gerin, 2002). Glucose-6-
phosphate is converted into fructose 6-phosphate which is readily further 
phosphorylated into fructose 1, 6 diphosphate, a reaction catalysed by 
phosphofructokinase. The later molecule is cleaved into a three carbon compound 
glyceraldehyde-3-phosphate, and each of which is then converted over five further 
steps into pyruvic acid and only a small amount of the free energy. The pyruvic 
acid molecule has the ability to pass through mitochondrial membrane and further 
converting into a molecule of acetyl coenzyme A (acetyl-CoA) that enters citric 
acid cycle. The citric acid cycle is a sequence of chemical reactions in the 
mitochondrial matrix in which the acetyl-CoA is degraded to carbon dioxide, water 
and releasing large amounts of energy in the form of ATP (Hall, 2015).  
 Insulin signalling pathway in skeletal muscle cell 1.8
Insulin is the master regulatory hormone of glucose haemostasis in the 
mammalian body. It promotes transport and oxidation of glucose and other 
metabolites as well as regulating the synthesis of proteins, triglycerides and 
glycogen within the cells. Skeletal muscle was chosen by many studies as a target 
of insulin action because of its role as an organ that is responsible for about 80% 
of the whole body glucose disposal in response to insulin (DeFronzo et al., 1981; 
Thiebaud et al., 1982). For a better understanding of events at the molecular level 
that occur in insulin resistant states, it is crucially important to know the insulin 
signalling pathway. This helps to explore the possible defect in each step of the 
pathway to identify abnormalities that may occur in insulin resistance and T2D. 
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1.8.1 The Insulin Receptor 
The insulin receptor is a tyrosine kinase receptor meaning its activation depends 
mainly on activation of tyrosine residues. Structurally, the insulin receptor is a cell 
membrane receptor consisting of four subunits, two α and two β subunits. α 
subunits lie totally outside the cell membrane and are linked together, and with the 
β subunits, by disulfide bonds. As shown in Figure  1-3, α subunits contain the 
ligand-binding domains whereas, the β subunits have both intracellular and 
extracellular with a transmembranous domains. The β subunits contain the 
tyrosine phosphorylation kinase domain that activates intracellular signalling 
pathways inside the cell (Lee and Pilch, 1994) 
 
 
Figure ‎1-3: A graphical representation of insulin receptor structure and 
activation.  
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Binding of insulin to the binding domains of α subunits leads to a conformational 
changes in the insulin receptor resulting in an auto-phosphorylation of the tyrosine 
kinase domain of the β subunit. This tyrosine phosphorylation in turn 
phosphorylates and activates multiple intracellular enzymes, including a group 
called insulin-receptor substrates (IRS) (White et al., 1984). These proteins are 
characterised by having Src Homology 2 (SH2) domains which are the phospho-
tyrosine binding domains that have the ability to recognise the phosphorylated 
tyrosine. Examples of these proteins are; the IRS family (Sun and Liu, 2009), Shc 
proteins (Taniguchi et al., 2005), Cbl CAP proteins (Baumann et al., 2000), and 
phospholipase C gamma1 (PLCγ1) (Kwon et al., 2003).  
In addition to insulin receptor tyrosine phosphorylation, insulin receptors can be 
phosphorylated on serine and threonine residues leading to decreased insulin 
signalling. Phosphorylation on serine or threonine residues can act as a negative 
feedback signalling mechanism or even inhibitory signalling that could contribute 
to the pathogenesis of insulin resistance (Dunaif et al., 1995; Barbour et al., 2007). 
1.8.2 The IRS molecules 
These molecules are family of proteins perform important roles in insulin 
signalling. There are eight proteins belonging to this family and they display some 
degree of structural homology. Structurally, IRS proteins are made up of three 
regions; an amino terminal pleckstrin homology (PH) domain for receptor docking, 
a phosphotyrosine binding domain that recognizes the phosphotyrosine residues 
of the insulin receptor,  and a COOH - terminal domain that contains multiple 
tyrosine and serine phosphorylation sites (Virkamäki et al., 1999). Among the eight 
members, IRS1 and IRS2 are considered to be the most important proteins in 
glucose metabolism and insulin signalling, and their deficiency is associated with 
insulin resistance in humans (Zhande et al., 2002). IRS1 is the major IRS in 
skeletal muscle while IRS2 is expressed predominantly in liver and β cells and is 
required for normal β cell function (Holt et al., 2011). Following insulin stimulation, 
numerous tyrosine sites are phosphorylated but Tyrosine 612 (Y612) and Tyrosine 
632 (Y632) are the critical residues for the downstream activation of PI-3 kinase for 
GLUT4 translocation (Esposito et al., 2001). IRS can be negatively regulated by 
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serine threonine kinases through serine phosphorylation and protein 
phosphatases. In humans, variants within the gene responsible for the coding of 
IRS1 (IRS1 gene) are associated with T2D and insulin resistance (Laakso et al., 
1994; Rung et al., 2009). 
1.8.3 Phosphatidylinositol 3-Kinase (PI3K) 
PI3- kinase is an enzyme consisting of two different macromolecules (hetero-
dimer), the p110 catalytic subunit (110 kDa) that contains the activation sites and 
mediates the kinase activity, and the p85 regulatory (85 kDa) adaptor subunit 
which is responsible for binding with IRS1. PI3-kinase is involved in different 
signalling pathways, and this enzyme has an essential role in insulin signalling and 
cell metabolism (Engelman et al., 2006).  
The cascade of activation of this kinase is as shown in Figure  1-4 insulin auto 
phosphorylates the insulin receptor leading to phosphorylation and activation of 
IRS1 that directly binds to the p85 subunit of PI3K. This binding leads to 
phosphorylation and activation of the catalytic p110 subunit facilitating the 
recruitment of the complex to the cell membrane which is the site of action. 
Subsequently, activated PI3-kinase facilitates phosphorylation of membrane 
phospholipids, phosphatidylinositol 4, 5-bisphosphate (PIP2) on the 3’ position 
forming phosphatidylinositol-3, 4, 5-triphosphate (PIP3). PIP3 then activates 
phosphoinositide-dependent protein kinase (PDK1 and PDK2). Activated PDK is 
responsible for phosphorylation and activation of protein kinase B (PKB/Akt) and 
atypical protein kinase C (aPKC) (Vollenweider, 2003; Engelman et al., 2006). 
Insulin has been shown to be a potent activator of PI-3 kinase (Shepherd et al., 
1998). Activation of PI3-kinase is a crucial step in the insulin signalling pathway for 
glucose uptake in skeletal muscle as proven by the use of specific chemical 
inhibitors of PI3- kinase, Wortmannin and LY294002 (Somwar et al., 2001; Foster 
et al., 2003). 
1.8.4 Akt 
Akt is a 56 kDa serine threonine kinase, also known as protein kinase B, and 
consists of an N-terminal PH domain followed by a catalytic kinase domain and C-
terminal tail. Originally, this enzyme was associated with cancer development, by 
promoting cell proliferation and inhibition of apoptosis. However, Akt has also been 
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shown to be activated acutely by insulin and other growth factors (Hemmings, 
1997).  
Akt has 3 isoforms; Akt1, Akt2 and Akt3, also known as Akt α, Akt β, and Akt γ, 
and these isoforms are expressed in different tissues (Björnholm and Zierath, 
2005; Kim and Novak, 2007). Akt1 and Akt2 isoforms are predominantly 
expressed in insulin sensitive tissues (liver, adipose and skeletal muscle) whereas 
Akt3 has been shown to be expressed mainly in the brain (Brazil and Hemmings, 
2001). In skeletal muscle, Akt2 is predominantly involved in glucose uptake and 
insulin responsiveness (Cho et al., 2001), and studies showed that overexpression 
of the Akt2 isoform in skeletal muscle significantly enhances glucose metabolism 
(Cleasby et al., 2007). Akt is activated by insulin via a PI3K-dependent pathway, 
and this activation facilitates its translocation and binding to the cell membrane. 
This translocation to the membrane is an essential step of enzyme activation 
(Gonzalez and McGraw, 2009). At the cell membrane, Akt is further activated by 
phosphoinositide-dependent protein kinase (PDK) and mTOR complex 2 (Mora et 
al., 2004). The full activation of Akt requires phosphorylation at two activation 
sites. The first, is Thr308 at the kinase domain which is activated by the upstream 
kinase PDK and accounts for about 10 % of the kinase activity (Schultze et al., 
2011). The second and most critical activation site is the Ser473 at the carboxyl 
terminal domain. The mechanism of activation at this site is still unclear but mTOR 
complex 2 and others like PDK1, PDK2, and auto phosphorylation are implicated 
(Brazil and Hemmings, 2001; Hajduch et al., 2001b).  
Metabolically, Akt seems to regulate glucose metabolism in skeletal muscle and 
adipocytes (Hajduch et al., 2001a; Vollenweider, 2003). Activation of Akt promotes 
translocation of the glucose transporter GLUT4 in response to insulin from the 
intracellular space to the plasma membrane. Studies have confirmed the role of 
the PI3K-Akt pathway in glucose transport in skeletal muscle (Wang et al., 1999) 
and adipocytes (Kohn et al., 1996; Bai et al., 2007). Numerous studies have 
shown that Akt mediates its GLUT4 translocation activity through a downstream 
target Akt substrate 160 (AS160). Activation of this enzyme by Akt was shown to 
be through phosphorylation at multiple key residues (Ser588, Thr642, Ser318, Ser570, 
and Thr751) (Sano et al., 2003; Zeigerer et al., 2004). 
 20 
 
1.8.5 AS160 substrate 
AS160 is a 160 kDa Rab GTPase-activating protein that is a downstream enzyme 
of Akt. It is also known as TBC1 domain family member 4 (TBC1D4) as it is 
encoded in humans by the TBC1D4 gene. AS160 emerges as a key protein in 
GLUT4 translocation and is implicated in the mechanisms of both insulin-
dependent and independent glucose uptake (Cartee and Wojtaszewski, 2007; 
Sakamoto and Holman, 2008).  
Rab proteins are highly involved in GLUT4 translocation processes (trafficking and 
exocytosis) (Moyers et al., 1996). In unstimulated conditions, GLUT4 remains in 
intracellular sites by inhibition of translocation via the effects of Rab-GAP activity. 
Under basal conditions, Rab-GAP activity remains in an inactive form (GDP-
loaded) and upon stimulation AS160 is phosphorylated leading to conversion of 
Rab-GAP activity into an active form (GTP-loaded). This alteration enables the 
translocation of GLUT4 vesicles from the cytoplasm to the plasma membrane 
(Sakamoto and Holman, 2008). 
Numerous activation sites on AS160 have been identified. Thr642 and Ser588 are 
considered the major residues that are phosphorylated and activated in response 
to insulin (Sano et al., 2003). However, Treebak et al. (2009) identified further sites 
involved in insulin-stimulated AS160 phosphorylation such as Ser318, Ser570, and 
Thr751.  
1.8.6 Atypical protein kinase C (aPKC) 
PKC is a family of kinases that play essential roles in many cellular processes. 
There are several different isoforms and they are involved in events such as 
growth, differentiation, and glucose and lipid metabolism. PKC is classified into 3 
subgroups according to structure and regulation; conventional (cPKC), novel 
(nPKC) and atypical (aPKC) (Bertram and Ley, 2011; Turban and Hajduch, 2011). 
The (aPKC λ/ ζ) are independent of both diacylglycerol (DAG) and Ca2+ for 
activation. In skeletal muscle, aPKC seems to be regulated by PDK1, the 
downstream target of PI3K (Etgen et al., 1999). Studies show that, overexpression 
of aPKC leads to an increase in both basal and insulin-stimulated glucose 
transport. Furthermore, muscle-specific abolition of both isoforms of aPKC disturbs 
insulin-stimulated glucose transport and GLUT4 translocation (Farese et al., 
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2007). These data suggest that aPKC is involved in the stimulation of glucose 
transport, independent of Akt. 
1.8.7 CAP/Cbl/TC10 pathway 
The CAP/Cbl/TC10 pathway was recognised to be activated by insulin in various 
insulin sensitive tissues (Ribon et al., 1998; Baumann et al., 2000; Chiang et al., 
2001). These proteins are involved in mediating insulin signalling independent of 
the PI3K-Akt pathway. It is reported that the CAP/TC10 pathway plays a role in 
glucose transport in adipocytes (Chiang et al., 2001) but, in  skeletal muscles the 
metabolic role of these proteins is not fully clarified.  
1.8.8 MAPK pathways 
The mitogen activated protein kinase (MAPK) pathway is another insulin controlled 
well-characterized signalling cascade. This pathway is activated in response to 
insulin, growth factors and cellular stress (Widegren et al., 2001). The 
establishment of activation of the MAPK pathway occurs at the level of IRS, which 
activates a series of signals involving the Ras/ERK cascade (Weng et al., 2001). 
Thus, activation of ERK-MAPK plays a pivotal role in regulation of gene 
transcription in response to insulin such as that involved in the cell cycle (Blenis, 
1993). 
 Glucose transporter in skeletal muscles 1.9
Glucose transporters are a family of specialized membrane-embedded transporter 
proteins known as GLUTs which are members of the solute carrier 2 (SLC2) family 
(Watson and Pessin, 2006; Marín-Juez et al., 2013). Different isoforms of GLUT 
have been identified in human skeletal muscle; GLUT1 and GLUT4 are the major 
contributors for glucose transport in basal and stimulated states respectively 
(Guillet-Deniau et al., 1994; Hansen et al., 1998; Ciaraldi et al., 2005). 
1.9.1 GLUT1 
Glucose transporter isoform 1 (GLUT1) is located at the plasma membrane and is 
responsible for basal glucose uptake into cells. GLUT1 plays a role in skeletal 
muscle development and it is expressed in abundance in myoblasts and 
expression tends to decrease dramatically after muscle differentiation (Gaster et 
al., 2000; Al-Khalili et al., 2003). In human skeletal muscle fibres, GLUT4/ GLUT1 
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expression is about 400/1 (Stuart et al., 2006). A study in adipocytes shows that 
prolonged exposure to insulin causes a steady increase in expression at both the 
mRNA and protein level of GLUT1 (Sargeant and Pâquet, 1993). 
1.9.2 GLUT4  
Glucose transporter isoform 4 (GLUT4) is the major glucose transporter in adult 
insulin responsive tissue such as skeletal muscle and adipose tissue. GLUT4 is 
activated in response to distinct stimuli including insulin and exercise (Marette et 
al., 1992; Lund et al., 1995). This transporter is well expressed in differentiated 
myotubes and its presence in myoblasts is scanty (Gaster et al., 2000; Al-Khalili et 
al., 2003). Under basal unstimulated conditions, GLUT4 remains within 
intracellular GLUT storage vesicles in the intracellular space (cytoplasm) and less 
than 5% of total GLUT4 cell content is located at the cell surface (Gould and 
Holman, 1993). Upon insulin stimulation these GLUT4 containing vesicles 
translocate to the cell membrane (increased exocytosis). For example, in brown 
adipose tissue insulin stimulation leads to a 40-fold increase in cell surface GLUT4 
compared to unstimulated cells (Slot et al., 1991). Simultaneously, myotubes 
previously stimulated with insulin have a 2-3 fold increase in plasma membrane 
levels of GLUT4 compared to non-stimulated cells (Fazakerley et al., 2010).  
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 Cascades of glucose transport into skeletal muscle cells 1.10
The major contributors of glucose transport activity in skeletal muscle are insulin 
and contraction. Under basal conditions, GLUT1, and to a lesser extent GLUT4, 
on the cell surface facilitate glucose transport. Upon insulin stimulation, insulin 
initiates a series of signalling events that involve insulin receptors, insulin receptor 
substrates, PI3K, PIP3 and/or PDK, AKT, aPKC and AS160. These events lead to 
translocation of GLUT4 storage vesicles from the intracellular space to the cell 
surface facilitating glucose transport. 
During exercise, glucose uptake into skeletal muscle increases independent of the 
insulin pathway. The increased glucose uptake into skeletal muscle is achieved by 
muscle contraction and not by increased blood flow associated with exercise. This 
was confirmed by in vitro contraction studies carried out in the absence of insulin, 
showing the same GLUT4 recruitment to the cell membrane (Goodyear et al., 
1990; Brozinick et al., 1994; Gao et al., 1994). It seems that exercise mediates its 
activity at least partially through the AMPK-dependent pathway. Studies show that 
muscle contraction or exercise mimetics such as AICAR induce GLUT4 
translocation from intracellular vesicles (cytoplasmic location) to the cell surface 
(Koistinen et al., 2003; Friedrichsen et al., 2012). Figure  1-4 summarises the 
glucose uptake mechanisms into skeletal muscle.   
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Figure ‎1-4: Presumed mechanisms of insulin/AMPK signalling and glucose 
uptake into skeletal muscle cells.
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 Insulin resistance in skeletal muscle 1.11
As previously mentioned, the term insulin resistant (IR) means an impairment of 
insulin action in insulin sensitive tissues such as skeletal muscle, liver and 
adipocytes. Regarding skeletal muscle, the primary action of insulin is 
enhancement of glucose uptake and metabolism. If a comparison takes place 
between healthy lean and insulin resistant individuals, the result will be a marked 
reduction in insulin stimulated glucose uptake as well as a delay in the insulin 
response in the insulin resistant individual as shown in Figure  1-5. Many studies 
show that the abnormality in insulin resistant skeletal muscle is not only a 
decrease in the magnitude of insulin action, but also a delayed onset of insulin to 
stimulate glucose uptake (Sargeant and Pâquet, 1993; Stuart et al., 2006; Abdul-
Ghani and DeFronzo, 2010). 
 
 
Figure ‎1-5: Dose-response curve of insulin-glucose uptake in response to an 
increasing dose of insulin ∗P < 0.01 adopted from (Groop et al., 1989; Abdul-
Ghani and DeFronzo, 2010). 
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 Defects in insulin signalling in insulin resistant skeletal muscle 1.12
Generally, it is well accepted that the ability of insulin to facilitate glucose disposal 
in skeletal muscle is impaired in T2D patients (DeFronzo et al., 1985; Hepburn et 
al., 1994).  
In skeletal muscle of insulin resistant individuals, insulin receptor tyrosine kinase 
activity has been shown to be impaired but this is regarded as an acquired 
secondary defect to abnormal glucose metabolism (Pratipanawatr et al., 2001). 
Reversing this metabolic defect by weight loss can restore normal insulin receptor 
tyrosine kinase activity (Freidenberg et al., 1988).  
Reduced IRS1 activity in skeletal muscle is associated with either decreased 
tyrosine phosphorylation or increased serine phosphorylation. In both in vitro 
(muscle culture or muscle strips) or in vivo (during hyperinsulinemic clamp) 
studies, skeletal muscle from T2D subjects was shown to have a reduced insulin-
stimulated IRS1 tyrosine phosphorylation activity (Krook et al., 1998; Cusi et al., 
2000; Kim et al., 2003). In addition, animal and human studies have demonstrated 
increased serine phosphorylation of IRS1 in the skeletal muscle of insulin resistant 
subjects (Yu et al., 2002; Morino et al., 2005). 
Aberrant activity of PI3K in human skeletal muscle from T2D subjects has been 
reported (Björnholm et al., 1997; Krook et al., 2000; Bandyopadhyay et al., 2005). 
Furthermore, binding of the p85 regulatory subunit of PI3K to IRS1 is also 
diminished in obese and T2D compared to normal lean subjects (Pratipanawatr et 
al., 2001).  
Data about the defects in Akt activity in insulin resistant subjects is debatable. On 
the one hand, a number of studies reported an impaired phosphorylation of Akt at 
Ser473 or Thr308 in skeletal muscle obtained from T2D and insulin resistant 
individuals (Krook et al., 1998; Meyer et al., 2002; Karlsson et al., 2005; Hojlund et 
al., 2008). On the other hand, no such impairments have been found in skeletal 
muscle of T2D (Kim et al., 1999; Krook et al., 2000; McIntyre et al., 2004).  
PI3K/Akt signalling to GLUT4 translocation is linked via AS160. In skeletal muscle 
from T2D subjects, the insulin-stimulated phosphorylation of AS160 is significantly 
decreased (Karlsson et al., 2005). Moreover, the decreased AS160 
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phosphorylation in T2D skeletal muscle is correlated with impairment in glucose 
transport (Karlsson et al., 2006).  
There is significant impairment in GLUT4 translocation from the intracellular sites 
to the membrane in skeletal muscle from T2D compared to control (Ryder et al., 
2000; Koistinen et al., 2003). No differences in GLUT4 content have been 
observed between skeletal muscle from T2D subjects and normal controls 
(Pedersen et al., 1990; Eriksson et al., 1992). Thus, the defects in insulin 
stimulated glucose uptake in skeletal muscles from T2D have been shown to be in 
insulin signalling affecting GLUT4 translocation and not in GLUT4 expression. 
 Role of inflammation in insulin resistance development 1.13
Insulin resistance has been identified to be associated with a state of low grade 
inflammation and therefore it is suggested that inflammation plays an essential 
role in the development of insulin resistance (Glass and Olefsky, 2012). Studies 
showed that patients with sepsis and septic shock were in an insulin resistant state 
(Clowes et al., 1978; Raymond et al., 1980). In addition, insulin resistance is 
observed in patients with chronic inflammatory diseases such as active 
rheumatoid arthritis (Svenson et al., 1987). Furthermore, induction of acute 
inflammation induces systemic insulin resistance in humans (Mehta et al., 2010). 
 One of the first and most important inflammatory cytokines to be associated with 
insulin resistance is TNFα. An early observation by Hotamisligil et al. (1993) 
primarily linked the increased expression of this cytokine in adipose tissue of 
different animal models, with insulin resistance. The same study showed that 
neutralisation of high TNFα enhances insulin sensitivity. In humans, a similar 
pattern of increased expression of TNFα in adipose tissue of individuals with 
insulin resistance has been observed (Kern et al., 1995), and after weight loss 
cytokine expression returned to normal levels (Dandona et al., 1998; Moschen et 
al., 2010). At the cellular level, TNFα has been shown to deactivate insulin 
signalling by inhibiting IRS1 activation (Aguirre et al., 2000). The classical isoform 
of PKC is involved in the TNFα inhibitory action (Sampson and Cooper, 2006). 
IL-6 is another important cytokine associated with insulin metabolism. The role of 
IL-6 in peripheral insulin resistance is debatable. On the one hand,  like TNFα, 
raised serum concentrations of IL-6 is linked to obesity and T2D (Hotamisligil, 
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2006). Adipose tissue is the major source of IL-6 in the body so an increased 
secretion and expression of the cytokine in obese subjects is expected, and is 
correlated with impaired whole-body insulin sensitivity (Bastard et al., 2002). On 
the other hand, acute exposure of insulin sensitive tissues (cultured skeletal 
muscles) to IL-6 is associated with improvement in insulin action (Al-Khalili et al., 
2006; Carey et al., 2006). Furthermore, circulatory levels of IL-6 seem to be 
elevated with muscle contraction and this is associated with an improvement in 
insulin action (Steensberg et al., 2000; Febbraio et al., 2004). Moreover, 
neutralisation of IL-6 in humans has been shown to improve insulin action and 
glucose levels (Schultz et al., 2010).              
In conclusion, acute and chronic inflammation is associated with whole body 
insulin resistance. Chronic elevation of these cytokines is associated with insulin 
resistance while the acute increase in response to exercise or direct treatment has 
positive insulin sensitisation effects.  
 AMP-activated protein kinase (AMPK)  1.14
Since 1987 the name AMP-activated protein kinase has been adopted for the 
serine-threonine kinase, but it was discovered long before that as an enzyme 
regulating FFA and cholesterol synthesis (Steinberg and Beck Jorgensen, 2007). 
Recently, AMPK emerged as an enzyme regulating several metabolic processes 
associated with glucose and lipid metabolism in skeletal muscle (Hardie et al., 
2012).   
Activation of AMPK by exercise leads to increased glucose uptake into skeletal 
muscle and enhances insulin stimulated glucose uptake. These effects of AMPK 
draw attention to its ability to improve glucose metabolism and control metabolic 
abnormalities associated with T2D (Hardie, 2013). In addition to metabolism-
related functions, AMPK is associated with cell growth, gene expression, protein 
synthesis, and other important cell functions (Richter and Ruderman, 2009). The 
fully functional enzyme kinase consists of three subunits, α (catalytic), and β and γ 
regulatory units. Activation of AMPK occurs in response to an increase in the 
AMP/ATP ratio either due to decreased ATP production such as in hypoxia and 
ischemia, or increased energy consumption as observed in muscle contraction 
(Witczak et al., 2008).  
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 Structure of AMPK 1.15
Structurally, AMPK consist of three subunits and each one of these subunits is 
present in different isoforms, there are two α subunits (α1 and α2), two β subunits 
(β1 and β2) while γ has three isoforms (γ1, γ2 and γ3). The ratio of these subunits 
is 1 α: 1β: 1γ, Thus, human cells could contain 12 different isoform combinations 
of AMPK (Hardie and Sakamoto, 2006),and this isoform diversity may have an 
influence on the activation of AMPK in response to different stimuli and also 
determine the subcellular localization of the kinase (Hardie, 2007; Oakhill et al., 
2009). In human skeletal muscle the predominant isoform expression is the 
α2β2γ3 heterotrimer (Chen et al., 1999).  
1.15.1 α subunit 
In skeletal muscle, this subunit has two isoforms, α1 and α2. Both have similar 
catalytic activities. The α subunit is highly conserved consisting of an N-terminal 
catalytic domain that contains the Thr172 residue that represents the activation or 
deactivation point by phosphorylation and dephosphorylation respectively, 
followed by  an auto inhibitory domain. The C-terminus in this subunit is 
responsible for binding to the β and γ subunits (Oakhill et al., 2009). The 
phosphorylation and dephosphorylation of the Thr172 residue are achieved by its 
by upstream kinases and phosphatases, respectively (Gowans et al., 2013). The 
presence of different isoforms of α subunit suggests diverse actions and 
subcellular localization within mammalian cells. For example, the α1 subunit is 
presents in non-nuclear location of AMPK, while the α2 subunit has nucleus, 
cytoplasmic and membrane activities (Salt et al., 1998).  
1.15.2 β subunit 
The β subunit is one of the two regulatory subunits of the kinase complex, has two 
isoforms (β1and β2), and each comprises three biochemical parts. The N-terminal 
is responsible for membrane docking of AMPK (Oakhill et al., 2009). The C-
terminal is required for the binding with α and γ subunits. The β subunit contains 
the central region which is termed the glycogen binding domain (GBD) (Hardie and 
Sakamoto, 2006) or it is sometimes called the carbohydrate binding module (CBM) 
(Oakhill et al., 2009). The binding of glycogen to the β subunit of AMPK seems to 
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directly regulate the kinase activity, the more abundant the glycogen store the less 
the AMPK activation (Wojtaszewski et al., 2002). 
1.15.3 γ subunit  
The AMPK allosteric binding sites of AMP or ATP are located within the γ subunit, 
which has an N-terminal region followed by four highly conserved cystathionine-
beta-synthase (CBS) sequence motifs. Each one of the CBS acts as a potential 
site for binding with adenine nucleotides and each two of these motifs together 
form a Bateman domain. So the γ subunit contains two Bateman domains which 
represent the functional site of this subunit (Towler and Hardie, 2007; Witczak et 
al., 2008).  
Mutations in the γ2 subunit in cardiac muscle results in a type of arrhythmic 
disorder known as Hereditary Wolff-Parkinson–White syndrome (WPW) which 
might be caused by high glycogen content of the cardiac muscle due to 
inactivation of AMPK (Scott et al., 2004). The γ3 subunit is expressed exclusively 
in skeletal muscle and mutation in the Bateman domain of this isoform is also 
associated with high glycogen content within muscles cells but the clinical 
outcome of this accumulation is not fatal like that of the cardiac muscle. Instead, 
the affected muscle seems to be more tolerant to high glycogen levels and 
becomes more resistant to fatigue (Barnes et al., 2005). 
 AMPK allosteric activation 1.16
This is achieved by the binding of adenine nucleotide in AMP/ADP or ATP to the 
Bateman domains in γ subunit of the kinase. The binding of the different adenine 
nucleotides to the AMPK supports the kinase characteristic energy sensor of the 
cell (Hardie and Sakamoto, 2006). AMP should compete with ADP and ATP to the 
binding sites on the γ subunit of the kinase complex because the γ binding sites 
have the same affinity for binding adenine nucleotides. The binding of AMP or 
ADP, but not ATP, causes conformational changes in the γ domains that facilitate 
activation of the catalytic α subunit by upstream kinases through phosphorylation 
of Thr172 and simultaneously inhibiting dephosphorylation by upstream 
phosphatases (Xiao et al., 2011). 
 
 31 
 
 AMPK upstream kinases activation 1.17
AMPK activation is achieved by phosphorylation and activation of the Thr172 
residue of α catalytic subunit of the kinase molecule. The activity of the kinase can 
be increased up to 100 times above its basal level through activation of α subunit 
(Thr172) by upstream kinase, in addition to the allosteric activation that result from 
the binding of AMP to γ subunit that may magnify the effect of the kinase up to 10 
times. The amplification of the kinase activity in response to exercise could reach 
up to 1000 time the enzyme  basal activity (Hardie et al., 2012). Figure  1-6 is a 
representative diagram for AMPK activation mechanisms. 
 
 
Figure ‎1-6: A schematic representation of AMPK activation showing both 
allosteric‎activation‎by‎AMP‎binding‎to‎γ‎subunit‎and‎activation‎of‎the‎α‎subunit‎
(Thr172) by upstream kinases. The figure was adapted from (Richter and 
Ruderman, 2009). 
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1.17.1 LKB1 (liver kinase beta 1) 
LKB1 is the major upstream kinase that phosphorylates Thr172 residue on the α 
subunit of the AMPK complex. It was first recognized as a complex with tumour 
suppressor activity, and suppressed LKB1 activity is recognised in a rare 
autosomal dominant disorder, Peutz-Jeghers syndrome, which is characterized by 
multiple benign tumours in the gastrointestinal tract (Hemminki et al., 1998; Jenne 
et al., 1998). In addition to this rare syndrome, gene defects of LKB1are related to 
sporadic cases of cancer (Sanchez-Cespedes et al., 2002).  
LKB1 has a complex structure and requires binding with two accessory protein 
subunits to be fully activated; these proteins are STRAD and MO25 (Hawley et al., 
2005). Experiments in human skeletal muscle cultured cells show that both of 
these subunits are essential for AMPK activation by AICAR (Woods et al., 2003). 
LKB1 represents the most important upstream activator of AMPK but it requires 
the presence of allosteric activation of the γ subunit by AMP. In other words LKB1 
acts as an activator only in the presence of AMP (Suter et al., 2006; Witczak et al., 
2008).  
1.17.2 CaMKKs (calcium/Calmodulin-dependent protein kinase kinases) 
In some experiments where LKB1 activity is inhibited or blocked, AMPK could be 
still activated (phosphorylated) in response to Ca2+ ions or contraction and this led 
to the discovery of CaMKKs (Woods et al., 2005; Fogarty et al., 2010). Activation 
of CaMKKs depends on an increase in intracellular Ca2+ levels. Elevated Ca2+ 
leads to the binding of Ca2+ with calmodulin, the resultant complex binds to 
CaMKK leading to an increase in its activity (Hawley et al., 1995). Studies show 
that CaMKK activates AMPK in an AMP-independent way as reviewed in Witczak 
et al. (2008). 
1.17.3  TAK1 (Transforming factor –beta- activated kinase 1) 
TAK1 is a serine/threonine protein kinase. TAK1 is expressed in different tissues 
in the mammalian body including skeletal muscle (McGee et al., 2008). In 
mammalian cells, TAK1 is activated by a number of cytokines such as 
transforming growth factor beta and TNFα, and is also activated by chemical 
agents that either alter or mimic AMP/ATP levels like AICAR and metformin (Xie et 
al., 2006). In cell-free studies, TAK1 directly phosphorylates the Thr172 residue of 
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the α subunit of AMPK in the same way that LKB1 and CaMKKs do (Kondo et al., 
1998). 
1.17.4 Upstream phosphatases (Protein phosphatases 2A and 2C) 
Protein phosphatases 2A and 2C mediate dephosphorylation of Thr172 of the 
AMPK complex (Suter et al., 2006). The effects of these phosphatases depend on 
the intracellular levels of AMP and lipid content within the cell (Wu et al., 2007). 
The adenine nucleotides indirectly regulate dephosphorylation of Thr172 via 
upstream phosphatases. By binding of adenine nucleotides (AMP or ADP) to the γ 
subunit a conformational change results that permits access of upstream kinases 
to activate Thr172 residue and prevent upstream phosphatases from causing 
dephosphorylation.  
1.17.5 Inhibition of AMPK by glycogen 
Glycogen plays a critical role in AMPK activity regulation in skeletal muscle. This 
regulatory role might be mediated by direct binding of glycogen to glycogen 
binding domain (GBD) on β subunit of the kinase (Hardie and Sakamoto, 2006). In 
experimental work on rodent muscle, AMPK activity was suppressed in response 
to AICAR or contraction in a high glycogen containing environment (Derave et al., 
2000; Wojtaszewski et al., 2002). In human studies, activation of AMPK was 
greater in glycogen-depleted compared to a glycogen-loaded muscles 
(Wojtaszewski et al., 2003). AMPK regulation is not only determined by energy 
availability (ATP) but also by fuel reserves (glycogen).  
 Physiological activators of AMPK 1.18
Leptin is a protein secreted from adipocytes. It plays an important role in whole 
body energy haemostasis, immunity, and inflammation (Antuna-Puente et al., 
2008). In skeletal muscle, leptin increases FFA oxidation and also reduces the 
lipid content inside the cell in an AMPK-mediated way (Minokoshi et al., 2002). 
Leptin also induces activation of AMPK in skeletal muscle by direct interaction of 
leptin with its receptor at the cell surface (Minokoshi et al., 2002).  
Adiponectin is an adipokine secrete from adipocytes. In skeletal muscle, 
adiponectin induces activation of AMPK and its downstream target ACC causing 
an enhancement of FFA oxidation (Yamauchi et al., 2002). In addition, adiponectin 
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causes an increase in glucose uptake in a mechanism independent of insulin 
(AMPK mediated) (Ceddia et al., 2005).  
During exercise, IL-6 is released from skeletal muscle into the circulation and its 
level increases up to 100 fold (Al-Khalili et al., 2006). Elevated IL-6 enhances 
glucose uptake via an insulin-independent and AMPK-dependent mechanism 
(Carey et al., 2006). Furthermore, IL-6 has an additive effect to insulin in 
enhancing glucose uptake (Geiger et al., 2007). Nieto-Vazquez et al. (2008) 
clarified the complexity of IL-6 behaviour with glucose uptake and insulin 
sensitivity. They found that, chronic treatment induces insulin resistance, while 
acute exposure enhances insulin stimulated glucose uptake via an AMPK 
dependent mechanism as discussed in 1.13.  
 Pharmacological activators of AMPK 1.19
Studies on AMPK became more productive after the use of AICAR (5-
aminoimidazole-4-carboxamide 1-b-D-ribofuranoside) due to its ability to produce 
an exercise-like effect in skeletal muscle (Witczak et al., 2008). AICAR is 
internalized to the cell by the adenosine transporter, and metabolized by the 
enzyme adenosine kinase into 5-aminoimidazole-4-carboxamide 1-b-D-
ribofuranosyl monophosphate (ZMP), an AMP analogue. ZMP acts like 
endogenous AMP by binding to the Bateman domains of the γ subunit of AMPK 
and promoting allosteric activation of the kinase (Gadalla et al., 2004). In cultured 
muscle cells from rodents or humans with T2D, treatment with AICAR causes an 
enhancement of glucose uptake and GLUT4 translocation via an insulin-
independent mechanism (Hayashi et al., 1998; Kurth-Kraczek et al., 1999).  
Thiazolidinediones (TZDs) are insulin sensitising drugs such as rosiglitazone and 
epioglitazone. Studies demonstrate that addition of TZDs to muscle cells in culture 
activates AMPK as well as its downstream effects including glucose uptake and 
FFA oxidation (LeBrasseur et al., 2006). Moreover, chronic treatment of skeletal 
muscle cells from obese mice that display a reduced AMPK activity leads to 
restoration of the normal kinase activity (Lessard et al., 2006). 
Metformin is the most widely used antidiabetic agent all around the world. It is 
derived from a plant extract (galegin) that was used in medieval Europe for 
treatment of diabetic-like conditions (Hardie et al., 2012). The therapeutic effects 
 35 
 
of the drug are mediated through inhibition of gluconeogenesis in liver cells as well 
as activation of AMPK in skeletal muscle. The exact molecular mechanism of 
activation of AMPK by metformin is not fully clarified. Studies showed that 
metformin treatment in rat skeletal muscle leads to AMPK activation and increased 
skeletal muscle glucose transport (Zhou et al., 2001). In human skeletal muscle of 
T2D subjects, metformin has been shown to increase phosphorylation of AMPK 
(Musi et al., 2002).  
 Downstream events and targets of AMPK 1.20
Activation of AMPK is achieved by contraction or any cellular events associated 
with increased energy demands. The downstream events of AMPK activation can 
be divided into two phases; an acute phase that consists of phosphorylation of 
metabolic enzymes which subsequently lead to either activation or deactivation of 
these enzymes (such as inhibition of fatty acid synthesis), and a chronic phase 
which comprises changes in gene expression (either increased or decreased), 
followed by specific protein production or cellular responses such as mitochondrial 
biogenesis and increased GLUT4 expression (Hardie and Sakamoto, 2006).  
 Regulation of lipid metabolism by AMPK 1.21
AMPK activation increases FA uptake by facilitating the translocation of FA 
transporters (FAT/CD36) to the cell membrane (Coort et al., 2004). Furthermore, 
activated AMPK mediates an inhibition of acetyl-CoA carboxylase2 (ACC2). This 
inhibition leads to a drop in malonyl-CoA levels which represents the key mediator 
for both FA synthesis and FA oxidation (Winder et al., 1997). Low malonyl-CoA 
has been associated with activation of Carnitine palmitoyltransferase-1 (CPT-1), 
an enzyme responsible for transferring cytosolic long chain fatty acyl group (LCFA-
CoA) into the mitochondria (a rate limiting step in FA oxidation) (McGarry and 
Brown, 1997). Thus, activated AMPK causes a reduction in malonyl-CoA levels, 
enhancement of internalization, and oxidation of FA in mitochondria.  
AMPK directly inhibits phosphorylation of ACC1 (acetyl-CoA carboxylase 1), which 
is the key enzyme in FA synthesis. Furthermore, hydroxymethylglutaryl-coenzyme 
A reductase (HMGR-CoA) that regulates cholesterol synthesis is inhibited by 
AMPK as well and glycerol phosphate transferase, the important enzyme in TGL 
 36 
 
synthesis and hormone-sensitive lipase (HSL) (Carling et al., 1987; Garton et al., 
1989). 
AMPK blocks the activation of transcription factors involved in lipogenic pathways. 
For example, SREBP1c (sterol regulatory element-binding protein 1c) which is a 
key transcription factor in lipogenic and FA synthesis (Foretz et al., 2005). 
 
 Exercise 1.22
1.22.1 Effects of exercise on glucose homeostasis 
A sedentary lifestyle represents a modifiable cause of various diseases including 
insulin resistance and T2D. Regular physical activity (exercise) combined with 
dietary intervention are recommended by health providers as a first line for 
prevention and treatment of T2D and could be more successful than drug 
treatment (Knowler et al., 2002). Both acute (single bout of exercise) and regular 
exercise training are known to correct the metabolic abnormalities associated with 
insulin resistance and T2D, and regular exercise training is recognised as a 
cornerstone in the prevention and management of T2D (Knowler et al., 2002; 
Haskell et al., 2007).  
Independently of each other, insulin and exercise can increase glucose uptake via 
an improvement in GLUT4 translocation from the cytoplasm to the cell membrane 
(van Dijk et al., 2012). During rest, skeletal muscle glucose uptake after meal is 
totally dependent on insulin action, whereas during exercise, the glucose flux into 
skeletal muscle is an insulin independent process. Muscle contraction stimulates 
GLUT4 translocation and glucose uptake in the complete absence of insulin and 
the effects of contraction and insulin are additive. These observations reveal that 
contraction and insulin stimulate glucose uptake by separate pathways (Holloszy 
and Hansen, 1996; Sakamoto and Goodyear, 2002; Holloszy, 2003).  
Muscle contraction stimulates glucose uptake by increase GLUT4 translocation 
into the cell surface. The particular mechanisms that involve the increase in 
GLUT4 expression at the cell membrane in response to contraction are not fully 
clarified but it is generally believed that AMPK is involved. However, some studies 
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on AMPK knockdown mice show a normal increase in GLUT4 expression level at 
cells membrane in response to contraction (Maarbjerg et al., 2009). 
When AMPK kinase is activated, it serves as an energy controlling enzyme by 
switching off cellular processes that cause energy consumption like protein, lipid, 
and glycogen synthesis as well as promoting and enhancing ATP production 
through increasing glucose uptake and metabolism and FFA uptake and oxidation 
(Hardie et al., 2006). 
1.22.1 Role of AMPK in exercise mediated glucose metabolism 
During exercise, intracellular glucose and glycogen are the main energy 
substrates in skeletal muscle and their consumption is related to the degree of 
exercise intensity (Holloszy et al., 1998). The sources of muscle glucose are either 
from plasma glucose or from degradation of muscle glycogen.  
Activation of AMPK by contraction or AICAR regulates glucose uptake by 
increasing GLUT4 translocation from intracellular vesicles (cytoplasmic location) to 
the cell surface (Merrill et al., 1997; Koistinen et al., 2003).  
Studies showed that the distal insulin signalling pathway could be involved in 
AMPK-stimulated glucose uptake. The identification of AS160 as a key substrate 
for the insulin signalling pathway was a critical challenge and represents the link 
between insulin signalling and GLUT4 translocation (Kane et al., 2002; Sano et al., 
2003). Moreover, skeletal muscle expressing mutant TBC1D4/ TBC1D1 at the key 
activating sites exhibit impaired insulin-stimulated glucose uptake (Kramer et al., 
2006b; Cartee and Wojtaszewski, 2007) and impaired contraction and AICAR 
stimulated glucose transport (Sakamoto and Holman, 2008; Pehmøller et al., 
2009) 
In addition, AMPK has an essential role in long term glucose uptake by increasing 
the expression of both GLUT4 and hexokinase (Holmes et al., 1999). The pathway 
by which AMPK activates GLUT4 expression involves the transcription coactivator 
PGC1-α (Jäger et al., 2007). This increase in GLUT4 expression and thereby 
production might contribute to the enhancement in glucose uptake in response to 
insulin after exercise and explain the additive effects of AMPK on insulin-activated 
glucose uptake. 
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AMPK activation leads to the inhibition of glycogen synthesis and promotes 
glycogen breakdown (glycogenolysis). By inhibiting glycogen synthesis, AMPK 
achieves two effects; it decreases energy consumption and provides a source of 
glucose supplement by degradation of the stored glycogen. In vitro studies show 
that AMPK phosphorylates glycogen synthase (GS) at site 2 (Ser7) and this leads 
to deactivation of the enzyme (Wojtaszewski et al., 2002). Moreover, β-subunit of 
AMPK has the ability to bind to glycogen at specific binding sites and the high 
glycogen contents inside the cell can inhibit AMPK activity (McBride et al., 2009).  
1.22.2 Exercise stimulates inflammatory cytokines release 
Skeletal muscle is considered an endocrine organ that releases a variety of 
cytokines which are called (myokines). Muscle contraction during exercise is 
supposed a key stimulus for both expression and release of myokines such as IL-6 
(Steensberg et al., 2000) and IL-8 (Steensberg et al., 2007). 
Cytokines are a family of polypeptides or proteins that play an essential role in cell 
to cell signalling. Once secreted, they can act on the same cells or on distant 
tissues. Cytokines produce from different tissues of the body including adipose 
tissue, immune cells and skeletal muscle. It is well accepted now that skeletal 
muscle contraction during exercise increases the production and release of 
particular cytokines into the circulation leading to elevated their blood levels 
(Pedersen et al., 2003; Febbraio and Pedersen, 2005). However, the increase in 
inflammatory cytokines such as IL-6 has been reported with metabolically 
disturbed events such as obesity and/or insulin resistance (Hotamisligil, 2006) and 
sepsis (Pedersen and Febbraio, 2008). The difference noted is that, unlike obesity 
that leads to insulin resistance, the increase of IL-6 with exercise is not 
continuous. In other words, it is variable with a rapid increase to reach the peak at 
the end of exercise or shortly after followed by a rapid decrease to return to the 
pre-exercise level (Steensberg et al., 2000). Another difference between cytokine 
response to exercise and sepsis is that the increase in inflammatory cytokines in 
response to exercise is not preceded by an elevation in plasma TNFα such as that 
observed in sepsis which could be responsible for the negative metabolic effects 
(Steensberg et al., 2000). 
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1.22.3 Electrical pulse stimulation (EPS) as an in vitro system to exercise 
cultured myotubes  
Exercise is a complex process at the cellular level and to fully understand this 
complexity, an in vitro system for studying exercise would be of value. The 
creation of an in vitro model of exercise helped to explore the molecular 
mechanisms and the cellular responses as well as the therapeutic implications of 
the exercise. For the last few decades, in vitro models of exercise comprised of 
skeletal muscle fibres activated by nerve impulse. Recently, a new technique 
involving electrical pulse stimulation (EPS) of cultured myotubes has been 
developed. Since the 1970s, early attempts can be tracked of the use animal 
primary skeletal cells in an in vitro model of exercise (Nikolić et al., 2016). The first 
published study that used EPS in human myotubes was in 2002. The results of 
that study showed an increase in glucose uptake in human cultured myotubes in 
response to EPS which was similar to that observed during in vivo muscle 
contraction (Aas et al., 2002).  
Two main protocols described for electrical stimulation. The first is comparable to 
an acute bout of exercise, with high-frequency stimulation for a short-duration 
(Egan and Zierath, 2013). The second, chronic low-frequency EPS is used as an 
analogue for chronic exercise training (Nikolić et al., 2012), and the data obtained 
from the latter model of EPS makes it more convenient for studying skeletal 
muscle contraction. Observations of studies like that performed by Nikolic et al. 
(2012) showed that chronic low frequency EPS causes increased glucose uptake 
as well as improving myotubes oxidative capacity for both glucose and FFA. 
These observations are similar to the adaptive changes observed during exercise 
training in vivo (Hayashi et al., 1997; Santos et al., 2008). However, variable 
metabolic effects of exercise were observed using chronic low-frequency EPS and 
certain adaptations observed with in vivo exercise cannot be reproduced by EPS, 
as shown in detail in Figure  1-6. 
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Figure ‎1-6: A comparison of the effects of different exercise models(In vitro and 
in vivo). The left column shows some gene, metabolic and signalling changes 
observed in response to In vitro exercise model (EPS) in cultured cells. The right 
column shows gene, metabolic and signalling changes observed in response to 
in vivo exercise studies. The middle column shows the changes in gene, 
metabolic and signalling responses that observed in common both in vitro and 
in vivo systems (Nikolić‎et al., 2016). 
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 Thrombin 1.23
Thrombin (factor IIa) is a serine protease that converts fibrinogen into fibrin in 
blood coagulation. It is involved in several biological processes in addition to its 
role in the coagulation cascade (Bailey et al., 1951). Thrombin is produced from 
the pro-enzyme prothrombin which is a vitamin K-dependent protein synthesized 
by the liver. It is proteolytically produced from prothrombin by the action of the 
coagulation factor Xa. Thrombin then converts the soluble fibrinogen into insoluble 
fibrin that acts on platelet aggregation in blood clot formation, the vital step in the 
body’s protective mechanism (Licari and Kovacic, 2009). In addition to clot 
formation and coagulation, thrombin has been observed to affect several cellular 
processes such as cell division (Chen and Buchanan, 1975), chemotaxis (Bar-
Shavit et al., 1983), cancer growth (Tsopanoglou and Maragoudakis, 2004), and 
inflammation and tissue repair (Johnson et al., 1998).  
Thrombin acts via its proteolytic activity, on the cell-surface receptor family of 
seven transmembrane G-protein-coupled receptors known as protease activated 
receptor family (PARs). PAR1, PAR3 and PAR4 are activated by thrombin 
whereas PAR2 is shown to be targeted by other proteases (trypsin) (Wang et al., 
2002). Thrombin acts as a protease enzyme on the cell surface receptors. 
Normally, the binding of thrombin to the PARs receptors leads to proteolytic 
degradation of the N-terminal of the receptor domain leading to formation of a new 
N-terminus that activates the receptor itself and initiates the intracellular signalling 
processes (Vu et al., 1991). This binding and activation facilitates different cellular 
downstream responses that vary according to cell types and need. Thus, 
stimulation of cells by thrombin leads to enzyme activation or deactivation, 
induction of gene expression, cell migration, and division in different cell types. 
 
1.23.1 Role of thrombin in coagulation and fibrinolysis 
Disruption of the endothelial surface leads to activation of the coagulation 
cascades, which is a balance between coagulation and fibrinolysis. Thrombin 
plays a central role in maintaining this balance. The coagulation process is 
reviewed by Licari and Kovacic (2009) and summarized in Figure  1-7. In brief, the 
process starts when circulating factor VII comes into contact with tissue factor (TF) 
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in the presence of Ca2+ and phospholipids. This contact is responsible for 
activation of factor X to produce Xa which leads to production of only trivial 
amounts of thrombin from prothrombin. The small amount of the produced 
thrombin activates factor VIII that results in more Xa production and activation of 
more Va. The combination of Xa, Va, Ca2+ and phospholipids represents the 
prothrombinase activity which ultimately catalyses more thrombin production. Most 
of the produced thrombin is on the surface of the platelets in order to localize the 
activation of thrombin rather than systemic activation which is prevented by other 
mechanisms. The main process mediated by thrombin is the conversion of 
fibrinogen into insoluble fibrin that is the cornerstone in thrombus formation. 
However, the positive feedback effect of thrombin on the production of the Va, 
VIIa, VIIIa and Xa results in amplification of thrombin production and recruitment of 
the coagulation cascades, but simultaneously thrombin exerts negative feedback 
on its production and by this means it takes part in the process of fibrinolysis or 
anti-coagulation. Thereby thrombin mediates a central role in preventing spread of 
clot to nearby or even remote tissues.
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Figure ‎1-7: Thrombin production and functions, thrombin is produced via 
coagulation system activation and variable reported functions, adapted from 
(Carr, 2001; Mann, 2003). 
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1.23.2 Action of thrombin at the cellular level in skeletal muscle cells 
Thrombin acts as a protease enzyme on the cell surface receptors. Distinct PARs 
are expressed in different tissue types, including skeletal muscle cell. PAR-1 
activation has diverse cellular responses including mobilisation of intracellular 
Ca2+, changes in the metabolism of membrane phospholipids, inhibition of 
adenylate cyclase, activation of c-Jun N-terminal kinase, protein kinase C, and 
mitogen-activated protein (MAP) kinases (Mackie et al., 2002; Ossovskaya and 
Bunnett, 2004; Arora et al., 2007).  
Expression of PAR1 in skeletal muscle cells depends on the developmental stage. 
First, receptor expression is mainly observed in myoblasts with minimal expression 
after cell differentiation (myotubes stage). In skeletal muscle myoblast cells, 
stimulation of the cells with thrombin results in activation of PAR-1 and 
mobilisation of intracellular Ca2+ from its store inside muscle cells while its 
treatment in myotubes does not cause Ca2+ mobilization (Suidan et al., 1996). 
However, other researchers reported that treatment of the cultured myotubes with 
thrombin causes Ca2+ mobilization from the intracellular stores and this activation 
depends on the age of the subject, the developmental stage and culture 
environment (Chevessier et al., 2001; Mbebi et al., 2001). Thrombin, through its 
binding to PAR-1, facilitates important biological processes in myoblasts which 
include inhibition of cell fusion and differentiation, inhibition of apoptosis, and 
increase in the rate of cell growth and division (De Niese et al., 2002).  
As mentioned earlier, clot formation is not the only function of thrombin. To 
specify, thrombin has been shown to stimulate increased expression of different 
cytokines, chemokines and other substances in different cell types. For example, 
in human adipocytes, thrombin enhances the production of IL-1β, IL-6, TNF-α and 
other cytokines (Strande and Phillips, 2009). Different cellular pathways are 
suggested to be involved in this process, including Ca2+ ion mobilization from 
intracellular stores as seen in the myoblast model (Suidan et al., 1996). PI-3 
kinase is also involved in PAR activation pathways as observed in mouse mast 
cells (Gordon et al., 2000). Tanaka et al. (2004) suggested that the p38 MAPK and 
tyrosine kinase pathways are involved in IL-6 secretion in response to PAR-1 
activation in human gingival fibroblast. A recent study on bone cells suggested an 
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AMPK-mediated pathway as a mediator for increasing cytokine production in 
response to receptor activation by thrombin (Tokuda et al., 2012). Therefore, it 
seems that activation of thrombin receptors (PARs) stimulates multiple sets of 
pathways sometime in the same cell line to produce different biological actions.  
1.23.3 Thrombin and diabetes 
Hypercoagulation is a feature of patients with T2D who are at high risk of 
thrombotic and vascular events (Carr, 2001). Firstly, T2D subjects are typically 
associated with increased markers of coagulation system activation (Tripodi et al., 
2011). Furthermore, T2D is accompanied by increased clotting factor levels. For 
example, fibrinogen is higher in T2D subjects compared to normal control (Acang 
and Jalil, 1992). Tissue factor (TF), Factor VII, Factor VIII, Factor XI and Von 
Willebrand factor are shown to be elevated in T2D individuals (Carr, 2001). The 
exact pathogenesis of hypercoagulability in patients with T2D or insulin resistance 
has been shown to be multifactorial and not fully clarified but two underlying major 
abnormalities are clear, chronic hyperglycemia and hyperinsulinemia.  
T2D is currently regarded as a low grade inflammatory state (Lopez et al., 2006; 
Daar et al., 2007) and simultaneously, inflammation has been shown to induce 
insulin resistance. To specify, T2D is associated with an increase in production of 
inflammatory cytokines such as TNFα, IL-6 and others (Hotamisligil, 2006). 
Thrombin, a final product of coagulation cascades, has an influence in 
inflammation. Different cytokines and chemokines expression were shown to be 
upregulated in response to thrombin in various tissue types. For example, in 
human adipocytes thrombin increases secretion of interleukin IL-1β, IL-6, TNFα 
and growth factors (Strande and Phillips, 2009). In addition, thrombin has been 
shown to induce an increase in inflammatory factors that mediate bladder 
inflammation (Vera et al., 2010). Therefore, high thrombin levels are associated 
with T2D and could play a role in inflammation and insulin resistance. 
In T2D, there is a strong association between metabolic abnormalities such as 
hyperglycaemia and increased coagulation (elevated thrombin level) (Rao et al., 
1999). In addition, a decreased insulin sensitivity is associated with enhanced 
thrombin production (Romano et al., 2003). Thus, a combination of factors such as 
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hyperglycaemia, hyperinsulinemia, increased inflammatory cytokines and hyper-
coagulation would predispose T2D individuals to vascular complications. 
The impairment of insulin sensitivity, elevated inflammatory markers, and elevated 
thrombin production are fundamental characteristics of T2D. In an animal model of 
insulin resistance, inhibition of thrombin action by 4 weeks administration of 
Argatroban, a selective thrombin inhibitor, results in an enhancement of insulin 
action in those animals (Mihara et al., 2010). Thus, the enhanced thrombin action 
in diabetic muscle might play a significant role in insulin resistance.  
Furthermore, there is emerging evidence of a correlation between the genetic 
basis of hypercoagulation and T2D. Genetic correlations were reported in a cohort 
of Mexican Americans for a number of coagulation factors traits, including 
prothrombin which was strongly associated with T2D risk (Warren et al., 2005). 
These observations are consistent with the proposal by Jarrett and Shipley (1988) 
and Stern (1995) about the common genetic origin of both T2D and cardiovascular 
disease, the ‘‘common soil’’ hypothesis. In addition, GWAS and other gene studies 
show multiple gene variants in common for T2D or insulin resistance, and 
coagulopathy. Zhang et al.(2016) showed that the IRS1 gene is associated with a 
high platelet reactivity in T2D individuals, and the platelets hyper-reactivity is 
strongly linked to high thrombin levels (Nylander and Mattsson, 2003). 
Additionally, carriers of the minor allele of TCF7L2 gene variants are associated 
with elevated procoagulant, impaired insulin secretion, and insulin resistance 
(Delgado-Lista et al., 2011).  
 
1.23.4 Effects of thrombin on glucose uptake 
The knowledge of the metabolic effect of hypercoagulation (increased thrombin) 
on glucose uptake and metabolism in human skeletal muscle is not well known. In 
other tissue types, thrombin was shown to have multiple metabolic effects on 
glucose uptake and metabolisms.  
In animal study by Mihara et al. (2010) showed that, inhibition of thrombin by 
selective thrombin inhibitor Argatroban in mice model of insulin resistance 
enhances whole body glucose clearance and improves insulin signalling in fat cells 
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of these mice. Furthermore in vascular smooth muscle cells, thrombin causes an 
increase in glucose uptake through p38 MAPK activation and this increase is 
shown to be insulin independent (Kanda and Watanabe, 2005).  
Moreover, thrombin has been shown to stimulate glucose uptake and metabolism 
in human platelets which could be a key metabolic step for the generation of 
energy required for thrombus formation (Heijnen et al., 1997).  
In mesangial cells of kidney, thrombin is considered as a regulator of glucose 
uptake and metabolism through its effects on Hexokinase enzyme activity which is 
the rate limiting enzyme of cellular glucose uptake and metabolism (Robey et al., 
2000)  
 Skeletal muscle cell culture 1.24
Human skeletal muscle satellite cells be isolated from muscle biopsies, nourished, 
grown in vitro and differentiated in to multinucleated myotubes. The cells in culture 
replicate individual human properties that open a way to examine important human 
physiology, diseases and treatment in the form of treatment response manner 
(Aas et al., 2013). Moreover, the cell culture system provides a great opportunity 
to study muscle metabolism and response to different stimuli due to two important 
causes; first, the cell culture system is entirely under strictly controlled conditions 
so that the serum and other environmental factors can be excluded. The second 
important feature is that the human muscle cells in culture retain phenotypic 
characteristics such as abnormal glucose metabolism in primary myotubes 
cultured from insulin resistant individuals (Thompson et al., 1996; McIntyre et al., 
2004). Therefore, the human skeletal muscle cell culture is regarded as an 
invaluable model for studying metabolism in response to different stimuli and 
contributes impressively to the current understanding of cellular metabolism.  
1.24.1 Cultured muscle cells metabolism 
Regarding substrate metabolism, by comparing both cultured myotubes and adult 
skeletal muscle fibres the following findings have been observed: 
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1. Basal level of glucose uptake tends to be higher in cultured cells than in adult 
human muscle fibres due to the presence of more GLUT1 transporters 
(Sarabia et al., 1992). 
2. There is a decrease in glucose uptake in response to insulin in cultured cells 
compared to muscle fibres. This seems to relate to the higher GLUT1/ GLUT4 
ratio in cultured muscle cells, and other reasons such as loss effects of in vivo 
nerve stimulation and growth factors. Usually, the increase in glucose uptake 
in response to insulin is about 40%-50% in cultured myotubes while it is much 
higher in muscle fibres. This decrease in insulin response in cultured cells 
leads to the use of higher concentrations of insulin that is more than the 
physiological level to get the same glucose uptake response in culture (Aas et 
al., 2002; Al-Khalili et al., 2003).  
3. Glycogen synthesis in response to insulin shown to be the same as that noted 
in adult muscle cells homogenates which is about double the basal level (Al-
Khalili et al., 2003; Aas et al., 2004; Al-Khalili et al., 2005). 
4. Regarding lipid metabolism, cultured myotubes represent an appropriate 
model for studying oxidative metabolism in muscle mitochondria based on the 
observations that both long chain FFA oxidation and enzymes involved in lipid 
metabolism are similar in both cultured cells and adult muscle fibres (Zuurveld 
et al., 1985; Jacobs et al., 1987). 
 
1.24.2 Preservation of metabolic features in cultured skeletal muscle 
Several studies have shown that some metabolic abnormalities observed in 
certain disease states are retained in cultured skeletal muscle cells grown from 
muscle biopsies from those subjects. For example, muscle cultures from diabetic 
patients display several metabolic features that characterise the disease state 
(Henry et al., 1996; Thompson et al., 1996; Gaster et al., 2002; McIntyre et al., 
2004). The exact mechanism by which cultured cells retain the metabolic 
characteristics of native muscle in vivo is not known till now but both genetic and 
epigenetic factors could be involved (Aas et al., 2013). 
  Limitation of cell culture system 
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In cell culture, the interaction between muscle cells and other cell types that are 
present in human muscle fibres is lost because cultured cells are isolated from 
other accompanied cells. This results in loss of cell-cell communication that 
naturally occurs (Trayhurn et al., 2011). Furthermore, as mentioned some of 
metabolic features are not exactly the same as that of the adult skeletal muscle 
such as glucose uptake in both basal and insulin stimulated. In addition, the 
effects of muscle fibre type are lost in cultured myotubes compared with that of the 
adult muscle fibres. As glucose uptake and insulin sensitivity is increased in 
oxidative slow twitch muscle fibres if compared with glycolytic fast twitch fibres 
(Zierath and Hawley, 2004). Moreover, some gene differences are observed in 
both groups (myotubes in culture versus adult muscle fibres) (Lund et al., 1997; 
Nehlin et al., 2011). 
Several genes that studied in muscle homogenates are over expressed compared 
to that in cultured skeletal muscles cells. This could be attributed to less numbers 
of cells are matured and act as active myotubes and also cells might be in 
dormant state in culture rather than active (Lund et al., 1997).  
Finally, there is a decrease in metabolic and phenotypic features as the number of 
passages of the cultured cells increases (Nehlin et al., 2011).  
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 General Hypothesis 1.26
Thrombin impairs insulin action in human skeletal muscle cells and this could 
illuminate the link between the hypercoagulability and insulin resistance in T2D.  
Furthermore, I explored the hypothesis that thrombin affects the metabolic 
response to exercise in skeletal muscle cells from control non-diabetic human 
subjects using a recently developed in vitro system to exercise the cultured muscle 
cells by electrical pulse stimulation (EPS).  
Moreover, skeletal muscle cell cultures have been established from insulin 
resistant diabetic patients, and shown that defects of insulin action are retained in 
cultured skeletal muscle cells (McIntyre et al., 2004). I investigated the hypothesis 
that in these cell cultures contraction mediated metabolic responses was 
preserved in response to EPS as a model of exercise.  
 Aims of the PhD study 1.27
1. To explore the effects of thrombin on insulin signalling pathway in cultured 
human skeletal muscle cells. 
2. To study the effects of thrombin on insulin stimulated glucose uptake as a 
metabolic parameter in cultured human skeletal muscle cells. 
3. To examine the effects of thrombin on exercising human skeletal muscle 
myotubes using an in vitro exercise model (EPS).  
4. To study the effect of an in vitro exercise (EPS) alone and in combination with 
insulin on skeletal muscle cell cultures  from insulin resistant T2D patients, 
measuring AMPK activation, cytokines release, glucose uptake, and distal 
insulin signalling. 
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CHAPTER 2 : GENERAL MATERIALS AND METHODS 
 
 Chemicals and reagents 2.1
Thrombin was purchased from Sigma-Aldrich, human actrapid insulin was from 
Novo Nordisk (Crawley, UK), both the PKC general inhibitor GF109203X (Cat. No. 
0741) and compound C (Cat. No. 3093) were from Tocris Bioscience and the 
classical PKC specific inhibitor GÖ 6976 (Cat. No. 365253) was from Calbiochem.  
Laboratory chemicals were either bought from Sigma-Aldrich (Dorset, UK) or 
British Drug House (BDH, Poole, UK). Protease inhibitor cocktail and standard 
BSA were from Thermo Scientific. 40% acrylamide was from Melford Laboratory 
Ltd (Suffolk, UK), imaging film was from Thermo Scientific, catalogue number 
#34089. Coomassie, Coomassie plus Protein Assay reagents, Restore TM 
western blot stripping buffer, SuperSignal West Pico Luminol Enhancer solution, 
SuperSignal West Pico Stable Peroxide solution and Western Blot Stripping Buffer 
all were purchased from Thermo Fisher Scientific. Ponceau’s solution (Sigma), 
nitrocellulose blotting membranes was from GE Healthcare Life science 
(Germany).  
Material of Cell culture and media will be mentioned separately in the subsequent 
sections. Phospho- IRS1Y612 (ab66153), Phospho-AS160Thr642 [EPR2733 -2] and 
Phospho-AS160S588 sheep antibody (ab65754) were purchased from Abcam. 
Phospho-AktSer473 (D9E), total Akt rabbit antibodies, Phospho-PKCζ/λThr410/403 
antibody (9378),total-PKCζ antibody (9372S), phospho-AMPKThr172 (40H9) rabbit 
antibodies and AMPKα (F6) mouse antibodies, total AS160 rabbit (C96A7)and 
total IRS1 (L3D12) mouse were supplied by New England Biolabs (Herts, UK). 
Anti‐Rabbit IgG (whole molecule) antibody was raised in Goat and peroxidase-
conjugated with Catalogue number (A0545), Anti‐Mouse IgG (whole molecule) 
peroxidase antibody was raised in rabbit Catalogue number (A9044), Anti‐sheep 
IgG (whole molecule) peroxidase antibody produced in donkey and has Catalogue 
number (A3415) all were supplied by Sigma‐ Aldrich. Anti-human thrombin 
receptor IgG (Abcam, UK), Cy3-conjugated anti-rabbit IgG was from Jackson 
ImmunoResearch Laboratories (711‐165‐152). 2-Deoxy-D-[2, 6-3H] glucose was 
  
52 
 
purchased from Hartmann Analytic (Germany). Scintillation liquid was from 
National Diagnostic (Atlanta, USA). LDH Cytotoxicity Kit II (PK-CA577-K313) was 
from PromoKine, IL-6 and IL-8 ELISA kits were obtained from Qiagen (Sussex, 
UK). 
 Cell culture material and reagents 2.2
Tissue culture plastic wares were obtained from Greiner Bio-One Ltd 
(Gloucestershire, UK), Pipettes were from Sarstedt (Leicester, UK). Coverslips 
and microscope slides were obtained from BDH (Leicester, UK). Ham's F-10 
media, Minimum Essential Media (MEM), penicillin/streptomycin (100units/ml and 
100µg/ml respectively), trypsin-EDTA (0.25%-0.02%) and foetal bovine serum 
(FBS) were purchased from Thermo Fisher Scientific. Chick embryo extract (CEE) 
was purchased from Sera Labs International (Salisbury, UK). PBS (Dulbecco 
without calcium and magnesium, PAA Laboratories). DMSO was obtained from 
Sigma (Poole, UK). For cell sorting system, magnet with stand, Minimac® beads 
and separation columns were purchased from Miltenyi Biotec (Bisley, UK). 
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 Cell culture media preparations 2.3
All cell culture procedures were carried out in a sterile environment in a Class II 
microbiological cabinet and all media were warmed to 37˚C in a water bath before 
nourishing cells. Table 2-1shows different media used and the recipe of each one. 
 
 
Table 2-1: Media recipes used in cell culture. 
 
Growth media – 
myoblasts 
 
Ham’s‎F-10 medium with L-glutamine 
20% (v/v) foetal bovine serum (FBS) 
2% (v/v) chick embryo extract (CEE) 
1% (v/ v) antibiotic penicillin (100units/ml)         
/streptomycin  (100µg/ml) 
 
Differentiation media – 
myotubes 
Minimum Essential‎Medium‎Eagle’s‎Medium‎with‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎‎
L-Glutamine (MEME) 
2% (v/v) FBS 
1% antibiotic penicillin/streptomycin. 
Reduced serum media 
– myotubes 
Minimum‎Essential‎Medium‎Eagle’s‎Medium‎with‎
(MEME) 
0.5% FBS. 
Freezing media 
50% (v/v) growth media 
40% (v/v) FBS 
10%(v/v) DSMO 
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 Muscle biopsy and isolating satellite cells 2.4
All the cells used in the study were kept in liquid nitrogen and were previously 
grown from samples taken from the vastus lateralis muscle biopsy either under 
general anaesthesia at time of hip surgery or needle biopsy under local 
anaesthesia. 
For control human muscle cells (thrombin work), samples were taken from the 
vastus lateralis muscle of healthy subjects with no family history of T2D and with 
normal glucose tolerance.  Local Ethic Committee approval was obtained before 
beginning the sample collection and all participants gave informed written consent.   
For the diabetes work, muscle biopsies were taken from T2D subjects with strong 
clinical evidence of insulin resistance. To specify, all patients taking >100 U 
insulin/day and had at least one first-degree relative with T2D. After diagnosis, 
patients had been treated with diet and oral hypoglycaemic drug for more than 3 yr 
before starting insulin. All enrolled patients had a body mass index (BMI) < 32 
kg/m2. Skeletal muscle biopsies were taken from six age- and BMI-matched 
nondiabetic control subjects with no family history of T2D. The study was 
approved by the Newcastle and North Tyneside Joint Ethics Committee and all the 
participants gave written informed consent.  
Satellite cells were isolated as described previously (Blau and Webster, 1981; 
Jackson et al., 2000). In brief, biopsies were collected in myoblast growth media. 
Fibrous or fat tissues were carefully dissected from the muscular tissue, and 
muscle tissue was cut into approximately 1mm diameter pieces. The tissue was 
then digested with trypsin-EDTA (0.25%-0.02%) at 37°C for 15 minutes after 
washing with phosphate buffered saline (PBS) 4 times to remove adherent blood 
cells. This digestion process was repeated for a maximum of 4 times depending 
on the biopsy sample size. After each trypsinisation, the resultant supernatant was 
removed and neutralised with FBS, centrifuged at 1700 rpm for 5 minutes then 1 
ml of myoblast growth media added to the cell pellet. Finally, the resuspended cell 
pellets were seeded in a T25 culture flask and incubated at 5% (v/v) CO2, 37°C in 
a humidified atmosphere. The next day, growth media was replaced with fresh 
media. 
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 Purifying myoblasts from Mixed Cell Culture 2.5
The established primary cell culture from the aforementioned digestion steps of 
the mixed tissue can be enriched for the myoblast fraction. Cultures were enriched 
as described previously (McIntyre et al., 2004) by the use of a magnetic bead 
system (Miltenyi Biotec). Briefly, cells were harvested with trypsin, re-suspended in 
50-80 μl of separation buffer (5% (v/v) FBS in PBS, 2 mM EDTA. PBS without 
magnesium and calcium) and incubated in the hood for 5 minutes. The appropriate 
amount of primary antibody (20 μl of NCAM CD56 antibodies, a cell surface 
protein marker present on muscle cells) was added and incubated at 4 oC for 10 
minutes and then incubated in the hood for a further 5 minutes. The cell 
suspension was then washed twice with 1.5 ml of separation buffer and 
centrifuged at 1700 rpm for 3 minutes. After being resuspended in 80 μl of buffer, 
20 μl of appropriate secondary antibodies attached to magnetic beads was added. 
The mixed cell suspension was left in the hood for 10 minutes then washed again 
with 2 ml of buffer and centrifuged at 1700 rpm for 5 minutes. The cell pellet was 
re-suspended in 500 μl of separation buffer and added to the magnetic column. 
The suspension was permitted to run through, labelled muscle cells were retained 
in the column by the magnetic beads within the magnetic field. Following washing 
of the cells on the column three times with 500 μl of separation buffer, the column 
was removed from the magnetic field and the labelled cells were eluted from the 
column using another 550 μl of separation buffer. The resultant cells were 
resuspended in an appropriate volume of growth media and seeded in a T25 flask. 
 Human muscle cell culture 2.6
Cells (myoblasts) resuspended in 1ml Freezing media were stored in Cryovials in 
liquid nitrogen. Cryovials were thawed at 37°C (water bath), and the contents 
transferred to a 75 cm2 flask (T75) containing an appropriate volume of growth 
media. Flasks were placed in a humidified incubator and the cells were maintained 
at 37°C under 5% CO2 atmosphere. 
2.6.1 Cell proliferation 
Growth medium was changed every 3-4 days to ensure cells were maintained in a 
proliferation phase. Cell concentration and wellbeing were checked every day 
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under a light microscope until cells reached 70-80 % confluence, at which point 
they were ready to be passaged. 
2.6.2 Cell passaging  
Cultured cells in T75 flasks were ready to be passaged when they were 70%- 80% 
confluent. Growth medium was aspirated, and cells rapidly washed with 5mL PBS. 
Cells were incubated with 3mL 1x trypsin-EDTA / flask for 4-6 minutes at 37°C, 
until the cells had rounded up and detached from the bottom of the flask. At this 
point trypsin was neutralised by addition of growth media. Cells were centrifuged 
(1750 rpm for 3 minutes), and the supernatant was aspirated. The cell pellet was 
re-suspended in an appropriate volume of growth media, plated and returned to 
the incubator. Confluent cell cultures of passage 5-8 were used in this study. 
2.6.3 Cell differentiation 
When myoblasts fuse together in culture, they form multinucleated myotubes that 
display key metabolic characteristics of mature human skeletal muscle cells. 
Myoblast cultures needed to be 80-90% confluent to facilitate fusion into 
myotubes. When this level of density was reached, the growth media was replaced 
by differentiation media. Media was changed frequently (every two days) and cells 
differentiated for seven days. All experiments were performed on day 7 myotubes. 
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 Immunofluorescence staining 2.7
Myoblasts were plated in cover slips in 6-well plates and fed with growth media 
until cells became confluent, and then allowed to differentiate by substitution of the 
media with differentiation media (MEME) for 7 days. All steps were then carried 
out at room temperature, on a shaker set to low speed. Fully differentiated 
myotubes (on cover slips) were washed with PBS three times for 5 minutes each 
and fixed with 10% formalin for 20 minutes. Cells were washed with PBS then 
permeabilized with 0.2% t-octylphenoxy polyethoxyethanol (Triton X-100, Sigma-
Aldrich) for 45 minutes. After washing with PBS, cells were incubated in blocking 
buffer (20% FBS in PBS) for 1 hour to block the non-specific binding sites. Cells 
were then incubated with rabbit anti-human thrombin receptor IgG (Abcam, UK), 
diluted 1:500 in 0.05% FBS in PBS for 1 hour (primary antibody). After washing 
with PBS, cells were incubated in Cy3-conjugated anti-rabbit IgG (secondary 
antibody), diluted 1:500 in 0.05% FBS in PBS for 1 hour in the dark (wrapped in 
aluminium foil). PBS washes were repeated in the dark then, cover slips were 
attached onto slides using a drop of Vectashield with DAPI to visualise nuclei and 
the edges glued to slides with varnish. Fluorescent microscopy was performed on 
an Olympus CKX41 to visualise staining and images taken using QCapturePro60 
software. 
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 Western Blot analysis 2.8
Western blotting is a technique often used in research to identify proteins that are 
separated on the basis of their molecular weight differences through gel 
electrophoresis. The detection of protein is achieved by specific antibodies 
targeting the protein of interest and then the bound antibody is detected by 
developing the film. The antibodies detect specific proteins with the intensity of the 
bands reflecting the amount of protein present (Mahmood and Yang, 2012). 
Different recipes for buffers and solutions used for western blotting experiments 
are listed in Table  2-2 below. 
Table ‎2-2: Different buffers used in SDS-gel electrophoresis. 
Protein extraction 
buffer 
100 mM Tris-HCl, pH 7.4 (at 4°C) 
100 mM KCl 
1 mM EDTA                                                                                                                              
25 mM KF 
0.1mM Na2VO4 
0.1% Triton 
Protease inhibitor cocktail supplied by Thermo Scientific 
Running buffer 
 
144.2g/l glycine 
30.3 g/l Tris base 
0.1% (w/v) SDS 
Transfer buffer 
 
10mM CAPS (3 cyclohexylamino-1-propanesulphonic acid), 
pH 11.1 
10% (v/v) Methanol/l dH2O 
Sample loading 
buffer 
0.25M Tris-HCl, pH 6.8 
8% (w/v) SDS 
40% (v/v) glycerol 
0.008 % (w/v) bromophenol blue  
200‎μl‎2-mercaptoethanol/ml 
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2.8.1 Protein extraction 
Cells were rapidly washed with ice cold PBS 5 times. the remnants of PBS was 
removed and 150 μl/ well of protein extraction buffer added, cells were scraped to 
ensure all cells detached from the wells (by using a plastic cell scraper) and 
lysates were collected in screw-cap Eppendorf tubes on ice. Cell lysates were then 
briefly sonicated for 10-15 seconds at 5μm amplitude to ensure cell lysis by using 
a sonicator (Sonipath, Dawe), and immediately snap frozen in liquid nitrogen, prior 
to storage at -80o C. Samples were thawed when further analysis was required 
and protein concentration in each sample determined by dye binding with 
Coomassie reagent. 
2.8.2 Protein concentration determination 
Before protein concentration determination, samples were defrosted on ice and 
centrifuged at maximum speed for 5 min at 4°C to exclude cell debris that could 
interfere with the determination and forthcoming processes. Spectrophotometric 
analysis of cell lysates was performed according to the modified Bradford dye 
binding colorimetric method for protein quantification (Bradford, 1976). A 2 mg/ml 
BSA stock (Thermo Scientific) was used to construct a standard curve in duplicate 
with the final volume made up to 10μl with protein extraction buffer. Duplicates of 
10μl of cell lysate samples were plated in a 96 well plate, 200μl of Coomassie blue 
stain (Thermo Scientific) was added to each well before being read on a plate 
reader at 595nm, and the protein concentration determined by plotting a standard 
curve as shown in the following Figure  2-1. 
           
Figure ‎2-1: Example of standard curve for protein concentration determination. 
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2.8.3 Protein sample preparation for SDS-PAGE 
The calculation of the protein concentration in each sample was performed and 
each sample was then normalised to contain a total of 10μg protein per well. The 
same volume (1/4 of the total volume) of loading buffer (was added to each 
sample, and the final volume was made up with PE buffer. Samples were heated 
to 95°C to denature the proteins for 3 minutes, and then the protein samples were 
loaded on the SDS–PAGE gel. 
2.8.4 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method of separation of proteins according to their size and molecular weight by 
applying an electrical current. A 10% running gel, and 4% stacking gel was used in 
these experiments.  
Table  2-3 shows the recipes that were used to make the 2 gels. The running gel 
solution was left to polymerise in a gel cassette (30-minutes). Then 4% stacking 
gel solution was added, a plastic comb was inserted to create wells, and left to set 
for about 1 hour. The gel cassette was then positioned onto the appropriate 
apparatus, with 1x electrode buffer. A molecular weight marker, (Pre-stained 
Broad Range 7-175 kDa, New England Biolabs, catalogue number P7708S), and 
all protein samples (10μg/well) were loaded into individual wells. The gel was run 
at 40 mA, the gel was electrophoresed until the tracking dye had migrated to the 
bottom of the gel and good separation of the molecular weight markers had been 
obtained.  
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Table ‎2-3: SDS-acrylamide gel recipes used to prepare 2 gels. 
 10% 6% 
dH2O 11.8ml 9.4ml 
acrylamide‎(40%‎solution) 6.4ml 1.5ml 
Buffer‎B‎(1.5M‎Tris,‎pH‎8.8) 6.3ml ‐ 
Buffer‎D‎(0.5M‎Tris,‎pH‎6.8) ‐ 3.8ml 
10%‎SDS 250μl 150μl 
10%‎APS 250μl 150μl 
TEMED 12.5 μl 7.5μl 
 
 
2.8.5 Gel transfer 
After SDS-PAGE, the separated proteins in the gel were transferred onto a 
nitrocellulose membrane (0.45 μm pore size), pre-wet with transfer buffer and then 
placed between 2 layers of 3 mM filter paper also pre-wet with transfer buffer. The 
‘sandwich’ was then inserted between the plates of the gel holder cassette and the 
transfer was performed using a mini-Hoeffer gel transfer tank (2-3 h, 250V) 
containing transfer buffer (10mM CAPS, 10% methanol). Once transfer was 
complete the membrane was briefly stained with Ponceau’s solution (Sigma) for 5 
minutes to check whether transfer was successful and equal loading of protein had 
been achieved. 
2.8.6 Blocking of membranes and treating with antibodies 
Non-specific sites on the nitrocellulose membranes were blocked by incubation 
with shaking in Tris buffered saline tween (TBST) /5% (w/v) milk or 3% (w/v) BSA 
as a blocking buffer for 1 hour at room temperature. Afterwards, the membrane 
was incubated with monoclonal primary antibody which was diluted in TBST 
containing 1% milk or BSA and the membranes were incubated overnight on a 
shaker at 4°C. Different antibodies targeting specific proteins were used in this 
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work and will be mentioned accordingly in their related chapters. Following primary 
antibody incubation, membranes were washed with TBST (3 x 5 min) on a shaker. 
They were then incubated with secondary antibody conjugated to horseradish 
peroxidase (HRP) diluted in TBS-Tween containing 1% milk or BSA for 2 hours on 
a shaker at room temperature. The membrane was washed with TBST (3 x 5 min) 
before addition of enhanced chemiluminescent (ECL) solutions.  
2.8.7 Chemiluminescence detection 
Membranes were soaked in chemiluminescence reagents, 2.5mL SuperSignal 
West Pico Peroxide Solution and 2.5mL Luminol/Enhancer Solution, for 5-minutes 
with shaking. HRP is used to catalyse the oxidation of luminol in the presence of 
hydrogen peroxide. Immediately after the oxidation, the luminol is in an excited 
state which emits light and the intensity of this light is directly proportional to the 
concentration of the bound antibody. By exposing a photographic film to the 
membrane, an image of the protein bands can be obtained. Once developed, dark 
bands show the protein of interest, to which the HRP was bound. The entire 
process must be achieved in a dark room using red lights.  
X-Ray film (CL-XPosure™ Film, Thermo Scientific, catalogue number #34089) 
was placed over the nitrocellulose membrane and the cassette lid closed. The film 
was exposed to the membrane for a certain time before being put into developing 
solution (Carestream® Kodak® autoradiography GBX developer/replenisher, 
Sigma-Aldrich, catalogue number P7042) for 1 minute. The film was washed 
briefly in water before being placed in fixer solution (Carestream® Kodak® 
autoradiography GBX fixer/replenisher, Sigma-Aldrich, catalogue number P7167) 
for 1 minute. The film was washed again with water and left to dry. The developer 
and fixer solutions were diluted 1:10 in water. 
2.8.8 Membrane stripping  
The membrane was treated with the stripping buffer Restore PLUS Western Blot 
Stripping Buffer (Thermo Fisher Scientific) (5 ml for 15minutes) when more than 
one primary antibody was to be used. Following detection of the first protein of 
interest the membrane was washed with TBST, stripping buffer was added to 
remove both primary and secondary antibodies from the membrane. This allows 
another re-probing of the membrane. Following incubation with the stripping buffer, 
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membrane was then re-blocked with blocking buffer before the next primary 
antibody incubation. 
2.8.9 Densitometric analysis  
Images were analysed by densitometry, performed using a Bio-Rad Molecular 
Imager GS-800 calibrated densitometer, and Quantity One software was used to 
quantify target protein bands. All proteins analysed were normalised to native 
proteins and expressed as a mean of phospho/native proteins. 
 Glucose uptake assay  2.9
Glucose uptake was measured by the incorporation of tritium (3H) labelled 2-
deoxyglucose (2-DG) into myotubes in culture in the presence or absence of 100 
nM insulin. In each experiment, 10 μM Cytochalasin B was added to one of the 
wells to measure non-specific deoxyglucose uptake as it causes inhibition of 
glucose transport through glucose transporters. 2-DG uptake was measured by 
liquid scintillation counting to quantify radioactivity. The radiolabelled 2-
deoxyglucose is not metabolised nor broken down upon entry into the cell. The 
assay was performed on 7 day differentiated myotubes that were cultured in either 
6well plates or 35mm dishes. 
 The differentiation media was changed to reduced serum media before the 
beginning of the assay. Cells were incubated with or without stimulus that could be 
treatment or EPS for a given time at 37°C. After treatment, cells were washed 
twice with warm Kreb's buffer, and then cells were incubated in Krebs' buffer (see 
Table  2-4) with or without 100nM insulin or cytochalasin B (10μM) for 20 minutes 
in the incubator at 37°C and 5% CO2. Glucose transport was initiated by the 
addition of hot glucose 50μl of 2-[3H]-deoxyglucose (Final concentration 50 μmol/l 
and 1 μCi/ml) to each well for 10 minutes. The reaction was stopped by inverting 
the plates rapidly to remove the incubation buffer, and then washing the plates 5 
times with ice-cold PBS. Subsequently, 250 μl of 0.05% SDS was added to the cell 
monolayers as a lysis solution and incubated at 37°C and 5% CO2 for 15-30 
minutes. Wells were scraped with a pipette to ensure all cell lysate was transferred 
to 1.5 ml Eppendorf' tubes. 200μl of the cell lysate was used for scintillation 
counting, added to scintillation fluid (2.5ml) with vigorous vortexing before counting 
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via liquid scintillation counting. The other 50μl of cell lysate was saved for protein 
determination as described previously.  
 
Table ‎2-4: Solutions used in glucose uptake assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Gene expression analysis 2.10
2.10.1 RNA extraction 
Total RNA was extracted by using the GenElute™ Mammalian Total RNA 
Miniprep Kit (Sigma) following the manufacturer’s instructions. For each 250 μl of 
lysis solution needed, 2.5 μl of β-mercaptoethanol was added to fully inactivate 
RNase enzymes. Media was removed from dishes and a single wash with PBS 
performed before addition of lysis solution (250μl per well). The cells were scraped 
using the end of a pipette tip, and the lysis solution in the wells was gently pipetted 
over the surface of the well numerous times to ensure most of the cells were 
lysed. The cell lysates either directly underwent RNA extraction, or were collected 
in tubes, snap frozen in liquid nitrogen and stored at -80°C until required.  
The first step of RNA extraction is to filter the lysate using filtration columns to 
eliminate cellular fragments and shear DNA. Lysates were centrifuged at 
maximum speed for 2 minutes and the filtration column discarded. Secondly, an 
Kreb’s‎buffer‎(KRH) 
pH 7.4 
500ml 
NaCl 136mM = 3.97g in 500ml 
KCl 4.7mM = 0.175g 
MgSO47H2O 1.25mM = 0.154g 
CaCl2H2O 1.2mM = 0.088g 
Hepes 20mM = 2.383g 
BSA 1g 
Hot glucose solution 2-deoxyglucose (2-DG) 2mM 
10‎μCi‎2-[3H]-deoxyglucose/ml 
Kreb’s‎buffer 
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equal volume of 70% ethanol was added to the filtered lysate, this was vortexed 
thoroughly to prepare the mixture for the binding step. Thirdly, the lysate was 
added to the binding column and centrifuged at maximum speed for 15 seconds.  
The column was washed with wash solution 1 before running a DNase digest. To 
ensure that the resultant RNA samples were free from DNA contamination, DNase 
enzyme was added to the binding column using RNase-Free DNase Set (Qiagen). 
DNase 1 stock solution was prepared by dissolving the provided solid DNase I in 
the RNase-free water. To each binding column, an appropriate volume of DNase 
incubation mix (10μl DNase 1 stock solution added to 30μl of the supplied DNase 
Digest Buffer per RNA binding column) was added and incubated at room 
temperature for 15 minutes. After DNase treatment, a series of washes was 
carried out including a last wash with 100% sterile filtered ethanol. Finally, RNA 
was eluted using the provided elution solution.  
2.10.2 RNA Quantification 
The concentration of RNA (ng/μL) in each sample was measured using a Thermo 
Scientific NanoDrop 2000 Spectrophotometer, together with the Nanodrop 2000 
software for analysis. 1μl of each sample was loaded onto the receiving fibre (end 
of the fibre optic cable) and the equipment acquired absorbance readings at 260 
nm for RNA, and assessed purity of samples. The volume of each RNA sample 
needed for cDNA synthesis was adjusted according to the obtained RNA 
concentrations. 
2.10.3 cDNA Synthesis 
Complementary DNA (cDNA) is double-stranded DNA synthesized from a single 
stranded RNA via a reaction catalysed by the reverse transcriptase enzyme. The 
synthesis of cDNA was carried out using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s 
instructions. Firstly, RNA samples were standardised to the same concentration 
(ng/µL) in a 10µL total volume; where necessary, RNase-free water was added. 
An appropriate volume of master mix was made up of the components that are 
presented in Table  2-5. For every set of samples a negative control was prepared, 
where the RT enzyme was replaced by RNase-free dH2O, hence cDNA could not 
be synthesised. 
 66 
 
Table ‎2-5: Reverse Transcription (RT) master mix components for cDNA 
synthesis. 
 
 
 
 
 
 
 
 
 
 
10μl of the RT master mix was then added to 10μl of the previously standardised 
RNA and pipetted gently to mix. The tubes were briefly centrifuged and loaded to a 
Thermocycler Gene AMP PCR System 9700 (Applied Biosystems) and the 
instrument set to the conditions defined in Table  2-6 that allowed reverse 
transcription. The produced cDNA was stored at -20 oC until further use. 
Table ‎2-6: Thermal cycler temperature settingsfor reverse transcriptase reaction.
                                       
 
 
 
 
 
 
2.10.4 Real time PCR 
Quantitative real-time PCR was performed on a Lightcycler 480 (Roche) using 
TaqMan primers and probes. β2-microglobulin (β2M) was used as a reference 
gene. For each assay two master mixes were prepared, one for the target gene 
Components Volume per sample 
10x RT Buffer 2.0μl 
25x dNTP Mix 0.8μl 
10x RT Random primers 2.0μl 
MultiScribe™‎Reverse‎Transcriptase 1.0μl 
Nuclease‐free H2O 4.2μl 
total 10‎μl 
Steps Stage Temperature (°C) Duration (min) 
1 Annealing 25 10 
2 Extension 37 120 
3 Final Extension 85 5 
4 Cooling 4 ∞ 
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and the other for the reference gene. Five serial dilutions were performed to 
generate a standard curve. A 96-well plate was used and each well held a 20μL 
reaction mix: 2μL cDNA and 18μL master mix, with each sample run in triplicate. 
The details of primers concentration and the probes used will be mentioned when 
appropriate. After loading of all samples, the plate was sealed with a transparent 
LightCycler®480 Sealing Foil, briefly centrifuged and loaded into the qPCR 
machine. The LightCycler®480 was programmed for thermal condition as shown 
in Table  2-7.    
  Table ‎2-7: LightCycler®480 program setting for qPCR. 
 
TaqMan probes were used in qPCR for quantification of the genes of interest. The 
principle action of this type of detection is based on 5´–3´ exonuclease activity of 
Taq polymerase. The probe contains a reporter dye attached to the 5’-end of the 
probe and a quencher at the 3’-end. The quencher molecule diminishes the 
fluorescence of the reporter when the reporter and the quencher are in close 
proximity. During the extension phase of the PCR cycle, the Taq enzyme 
synthesises and extends the targeted piece of DNA strand and when the 
extension reaches the 5´–3´ region of the probe the enzyme degrades the probe 
and separates the reporter from the quencher permitting the emission of the 
fluorescence, and the amount of the fluorescent light emitted in the exponential 
phase is proportional to the quantity of the targeted gene (Bustin, 2000).  
2.10.5 Quantification of Gene Expression 
The results of qPCR were calculated by measuring the cycle threshold, CT value, 
which is the cycle number at which the fluorescence increases above the baseline. 
This value is used for quantitative analyses either indirectly (standard curve 
Detection Stage No. of 
Cycles 
Temperature 
(°C) 
Duration 
(mim:sec) 
Genes 
 
TaqMan 
(Qiagen) 
Pre-
incubation 
1 95 02:00  
GLUT1 
GLUT4 
B2M 
Amplification 45 95 00:10 
 60 00:30 
Cooling 1 40 Continuous 
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method) or directly (ΔΔCT method). For the standard curve method, standard 
curves were generated from a 5-fold serially diluted cDNA sample. The standard 
curve was plated in duplicate with every qPCR run. Two separate standard curves 
were generated, one for the target and the other for the reference gene. Figure  2-2 
is an example of the standard curve generated for calculation of GLUT1 gene 
expression in response to thrombin. 
 
 
Figure ‎2-2: Standard curve for gene quantification used in GLUT1 gene 
expression in response to thrombin.  
 
The ΔΔCT method 
 The comparative CT method was used for calculation of gene expression for 
GLUT4 in response to thrombin due to difficulties in constructing standard curves 
as this gene is poorly expressed in our cell system. In case that the reaction 
efficiencies between the target gene and the reference gene are relatively 
equivalent, and as TaqMan® Gene Expression Assays was used relative 
quantification can be achieved by using this method (Biosystems, 2004).  
A series of arithmetic formulas was applied to obtain the relative expression of the 
gene. In brief, after obtaining average CT and standard deviation for both target 
sample and reference, ΔCT was calculated. 
ΔCT = CT target – CT reference. 
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After obtaining ΔCT for each sample, the ΔΔCT was calculated by applying the 
following formula; 
ΔΔCT = ΔCT treated ‐ ΔCT untreated. 
Subsequently, fold changes were determined by using;  
Fold change = 2‐ΔΔCt 
When all the experiments were completed, standard deviation and standard error 
of the mean (SEM) were determined and expressed in the results.  
 
 Enzyme Linked Immunosorbent Assay (ELISA)  2.11
Conventional Enzyme Linked Immunosorbent Assay (ELISA) was used to 
measure cytokine release into media in response to a stimulus. The analysis is 
based on the interaction of target protein (antigen) with protein-specific capture 
antibodies. Samples were prepared from an experiment by removing the media 
and centrifuging at 1000g for 10min. Media was assayed for secretion of IL-6 and 
IL-8 according to the manufacturer’s protocol. Briefly, following the preparation of 
all reagents needed, a standard curve was constructed using the provided 
standard antigen (1μg/ml) and a suitable dilution of the sample with sample 
dilution buffer was performed in order to ensure the samples would fall within the 
range of the standard curve. All samples and standard were analysed in duplicate. 
Equivalent volumes of sample and standard were added to the pre-coated plate 
and incubated for 2 hours followed by 3 washes, and then detection antibodies 
were added and incubated for 1 hour and followed by 3 washes. Subsequently, 
Avidin-HRP was added and incubated for 30 minutes and followed by 4 washes. 
Development solution was added and incubated for 15 minutes in the dark and 
finally stop solution was added and the absorbance was read at 450nm. 
Background absorbance was subtracted from the values and the protein 
concentrations of the samples calculated from the standard curve. 
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 Measurement of lactate dehydrogenase (LDH) release 2.12
Lactate dehydrogenase (LDH) enzyme is found inside nearly all cell types and any 
injury to the cells that lead to cell membrane damage can result in the release of 
the enzyme into the culture medium making it a good marker of cytotoxicity. 
Samples were prepared by collecting the media from the appropriate experiments 
and LDH release into the media was determined colorimetrically at 450 nm 
according to the manufacturer’s instructions, LDH Cytotoxicity Kit II (PK-CA577-
K313) was from PromoKine. In brief, the lactate dehydrogenase assay working 
solution was prepared by mixing WST substrate with a suitable volume of LDH 
assay buffer. An equal volume of LDH assay working solution and the media 
sample were added and incubated in the dark for 30 min at room temperature. The 
colour intensity produced from the reaction was measured spectrophotometrically 
at 450nm.   
 Statistical analysis 2.13
All data values presented in the results sections are expressed as mean ± 
standard error of the mean (SEM). Where (n) value is given, n represents the 
number of experimental repeats from different cell lines (individuals) of primary cell 
cultures. No power calculation has been performed due to the limited number of 
samples available but in all experiments more than three primary cell lines in each 
group were investigated which is the lowest number required for statistical repeats. 
All data were tested for normal distribution using the Kolmogorov-Smirnov test. 
The variables presented were shown to be normally distributed, data were 
analysed using one-way ANOVA, for multiple comparisons especially for the 
glucose uptake and distal insulin signalling pathway data analysis when the 
multiple comparison between means were required. The unpaired t-test was used 
in all data to compare between means of two groups. A p-value of <0.05 was 
considered significant. Statistical analyses were performed using GraphPad Prism 
(California) software.  
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CHAPTER 3 : EFFECTS OF THROMBIN ON INSULIN SIGNALLING 
AND GLUCOSE UPTAKE IN CULTURED HUMAN MYOTUBES. 
 Introduction 3.1
Thrombin is a multifunctional serine protease enzyme. It is involved in several 
biological functions such as cell division (Chen and Buchanan, 1975), chemotaxis 
(Bar-Shavit et al., 1983), cancer growth and inflammation (Licari and Kovacic, 
2009), with its primary role in the coagulation cascade. It is generated from the 
precursor molecule prothrombin by proteolytic cleavage and thrombin acts on the 
cell surface receptors known as protease activated receptors (PARs) (Bailey et al., 
1951). The binding of thrombin to the PARs leads to proteolytic degradation of the 
N-terminal of the receptor domain leading to formation of new N-terminus that 
activates the receptor itself and initiates the intracellular signalling processes (Vu 
et al., 1991). 
PAR1, PAR3 and PAR4 are considered to be activated by thrombin, whereas 
PAR2 has been shown to be targeted by other proteases such as trypsin (Wang et 
al., 2002). The binding of thrombin to its receptors on the cell surface leads to 
receptor activation which facilitates different cellular downstream responses that 
vary according to cell type and need. The mobilisation of intracellular Ca2+, 
activation of membrane phospholipids, metabolic enzyme alterations and PKC 
activation are important second messengers that facilitate transmission of 
thrombin action (Mackie et al., 2002; Ossovskaya and Bunnett, 2004).  
Distinct PARs are expressed in different tissue types, including skeletal muscle 
cells. In skeletal muscle cells PAR expression depends on developmental stage 
and cellular needs. For example, PAR1 is expressed more abundantly in 
myoblasts than in myotubes and receptor activation with thrombin or PARs 
activators at this stage plays an important role in muscle development (Suidan et 
al., 1996) and regeneration after injury (Bedair et al., 2007).  
Skeletal muscle is the primary peripheral tissue site of insulin stimulated glucose 
uptake (DeFronzo et al., 1981) and the key peripheral site of insulin resistance in 
T2D (Cline et al., 1999). In skeletal muscle cells, insulin stimulates glucose uptake 
by initiation of insulin signalling cascades that start with activation of insulin 
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receptors and end with translocation of insulin sensitive glucose transporters 
GLUT4 from the cytoplasm to the plasma membrane as described in details in 
section  1.8. 
Insulin resistance is defined as a reduction in the ability of the target cell or tissue 
to respond to a normal physiological level of insulin. Insulin resistance has 
detrimental effects on glucose homeostasis and is considered a characteristic 
early feature of T2D (DeFronzo et al., 1992). The mechanism of development of 
insulin resistance is multifactorial; genetics, obesity, and activation of 
proinflammatory pathways are all involved. Two important aspects of insulin 
activity altered during insulin resistance are, insulin signalling and insulin 
stimulated glucose uptake.  
Hypercoagulation (increased thrombin production and action) is a feature of T2D 
patients who are shown to be at high risk of thrombotic and vascular events (Carr, 
2001). In T2D, a strong association between metabolic abnormalities such as 
hyperglycaemia and increased coagulation (elevated thrombin level) has been 
recognised (Rao et al., 1999). Additionally, a decline in insulin sensitivity is linked 
with elevated thrombin production (Romano et al., 2003). Furthermore, T2D is 
currently regarded as a low grade inflammatory state (Lopez et al., 2006; Daar et 
al., 2007). Strong links have been identified between increased inflammatory 
mediators with both increased hypercoagulability and reduced insulin sensitivity in 
insulin resistant individuals (Romano et al., 2003). In addition, thrombin receptor 
activation has been shown to stimulate increased expression of different 
proinflammatory cytokines. For example, in human adipocytes thrombin enhances 
the expression and secretion of IL-1β, IL-6, TNF-α and other cytokines(Strande 
and Phillips, 2009). Finally, inhibition of thrombin in insulin resistant animals has 
been shown to enhance insulin sensitivity (Mihara et al., 2010).  
In addition, there is a strong genetic association between haemostasis factors of 
hypercoagulation and T2D development. Warren et al. (2005) showed that genetic 
traits leading to increased thrombin activity is a risk factor for T2D. These 
observations are consistent with the proposal by Jarrett and Shipley (1988) and 
Stern (1995) about the common genetic origin of both T2D and cardiovascular 
disease, the ‘‘common soil’’ hypothesis. GWAS also show that multiple gene 
variants are common to both T2D or insulin resistance and coagulopathy. The 
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IRS-1 gene and some variants of TCF7L2 have been linked to both increased 
coagulopathy and insulin resistance (Delgado-Lista et al., 2011; Zhang et al., 
2016). 
Very little is known about the metabolic effects of hypercoagulation (increased 
thrombin) on insulin signalling and glucose metabolism in human skeletal muscle. 
Therefore this study set out to explore the effects of thrombin on insulin signaling 
and glucose uptake in cultured human skeletal muscle cells 
 
We hypothesize that thrombin directly contributes to the insulin resistant state.  
The aims of the current chapter are: 
1- To explore the effects of thrombin on proximal insulin signalling pathway in 
cultured human skeletal muscle cells. 
2- To explore the effects of thrombin on basal glucose uptake or in response to 
insulin in cultured human skeletal muscle cells. 
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 Methods 3.2
3.2.1 Cell culture 
Muscle biopsies were taken from Vastus lateralis muscles of healthy human 
subjects with no family history of T2D. Satellite cells were prepared as described 
previously in general methods sections  2.4 2.5. Cells were treated with thrombin on 
day 7 of differentiation. All experiments were performed on day 7 after initiation of 
differentiation of myotubes; passages were between 5 and 8.  
3.2.2 Immunofluorescent Staining  
This procedure is explained in detail in general Materials and Methods section  2.7. 
Briefly, fully differentiated myotubes were grown on cover slips and fixed with 10% 
formalin for 20 minutes, cells were permeabilized with 0.2% t-octylphenoxy-
polyethoxyethanol (Triton X-100, Sigma-Aldrich) for 45 minutes and incubated in 
blocking buffer (20% FBS in PBS) for 1 hour. Cells were then incubated with rabbit 
anti-human thrombin receptor IgG diluted 1:500 in 0.05% FBS in PBS for 1 hour. 
After washing with PBS, cells were incubated in Cy3-conjugated anti-rabbit IgG, 
diluted 1:500 in 0.05% FBS in PBS for 1h in the dark. After washing in PBS again 
cover slips were mounted onto slides using a drop of Vectashield with DAPI.  
A negative control is performed by incubating cells without primary antibody, 
followed by incubation with secondary antibodies (Cy3-conjugated anti-rabbit IgG). 
This to ensure that staining is produced from detection of the antigen by the 
primary antibody and not by the experimental artefacts. 
No positive control has been performed as the expression of thrombin receptors at 
both gene and protein level (Immunofluorescent Staining) in primary muscle cells 
(myoblast) has been examined by a previous member of our lab, Dhanisha Lukka, 
as part of her MRes project. 
Fluorescent microscopy was performed on an Olympus CKX41 to visualise 
staining and images taken using QCapturePro60 software. 
3.2.3 Thrombin preparation 
Thrombin from human plasma (Sigma) was obtained in the form of lyophilised 
powder, and reconstituted with 100μL sterile PCR grade water to give a final 
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concentration of 1unit/μL thrombin, which was then aliquoted into small Eppendorf 
tubes and stored at -20°C. 
3.2.4 Adjusting thrombin dose and duration in cultured muscle cells 
The work of choosing the appropriate dose and duration of thrombin treatment 
was performed by a previous member of our lab, Dhanisha Lukka, as part of her 
MRes project and the results of the work are described below: 
Myotubes were grown and differentiated in 6-well plates and at day 7 of 
differentiation were incubated with reduced serum media, before being treated 
with thrombin. Three different concentrations of thrombin were used; 1unit, 5 units 
or 10units. The controls were 1μL, 5μL or 10μL/mL of PCR grade water. Treated 
cells were incubated at 37°C, 5% CO2 for either 6 hours or 24 hours. After the 
given time, cell morphology after thrombin treatment was examined, media was 
taken to run LDH cytotoxicity tests and RNA was extracted to measure cytokine 
expression levels (dose effects measurement).  
The obtained data helped to decide both the optimal concentration and incubation 
period of thrombin that could be tolerated by the myotubes without adverse 
cytotoxic effects. Under the light microscope cultured myotubes were examined for 
their tolerance to treatment, changes in morphology, and cell death. Cell images 
were taken at the end of each incubation period, as illustrated in Figure  3-1.  
Light microscope images of cells incubated for 6 hours show no visual differences 
in cell morphology between control upper panel image and thrombin treated lower 
panel image (Figure  3-1 A), both show healthy muscle cells which remained 
attached to the bottom of the plates with an elongated spindle shape. On the other 
hand, 24 hours of thrombin treatment was shown to be detrimental to cultured 
myotubes. Cells adopted rounded shapes and eventually become suspended in 
the culture media as cell debris particularly with 10 units/ml thrombin (Figure  3-1 
B). Overall, cells were more confluent and healthier in appearance after 6 hours 
thrombin treatment compared with 24 hours treatment. 
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Figure ‎3-1: Light microscope images of cultured human myotubes after thrombin 
treatment with different concentrations of thrombin for variable durations.               
A: Myotubes with 6 hours thrombin treatment. B: Myotubes with 24 hours 
thrombin treatment.  
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3.2.5 LDH cytotoxicity results in response to thrombin treatment 
LDH cytotoxicity measurements were performed on media collected from 4 
different thrombin-treated and 4 control cultures. Results showed that 24 hours 
treatment released significantly more LDH into the media than 6 hours treatment 
at all thrombin concentrations. Moreover, 24 hours LDH release from cells into the 
media was significantly higher even in non-thrombin treated myotubes. 
Furthermore, at 6 hours application of thrombin, 10 U/ml thrombin treatment 
caused a significant increase in LDH release compared to 1 and 5 U/ml (# 
p<0.05). The LDH assay was performed in triplicate and the results showed in 
Figure  3-2. 
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  Figure ‎3-2: LDH cytotoxicity datafrom 4 different cultures of myotubes, treated 
with varying concentrations of thrombin for 6 hours and 24 hours, performed in 
triplicate. *p<0.05, **p<0.01, ***p<0.01 (comparing 24 hours versus the 
corresponding 6 hours treatment) and # p<0.05 (comparing 10U/ml treatment 
with 1U/ml and 5U/ml for 6 hours thrombin treatment). 
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3.2.6 Effect of thrombin on pro-inflammatory cytokine gene expression 
IL-8, IL-6 and CCL2 gene expression were evaluated in response to increasing 
concentrations of thrombin for 6 and 24 hours to assess the effective 
concentration of thrombin with regard to its action. From 3 different cultures of 
myotubes performed in triplicate, the results were as shown in the following 
Figure  3-3. 
1 U, 5 U, and 10 U/ml of thrombin for 6 hours showed a significant increase in 
gene expression of IL-8, IL-6 and CCL2 in myotubes compared with non-thrombin 
treated matched controls (p<0.01). In addition, the use of 5 U/ml thrombin 
treatment for 6 hours showed more stimulation of gene expression than 24hour 
treatment for the three examined cytokines. Furthermore, the highest expression 
for IL-8 and CCL2 was associated with the use of 5 U/ml thrombin treatment for 6 
hours, unlike IL-6 whose expression continued to increase with the use of 10 U/ml. 
Based on these results (examination under microscope, LDH cytotoxicity assay 
and cytokine gene expression) the decision was made to treat muscle cells with    
5 units/mL thrombin for 6 hours.  
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Figure ‎3-3: qPCR data for determining optimal thrombin dose and duration.       
(A) IL-8, (B) IL-6, and (C) CCL2 relative gene expression in cultured human 
myotubes treated with varying concentrations of thrombin for 6 and 24 hours. 
*p<0.05, **p<0.01, and # p<0.01 comparing thrombin treated cultures to the non-
thrombin treated corresponding controls. 
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3.2.7 Western Blot 
The detail of the protocol was discussed in general material and methods 
section  2.8. Membranes were incubated with monoclonal primary antibody (1°Ab) 
diluted in 5% (w/v) skimmed milk powder in TBST, overnight at 4°C. After washing, 
membranes were incubated with a horseradish peroxidase (HRP) conjugated 
secondary antibody IgG, diluted in 5% blocking buffer. Detection was done using 
enhanced chemiluminescence and densitometry measurements performed. 
Phospho-AktSer473 antibody was used at a 1:10000 dilution while native Akt was 
used at a 1:2000 dilution and Phospho-IRS1Y612 and native-IRS1 were used at 
1:1000 dilutions.  
3.2.8 Glucose uptake assay 
Cells were cultured on 6 well plates and incubated with or without thrombin, at 
37°C in serum free media for 6 hours prior to use. After treatment, cells were 
washed twice with Kreb's buffer, then treated with or without 100nM insulin, or 
10μM Cytochalasin B for 30min. Hot glucose solution (0.1mM 2-deoxy-glucose 
and 0.5μCi (2, 6-3H) 2-deoxyglucose) was added for the last 10 minutes before the 
reaction was stopped by washing with ice-cold phosphate buffered saline (PBS). 
The detail of the protocol was discussed in general material and methods chapter 
section  2.9. 
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 Results 3.3
3.3.1 Expression of thrombin receptor proteins 
Generally, the protease-activated receptors, PAR1, PAR3 and PAR4, are all 
activated by thrombin, a serine protease, and referred to as thrombin receptors. 
Immunofluorescent staining of human myotubes was performed using a general 
anti-thrombin receptor antibody (rabbit anti-human thrombin receptor IgG), to 
visualise the distribution of thrombin receptor on the surface of human skeletal 
muscle cells as shown in (A). From the images taken using fluorescent 
microscopy, it is clear that thrombin receptors (in red) are abundant and widely 
spread across the cell membrane. Nuclei were visualised using DAPI (blue). (B) 
Represents the negative control of the staining, cells incubated with no primary 
antibody and no thrombin receptors can be visualised. 
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Figure ‎3-4: Immunofluorescent staining of thrombin receptorson the cell 
membrane of human skeletal muscle cells. (A) Showing: anti-thrombin receptor 
antibody (Cy3-red) and nuclei (DAPI-blue); staining in myotubes at x20 
magnification. (B) A negative control of the image when no primary antibody 
was added to cultured myotubes and no thrombin receptors (in red) can be 
detected. 
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3.3.2 Effects of thrombin on insulin signalling 
 
The effect of thrombin on the insulin signalling pathway was investigated by 
treating human muscle cells in culture with thrombin then stimulating these cells 
with insulin and examining the degree of activation of the key insulin signalling 
molecules, IRS1 and PKB (Akt) at the well-known activation residues.  
IRS1 is the major IRS in skeletal muscle. Upon insulin stimulation, multiple 
tyrosine sites are phosphorylated with tyrosine 612 (Y612) found to be the critical 
residue for downstream activation of the PI-3 kinase for GLUT4 translocation 
(Esposito et al., 2001).  
As shown in Figure  3-5 A and B, treatment of myotubes with  5 U/ml of thrombin 
for 6 hours resulted in a significant reduction (p< 0.01) in the phosphorylation of 
IRS1Y612 following insulin treatment of 100 nM for the last 10 minutes of thrombin 
exposure. 
Akt phosphorylation and activation is a crucial step for insulin signalling and 
glucose uptake in skeletal muscle. The most critical activation site is Ser473 at the 
carboxyl terminal domain of the Akt enzyme. Following insulin stimulation, AktSer473 
phosphorylation was examined in both thrombin and non-thrombin treated cells. 
Figure  3-6 A and B shows that treatment of the cells with 5 U/ml thrombin for 6 
hours resulted in a significant reduction (p< 0.01) in the phosphorylation of 
AktSer473 following insulin treatment of 100 nM for the last 10 minutes of thrombin 
exposure. 
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Figure ‎3-5: Thrombin inhibits insulin stimulated IRS1 activation in cultured 
myotubes. IRS1 phosphorylation at Y612 was measured by Western blot analysis. 
Cells were treated with thrombin (5 U/ml) for 6 hours then stimulated with insulin 
(100 nM) for the last 10 minutes of thrombin treatment. (A) Shows representative 
blots of phosphorylated IRS1 protein and blots of native IRS1. (B) A graph 
shows the results of densitometry analysis of P-IRS1 (phosphorylated IRS1)/N-
IRS1 (Native IRS1) in insulin stimulated cells from both thrombin treated and 
non-treated cells. Values are expressed as the mean ± SEM, n=4, **p<0.01. 
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Figure ‎3-6: Thrombin inhibits insulin stimulated Akt activation in cultured 
myotubes. Akt phosphorylation at Ser473 was measured by Western blot 
analysis. Cells were treated with thrombin (5 U/ml) for 6 hours then stimulated 
with insulin (100 nM) for the last 10 minutes of thrombin treatment. (A) Shows 
representative blots of phosphorylated Akt and blots of native Akt. (B) A graph 
shows the results of densitometry analysis of P-Akt (phosphorylated Akt)/N-Akt 
(Native Akt) in insulin stimulated cells from both thrombin treated and non-
treated cells. Values are expressed as the mean ± SEM, n=8, **p<0.01. 
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3.3.3 Role of PKC in mediating thrombin inhibitory effect on insulin 
signalling 
3.3.4 PKC general inhibitor GF109203X 
PKCs are involved in the insulin signalling pathway in skeletal muscle cells. To 
explore whether the inhibitory effect of thrombin on insulin-mediated Akt 
phosphorylation involves PKCs, human skeletal muscle cells in culture were 
treated with thrombin and increasing concentrations of the PKC general inhibitor 
GF109203X that is reported to inhibit all PKC isoforms. Final concentrations of 1, 
10 and 100 nM GF109203X were used in both thrombin and non-thrombin treated 
cells for the last 30 minutes of thrombin treatment before stimulating cells with 100 
nM insulin for the final 10 minutes. Subsequently, AktSer473 phosphorylation was 
measured to explore whether PKCs mediate the inhibitory effects of thrombin on 
insulin signalling.  
 
Where cells were not treated with thrombin and subjected to the same doses of 
the PKC general inhibitor, no inhibition of AktSer473 phosphorylation in response to 
insulin was observed as shown in Figure  3-7. 10 and 100nM of GF109203X 
reversed the inhibitory effect of thrombin on insulin-mediated AktSer473 
phosphorylation whereas 1nM displays no enhancement in Akt activation as 
shown in Figure  3-8. 
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Figure ‎3-7: PKC general inhibitor GF109203X in non-thrombin treated cells has no 
effect on AktSer473 phosphorylation. A representative blot of phosphorylated 
AktSer473 and native Akt in non-thrombin treated cells with or without 100 nM 
insulin stimulation with increasing doses of inhibitor, n =1. 
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Figure ‎3-8: PKC general inhibitor GF109203X in thrombin treated myotubes.Cells 
were treated with thrombin (5 U/ml) for 6 hours; different doses of GF109203X 
were added for the final 30 min before cells were stimulated with 100 nM insulin 
for 10 mins. (A) Representative blots of phosphorylated Akt Ser473 and native Akt 
in thrombin treated cells with or without 100 nM insulin stimulation with 
increasing doses of inhibitor. (B) Graph shows the results of densitometry 
analysis of P-Akt (phosphorylated Akt)/N-Akt (Native Akt) in insulin stimulated 
cells with different doses of PKC inhibitor. Values are expressed as the mean ± 
SEM, n = 6, *p< 0.05, **p<0.01.  
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3.3.5 PKC Conventional isoform selective inhibitor (GÖ 6976) 
PKC has many isoforms and several of them have been linked to the insulin 
signalling pathway. The conventional PKC selective inhibitor Indolocarbazole   
(GÖ 6976), which is specific for the Ca2+ dependent isoforms α and β, was used in 
this study to investigate the inhibitory effects of thrombin on insulin signalling.  
 
Non-thrombin treated cells were subjected to the same doses of the inhibitor     
GÖ 6976 and this shows no inhibition of AktSer473 phosphorylation in response to 
insulin as shown in Figure  3-9. The inhibitory effect of thrombin on insulin-
mediated Akt phosphorylation was reversed in a dose dependent manner by     
GÖ 6976 treatment. There was a significant (p< 0.05) increase in AktSer473 
phosphorylation even with the lowest concentration of inhibitor as shown in 
Figure  3-10.  
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Figure ‎3-9: PKC selective inhibitor (GÖ 6976) in non-thrombin treated cells has no 
effects on phosphorylation of AktSer473. Representative blots of phosphorylated 
forms of Akt, native Akt in non-thrombin treated cells with or without 100 nM 
insulin stimulation with increasing doses of inhibitor, n =1. 
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Figure ‎3-10: PKC selective inhibitor (GÖ 6976) in thrombin treated myotubes. 
Cells were treated with thrombin then different doses of the inhibitor were 
applied, finally cells were stimulated with 100 nM insulin. (A) Shows a 
representative blot of phosphorylated forms of AktSer473 and blot of native Akt (B) 
Graph shows the results of densitometry analysis of P-Akt (phosphorylated 
Akt)/N-Akt (Native Akt) in insulin stimulated cells with different doses of the 
inhibitor. Values are expressed as the mean ± SEM, n = 4, *p< 0.05, **p< 0.01. 
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3.3.6 Effects of thrombin on glucose uptake in cultured muscle cells 
 
To examine the effect of thrombin on glucose uptake in cultured human muscle 
cells, radiolabelled glucose uptake was measured in the presence and absence of 
5 U/ml of thrombin and 100nM of insulin. As shown in Figure  3-11 A, interestingly, 
thrombin increases glucose uptake to 659.8 ± 102.4 pmol/min/mg which is 
significantly above basal glucose uptake 501.6 ± 61.66 pmol/min/mg (p<0.05). 
Furthermore, in non-thrombin treated myotubes insulin increased glucose uptake 
to 780.7 ± 132.2 pmol/min/mg which was significantly higher than basal uptake in 
the absence of thrombin (p<0.05).  
Insulin stimulated glucose uptake in thrombin treated myotubes continues to 
increase to 888.3 ± 166.3 pmol/min/mg; however, this was statistically not 
significant.  
Fold change represents an alternative way of expressing glucose uptake. It is 
used to overcome the increased basal glucose uptake with thrombin treatment. 
The fold changes computed as the ratio of insulin over basal glucose uptake in 
both thrombin and non-thrombin treated cells showed that there was no significant 
difference in fold change between thrombin (1.3 fold) and non-treated myotubes 
(1.5 fold) as shown in Figure  3-11B. 
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Figure ‎3-11: Glucose uptake in skeletal muscle myotubes. (A) Represents the 
absolute values of glucose uptake, basal and insulin stimulated for both the 
thrombin (+) and non-thrombin (-) treated myotubes. (B) Fold change in glucose 
uptake, I/b (glucose uptake in response to insulin/basal uptake) in the presence 
or absence of thrombin. The values are presented as mean ± SEM, n=5, *p<0.05. 
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 Discussion 3.4
To our knowledge, this is the first work to examine the metabolic effects of 
thrombin treatment in skeletal muscle. In the present study, elevated thrombin 
causes a reduction in insulin signalling characterised by a decrease in IRS1 and 
Akt phosphorylation and this reduction in human myotubes was shown to be 
mediated, at least in part, through classical PKC. In addition, thrombin was found 
to directly increase glucose uptake with evidence that this is facilitated through an 
insulin independent pathway. 
The activation of IRS1 tyrosine phosphorylation and PI3K-Akt pathways by insulin 
are fundamental steps of insulin signalling, insulin stimulated glucose uptake and 
metabolism (Pessin and Saltiel, 2000). In this study, thrombin decreased insulin-
stimulated IRS1Y612 and AktSer473 phosphorylation. These results are consistent 
with the results obtained from other studies measuring Akt activity in response to 
insulin and thrombin in adipocytes (Mihara et al., 2010) and growth factor and 
thrombin in endothelial cells (Thors et al., 2003). 
However, the results differ from some published studies on platelets which show 
that thrombin directly causes an increase in phosphorylation of Akt and activation 
of platelets (Kroner et al., 2000; Barry and Gibbins, 2002). This appears to be 
different to the situation in skeletal muscle, as we observed no activation of Akt by 
thrombin in myotubes in the absence of insulin. This inconsistency in the results of 
thrombin effects on insulin signalling between platelets and other cell lines, could 
be attributed generally to the fact that platelets are directly stimulated by thrombin 
and have no need of insulin for activation. In addition, in these studies there was a 
difference in duration of thrombin treatment. Moreover, Akt activation in platelets 
has been shown to be transient and only for short duration and it seems to return 
to the deactivated state after 1 hour of thrombin treatment. This differs from the 
method used in this study in which thrombin treatment was applied for 6 hours 
before measuring the response.  
The inhibition of Akt activation by thrombin seems to be via a PKC-related 
mechanism. Protein kinase C is a serine-threonine kinase that is expressed 
abundantly in skeletal muscle. Different PKC isoforms are expressed and 
classified according to their structure and regulatory cofactors of activation into 
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three families as conventional, novel, and atypical (Parker and Murray-Rust, 
2004). PKC isoforms play different roles in modulating biological activities such as 
growth, differentiation and signal transduction in different cell lines including 
human skeletal muscle (Buchner, 1995). 
With regard to the insulin signalling pathway, different PKC isoforms exert different 
effects, that range from an activation of signal transduction in response to insulin 
such as for the PKC delta and zeta isoforms, to an inhibition of signal transduction 
such as for the PKC theta isoform (Sampson and Cooper, 2006). The diversity of 
functions of PKC isoforms in response to insulin could be summarized as below 
(Figure  3-12). 
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Figure ‎3-12: A summary of PKC isoforms role in the insulin signalling pathway in 
skeletal muscle.  
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GF109203X is a PKC general inhibitor that has been shown to inhibit the 
activation of PKC in skeletal muscle (Kim et al., 2002; Wright et al., 2003). The 
addition of the PKC general inhibitor improves insulin sensitivity in human skeletal 
muscle through an improvement of IRS1 tyrosine phosphorylation (Cortright et al., 
2000). The results of the present study show that GF109203X treatment in 
thrombin-treated cells reversed the inhibitory effects of thrombin on insulin 
signalling through an enhancement in Akt phosphorylation. These findings are in 
line with those observed in endothelial cells in which GF109203X reversed the 
inhibitory effect of thrombin on growth factor stimulation of Akt (Thors et al., 2003). 
In order to clarify the specific PKC isoform involved in the inhibitory effects of 
thrombin on insulin action, a specific PKCα isoform inhibitor was used. Studies 
found that activation of PKCα causes inhibition of insulin action (causes insulin 
resistance), and PKCα knockout mice show an improvement in insulin signalling 
and sensitivity compared to wild type (Letiges et al., 2002). In addition, PKCα has 
been shown to be constitutively associated with IRS1 and this linkage causes a 
reduction in insulin activation, but upon insulin stimulation there is a dissociation of 
PKCα from IRS1 and an increase in downstream activity towards increased insulin 
signalling (Chin et al., 1994; Liu and Roth, 1994; Andreozzi et al., 2005). 
Inflammatory cytokines, like TNFα, have been shown to increase PKCα-IRS1 
association, leading to insulin resistance. Sampson and Cooper (2006) in their 
review, suggested that any stimuli that strengthens the PKCα -IRS1 association 
would inhibit insulin signalling and could contribute to insulin resistance. 
Experiments in this study were designed to explore whether thrombin might act 
through the same mechanism, and the results show that selective inhibition of the 
cPKC isoform using the GÖ 6976 (cPKC specific inhibitor) reversed the inhibitory 
effect of thrombin on insulin-mediated Akt phosphorylation. This would suggest 
that PKCα is involved in the inhibitory effects of thrombin on the insulin signalling 
pathway.  
While clear evidence was found that thrombin decreased insulin signalling in 
human skeletal muscle cells, it was also found that thrombin directly increases 
glucose uptake in both the basal and to some extent the insulin stimulated state. 
This is consistent with the findings of Kanda and Watanabe (2005) who showed 
that thrombin causes an increase in glucose uptake in vascular smooth muscle 
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cells. Furthermore, thrombin has been shown to have some similarity with other 
proinflammatory cytokines such as TNFα, which, despite interference with 
proximal insulin signalling pathways (decreased IRS1 and Akt activation), does not 
downregulate insulin-induced glucose transport, and even has a positive effect by 
inducing an increased basal glucose transport (Storz et al., 1999). 
In conclusion, this is the first study to look at thrombin and insulin action/signalling 
in human skeletal muscle. It was found that thrombin decreased insulin-stimulated 
IRS1 and Akt activation which was mediated through PKCα and simultaneously, 
thrombin directly increased glucose uptake and did not downregulate insulin-
induced glucose transport. 
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CHAPTER 4 : THE EFFECTS OF THROMBIN ON DISTAL INSULIN 
SIGNALLING AND STIMULATION OF AMPK IN CULTURED 
HUMAN MYOTUBES. 
 Introduction 4.1
Thrombin is a multifunctional proteolytic enzyme and stimulation of cells with 
thrombin leads to protein phosphorylation, gene expression, contractility, and 
proliferation in a variety of cells, including skeletal muscle cells (Mackie et al., 
2008). In the previous chapter, it was shown that thrombin receptors were 
expressed in cultured human skeletal muscle cells and that thrombin has multiple 
metabolic and signalling effects represented by a decrease in proximal insulin 
signalling as assessed by measuring phosphorylation of IRS1 and Akt, without a 
concomitant decrease in insulin stimulated glucose uptake. In addition, thrombin 
by itself exerts a positive effect by enhancing basal glucose transport.  
Glucose uptake into skeletal muscle cells is carried out by facilitated transport via 
glucose transporters. GLUT1 and GLUT4 are the most important members of the 
glucose transporter family in skeletal muscle cells.  
GLUT1 in skeletal muscle cells is postulated to be responsible for the majority of 
basal glucose uptake, and this assumption is supported by studies in transgenic 
mice, where GLUT1 is overexpressed in skeletal muscle (Marshall et al., 1993). 
An abnormal cell surface content of GLUT1 has been reported in human cases of 
insulin resistance and T2D (Miele et al., 1997). However, Vogt et al. (1992) and 
Pedersen et al. (1990) found no differences in GLUT1 expression between T2D 
patients and control subjects. Furthermore, factors such as TNFα which have been 
shown to increase basal glucose uptake in skeletal muscle is reported to cause an 
increase in expression of GLUT1 at both gene and protein levels (Storz et al., 
1999).  
GLUT4 was discovered in the late 1980s by James et al. (1988), and since then it 
has received the greatest attention of all transporter proteins due to its importance 
in whole body glucose homeostasis. The results of transgenic overexpression and 
knock-out of muscle-specific GLUT4 in mice increases basal and insulin-
stimulated whole body glucose disposal. This observation confirms the crucial role 
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of this transporter in regulating muscle-specific and whole body glucose 
metabolism (Ren et al., 1995; Zisman et al., 2000). The critical step in glucose 
transport in response to stimuli is the translocation of GLUT4 from the cytoplasm 
to the plasma membrane. AS160 is a Rab GTPase activating protein that acts as 
an upstream mediator for GLUT4 translocation in response to insulin (Gonzalez 
and McGraw, 2006) and contraction or exercise mimetics, such as AICAR (Kramer 
et al., 2006a). Atypical PKC has also been implicated in insulin stimulated GLUT4 
translocation but its precise pathway is not fully understood (Farese et al., 2007). 
Other PI3K-independent kinases have also been proposed to contribute to GLUT4 
activation in response to insulin such as c-Cbl, CAP, and TC10 (Saltiel and 
Pessin, 2003). Skeletal muscle contraction also induces translocation of GLUT4 
from intracellular compartments to the plasma membrane that presumably occurs 
via the activation of AMPK kinase, which is considered a sensor of intracellular 
energy (Jessen and Goodyear, 2005). Furthermore, studies show that factors that 
activate AMPK such as muscle contraction, AICAR, and others result in a rapid 
increase in GLUT4 gene and protein expression (Sherman et al., 1993; Zheng et 
al., 2001; Ojuka et al., 2002). 
It is reported that in many cell lines, thrombin exerts its effects via AMPK 
activation. For example, in human umbilical vein endothelial cells, inhibition of 
AMPK using compound C, an AMPK inhibitor, ameliorates thrombin-induced 
action (Gunduz et al., 2015). Moreover, in human platelets, studies found that 
AMPK-α1 was directly activated by thrombin. Thrombin activates AMPK via the 
Ca2+/calmodulin-dependent kinase kinase β (CaMKKβ)-dependent pathway and 
the use of a chemical inhibitor of CaMKKβ blocks thrombin-induced platelet 
response (Onselaer et al., 2014; Randriamboavonjy and Fleming, 2014). In 
addition, in bone cells (osteoblasts) thrombin-stimulated IL-6 synthesis was 
proposed to be an AMPK dependent, and the use of compound C produces a 
dose dependent suppression in thrombin-stimulated IL-6 release (Tokuda et al., 
2012). 
Having observed an inhibitory effect of thrombin on insulin signalling, it was 
surprising to observe that insulin stimulated glucose uptake tended to increase in 
the presence of thrombin although this was not statistically significant.  
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Therefore the experiments described in this chapter were designed to explore the 
possible pathway by which thrombin exerts its effects on glucose uptake.  
Our hypothesis was that, thrombin increased glucose uptake in an insulin 
independent pathway that would bypass its inhibitory effects on proximal insulin 
signalling. 
Aims of this chapter: 
1- Exploring the effects of thrombin on distal insulin signalling pathway. 
2- Examining other pathway by which thrombin exerts its effects on glucose 
uptake. 
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 Methods 4.2
4.2.1 Experimental design 
Skeletal muscle cells were seeded in 6 well plates, grown to confluence and 
allowed to differentiate for 7 days. Media was changed to reduced serum media 
(minimal essential media supplemented with 0.25 % (v/v) FBS), the cells treated 
with 5 U/ml thrombin or the same volume of water as a control, according to the 
previous optimisation of the dose and duration. For all experiments insulin was 
added at a concentration of 100nM for the last 10 minutes. For AMPK inhibitor 
compound C, all cells were treated with thrombin for six hours then for the last 30 
minutes 40 µM of compound C was applied. 
4.2.2 Western Blot 
The detail of the protocol was discussed in general material and methods chapter. 
section  2.8, with the following exception; 10μg samples were loaded on 10% SDS-
PAGE gels in loading buffer for the AMPK and aPKC experiments and 8% SDS-
PAGE gels for AS160 were used for better separation of high molecular weight 
protein “about 160 kDa”. After separation, proteins were transferred onto a 
nitrocellulose membrane (0.45 μm pore size), with a longer period for transfer (3 
hours) for the high molecular weight proteins. Non-specific antibody binding sites 
on the nitrocellulose membranes were blocked by incubation in Tris buffered 
saline tween (TBST) containing 5% (w/v) milk for AMPK and aPKC and 3% (w/v) 
BSA for AS160 for 1 hour at room temperature. Membranes were incubated with 
monoclonal primary antibody (1°Ab) diluted in 5% (w/v) milk in TBST or 1 % BSA 
accordingly, overnight at 4°C. After washing, membranes were incubated with a 
horseradish peroxidase (HRP) conjugated secondary antibody IgG, diluted in 
blocking buffer. Detection was done using enhanced chemiluminescence and 
densitometry measurements performed. Phospho and native aPKC antibodies 
were used at a 1:1000 dilution, phospho and native AMPK antibodies were used at 
a 1:1000 and phospho and native AS160 were 1:500 dilutions.  
4.2.3 Glucose uptake assay 
Cells were cultured and grown on 6 well plates and allowed to differentiate and, 
when confluent media was changed to differentiation media. On day seven, the 
media was changed to reduced serum media and cells were incubated with or 
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without 5 U/ml of thrombin, at 37°C for 6 hours prior to use. Glucose uptake was 
then performed as described in general Materials and Methods chapter, 
section  2.9. 
4.2.4 RNA isolation and cDNA synthesis 
Total RNA was extracted from human skeletal muscle cells using the GenEluteTM 
Mammalian Total RNA Miniprep kit (Sigma) following the manufacturer’s 
instructions that are described in detail in general material and method chapter, 
section  2.10. Total RNA was treated with DNase and 200ng was reverse-
transcribed using the High Capacity cDNA reverse transcription kit (Applied 
Biosystems) in a final volume of 20μl. 
4.2.5 Quantitative real-time PCR 
Quantitative real-time PCR was performed on a Lightcycler 480 (Roche) using 
TaqMan primers and probes. GLUT4 (Hs.380691) and GLUT1 (Hs.473721) were 
obtained from Applied Biosystems as predesigned TaqMan primer-probe mixes 
and were used at the recommended 1:20 dilution. β2-microglobulin (β2M) was 
used as a reference gene with the following sequences:                                                                                                                
Forward primer; GCCTGCCGTGTGAACCAT,                                                                                            
Reverse primer; TTACATGTCTCGATCCCACTTACCTATC,                                                          
Probe; FAM-TGACTTTGTCACAGCCCA-TAMRA.                                                           
The concentration of both primers was 300 nM per reaction and 250 nM for the 
probe. 10μl of Gene expression mastermix (Applied Biosystems) was added to 
each reaction with 20ng of template. Results were analysed either by the standard 
curve method for GLUT1 or by the ΔΔCT method for GLUT4 as it is sparsely 
expressed in myotubes and failed to achieved a readable standard curve. Relative 
quantification was performed with data normalised to β2-microglobulin. 
4.2.6 ELISA 
Secretion of IL-6 from day 7 differentiated myotubes was determined by enzyme-
linked immunosorbent assay (ELISA) using the Single-Analyte ELISArray 
(Qiagen). At day seven differentiated myotubes, media was changed to reduced 
serum media before treatment. Cells were treated with or without 5 U/ml of 
thrombin for 6 hours. The media of both thrombin treated and non-thrombin 
treated cells was collected, centrifuged at 1000g for 10 minutes and analysed for 
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secretion of IL-6 according to the manufacturer's protocol. A standard curve was 
generated by serial dilution of the antigen provided. Standards and test 
absorbance were read at 450nm. Background absorbance was subtracted from 
the values.  
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 Results 4.3
4.3.1 Effect of thrombin treatment on glucose transporter GLUT1 expression 
In order to assess the stimulatory effects of thrombin on glucose transport, glucose 
transporter gene expression was examined using qPCR methods. GLUT1 is one 
of  the major glucose transporters predominantly expressed in human muscle cells 
and represents the main way by which basal glucose uptake takes place (Ciaraldi 
et al., 2005). The addition of thrombin to fully differentiated myotubes causes a 
significant increase in GLUT1 gene expression (p<0.05) compared with non-
thrombin treated cells as displayed in Figure  4-1. 
4.3.2 Effect of thrombin treatment on glucose transporter GLUT4 expression: 
GLUT4 is the principal transporter involved in insulin- and muscle contraction-
responsive glucose uptake in skeletal muscle. Upon stimulation, GLUT4 
translocates from the cytoplasm to the cell membrane facilitating increased 
glucose uptake. GLUT4 is highly expressed in myotubes compared to myoblasts 
as a reflection of functional demands (Santalucia et al., 1992). From the data in 
Figure  4-2, it is apparent that GLUT4 gene expression is significantly higher 
(p<0.05) in response to thrombin treatment compared to myotubes without added 
thrombin. 
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Figure ‎4-1: Effect of thrombin on GLUT1 gene expression. An increase in GLUT1 
(glucose transporter) gene expression is observed in myotubes treated with 
thrombin compared to non-thrombin cells. Values are normalized to the level of 
β2-microglobulin mRNA as a reference gene and expressed as the mean ± SEM, 
n =4, *p<0.05. 
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Figure ‎4-2: Effect of thrombin on GLUT4 gene expression. GLUT4 expression in 
myotubes is increased in response to thrombin. Values are normalized to the 
level‎of‎β2-microglobulin mRNA as a reference gene. Data expressed as mean ± 
SEM, n =5, *p<0.05.  
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4.3.3 Effects of thrombin on the distal insulin signalling pathway 
The results of the work in the previous chapter showed that thrombin causes a 
decrease in the proximal insulin signalling pathway, represented by a reduction in 
the phosphorylation of both IRS1Y612 and AktSer473 following insulin treatment, 
without a concomitant reduction in insulin stimulated glucose uptake. Furthermore, 
thrombin per se causes an increase in basal glucose uptake. Therefore the work in 
this chapter was designed to explore alternative pathways by which thrombin 
exerts its effects.  
4.3.4 Effects of thrombin on aPKC activation  
Insulin continued to increase glucose uptake in the presence of thrombin, which 
was unexpected in view of the inhibitory effect of thrombin on insulin-mediated Akt 
activation. We therefore explored the impact of thrombin on insulin activated aPKC 
by measuring the phosphorylation of PKC ζ/λThr410/403. Thrombin did not affect 
aPKC stimulation with insulin compared to non-thrombin treated cells as shown in 
Figure  4-3.
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Figure ‎4-3: Effect of thrombin on insulin stimulated aPKC activation in cultured 
myotubes.‎The‎phosphorylation‎of‎PKC‎ζ/λThr410/403 was measured by Western 
blot analysis. Cells were treated with thrombin (5 U/ml) for 6 hours then 
stimulated with insulin (100 nM) for the last 10 minutes of thrombin treatment. 
(A) Representative blots of phospho-PKC‎ζ/λ‎(Thr410/403) and blots of native 
aPKC. (B) Graph showing the densitometric analysis of P-aPKC (phospho-PKC 
ζ/λ‎Thr410/403)/N-aPKC (native aPKC) in basal and insulin stimulated cells in 
thrombin treated or non- treated cells. Values are expressed as the mean ± SEM, 
n=5. 
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4.3.5 Effect of thrombin on AS160 activation 
AS160 is the direct downstream signalling molecule activated by both insulin and 
contraction, which results in an increase in glucose uptake. The effect of thrombin 
on AS160 activation was investigated by measuring Thr642 phosphorylation. 
Thrombin showed no inhibitory effect on insulin-mediated AS160 activation 
compared with untreated cells and simultaneously thrombin caused an increase in 
basal AS160 activation compared to non-thrombin treated cells (p<0.05) 
(Figure  4-4). 
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Figure ‎4-4: Effect of thrombin on insulin stimulated AS160 activationin cultured 
myotubes. Phosphorylation of AS160Thr642 was measured by Western blot 
analysis. Cells were treated with thrombin (5 U/ml) for 6 hours then stimulated 
with insulin (100 nM) for the last 10 minutes of thrombin treatment. (A) 
Representative blots of phospho- AS160Thr642 and native AS160. (B) Graph 
showing the densitometric analysis of P-AS160 (phospho- AS160Thr642)/N-AS160 
(Native AS160). Values are expressed as the mean ± SEM, n=4, *p<0.05, **p<0.01, 
***p<0.001. 
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4.3.6 Thrombin increases AMPK activation 
To explore the possible mechanisms resulting in increased basal glucose uptake, 
the effect of thrombin on AMPK activation was assessed by measuring AMPKThr172 
phosphorylation.  
As shown in  
Figure  4-5, thrombin significantly increased AMPK activation (p<0.001) compared 
to untreated cells.  
Furthermore, to prove that thrombin mediates its action via AMPK activation, 
compound C, an inhibitor of AMPK, was used. Incubation with 40µM compound C 
for the last 30mins of thrombin treatment resulted in a partial reversal of the 
stimulatory effect of thrombin on AMPK phosphorylation (p<0.01) ( Figure  4-6). 
 
In addition, the decrease in AMPK phosphorylation after compound C treatment 
was also associated with a partial reversal of the stimulatory effect of thrombin on 
glucose uptake (Figure  4-7). Glucose uptake decreased from 813±113.38 
pmol/min/mg after thrombin treatment to 484.6±80.24 pmol/min/mg (p<0.05) after 
treatment with both thrombin and compound C. Taking these data together, 
thrombin increases glucose uptake that is in part mediated by the activation of 
AMPK. 
 
4.3.7 Thrombin increases IL-6 secretion  
From the same experiments that show that thrombin causes an increase in AMPK 
activation, media was kept to measure the effects of thrombin on IL-6 secretion. 
As shown in Figure  4-8, thrombin causes a significant increase in IL-6 liberation 
into the media (p<0.05) compared to non-thrombin treated cells. 
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Figure ‎4-5: Effect of thrombin on AMPK activation in cultured myotubes. AMPK 
activation assessed in myotubes treated with thrombin (5 U/ml) for 6h and 
measurement of AMPKThr172 phosphorylation by Western blot. (A) Shows the 
representative blots of phospho- AMPKThr172 and total AMPK in both thrombin 
and non-thrombin treated cells. (B) Graph of densitometric analysis results of 
AMPK activation at Thr172. Values are expressed as the mean ± SEM, n=5, 
***p<0.001. 
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Figure ‎4-6: Use of the AMPK chemical inhibitor compound C on thrombin-treated 
cells. Cells were treated with thrombin (5‎U/ml)‎for‎6‎hours‎with‎or‎without‎40μM‎
compound C that was added for the last 30 minutes before measuring 
AMPKThr172 phosphorylation by Western blot. (A) Shows the representative blots 
of phospho-AMPKThr172 and total AMPK in both thrombin and compound C 
treated and non-treated cells. (B) Graph of densitometric analysis of AMPK 
activation at Thr172 for the above treatment. Values are expressed as the mean ± 
SEM, n=4, **p<0.01. 
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Figure ‎4-7: Effect of compound C on thrombin induced glucose uptake.Cultured 
human myotubes treated with thrombin (5 U/ml) for 6 hours, and then 40μM‎
compound C was added for the last 30 minutes followed by measurement of 
radiolabelled glucose uptake into cells. The graph is representative of basal 
glucose uptake in skeletal muscle myotubes for control (no thrombin), thrombin 
and thrombin with compound C. Values are expressed as mean ± SEM, n=5, 
*p<0.05. 
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Figure ‎4-8: IL-6 secretion in response to thrombin treatment in human myotubes. 
Graph of the ELISA results of IL-6 secretion from muscle cells in response to 
thrombin treatment, day 7 differentiated myotubes were treated with or without 
thrombin (5 U/ml) for 6 hours then the media collected and IL-6 measured by 
ELISA. Values are expressed as mean ± SEM. n=4, *p<0.05.  
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 Discussion 4.4
The present study provides new insights into the mechanisms of the effects of 
thrombin on insulin signalling and glucose uptake in human skeletal muscle cells. 
These data showed that thrombin, despite interference with the proximal insulin 
signalling pathway, does not downregulate insulin-induced glucose transport, and 
even exerts a positive effect by enhancing basal glucose transport. In addition, it 
was shown that thrombin directly increased glucose uptake with evidence that this 
is facilitated through AMPK activation. 
Glucose is transported into the cell via a family of specialized transporter proteins 
(GLUTs). Different isoforms of GLUT have been identified in human skeletal 
muscle; GLUT1 and GLUT4 are the major contributors to glucose transport in 
basal and stimulated states, respectively. In this study, thrombin was recognised 
to enhance gene expression of both GLUT1 and GLUT4, which would be 
predicted to contribute to the observed increase in both basal and insulin mediated 
glucose uptake. GLUT4 translocation to the cell membrane is the critical step of 
stimulated glucose uptake, therefore measurement of the GLUT4 translocation or 
protein expression of the membrane fraction is considered more important than 
gene expression. However, GLUT4 protein is particularly difficult to detect in 
cultured primary human skeletal muscle cell cultures and so investigating such 
measures would be highly unfeasible in such a cell system. These results suggest 
that thrombin stimulates basal glucose transport by upregulation of GLUT1 gene 
expression in human skeletal muscle cells. Many metabolic effects of thrombin are 
in common with other proinflammatory cytokines used in other studies such as that 
observed by Storz et al. (1999) who used TNF and found that the increase in basal 
glucose uptake is associated with increased protein expression of GLUT1 in 
skeletal muscle cells. 
It is interesting to note that thrombin had inhibitory effects on insulin signalling as 
represented by decreased activation of both IRS1 and Akt phosphorylation. What 
is surprising is that insulin stimulated glucose uptake tended to increase in the 
presence of thrombin however, this was not statistically significant.  
Akt exists at a central hub in the regulation of insulin stimulated glucose uptake but 
a substantial evidence also indicates aPKC acts downstream of PDK1 and 
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displays a role in insulin signalling to GLUT4 translocation (Farese et al., 2005; 
Farese et al., 2007). Additionally, other studies state that aPKC can be activated in 
response to muscle contraction (Chen et al., 2002; Santos et al., 2014). Further 
downward dissection of the signalling pathway towards increased insulin 
stimulated glucose uptake is also required and represented by the direct target of 
Akt, AS160. Therefore experiments were designed to examine the effect of 
thrombin on insulin stimulated phosphorylation of both aPKC and AS160. In the 
current study, no inhibitory effect of thrombin treatment was found with either 
signalling molecule. These findings would suggest that insulin action is not 
inhibited in the presence of thrombin through the activation of both AS160 and 
aPKC that effectively bypasses the inhibitory effect of thrombin on IRS1 and Akt. 
Previous studies in many cell lines report that AMPK activation is involved in 
mediating the function of thrombin. In this study, it was demonstrated that thrombin 
markedly induced the phosphorylation of AMPK α-subunit (Thr172). AMPK is a 
serine threonine heterotrimeric complex that consists of three subunits, α, β and γ, 
and is a kinase that acts as a metabolic sensor and a key regulator of cellular 
energy homeostasis in skeletal muscle and other cells (Hardie et al., 2006). AMPK 
is activated upon any condition that causes the cell to be in a state of decreased 
ATP either from decreased energy production or from an increased consumption. 
Activated AMPK causes switching off of the metabolic processes that cause 
increased energy consumption (protein synthesis, lipid synthesis and glycogen 
synthesis) and simultaneously, switching on the processes that increase energy 
production including glucose uptake (Hardie et al., 2012).  
The increased AMPK activation upon thrombin treatment in human skeletal 
muscle cells is consistent with results obtained from studying different cell lines. In 
vascular endothelium, thrombin directly increases AMPKThr172 phosphorylation and 
activation with an increase in AMPK downstream effects (Thors et al., 2004). In 
platelets, thrombin is a potent platelet activator and plays a central role in platelet 
aggregation and clot retraction (Lundblad and White, 2005), and this activation is 
recognized to be AMPK-mediated (Randriamboavonjy et al., 2010; Onselaer et al., 
2014). In bone forming cells (osteoblasts), chemical inhibition and siRNA AMPK 
  
121 
 
knockdown cause a remarkable reduction in AMPK mediated action (Tokuda et 
al., 2012). 
The increase in AMPK activity in response to thrombin treatment was attenuated 
with the use of an inhibitor of AMPK (compound C). Although compound C is likely 
to inhibit other kinases, in this study it was used at a concentration to ensure 
maximal effects on AMPK action (Bain et al., 2007). The usage of compound C as 
an inhibitor of AMPK activation in human skeletal myotubes in this study, is 
consistent with data obtained from other studies (Thors et al., 2004; Nieto-
Vazquez et al., 2008; Benziane et al., 2012). The observed decrease in AMPK 
activity by using compound C was associated with a decrease in thrombin-
mediated basal glucose uptake.  
Previous studies (Kramer et al., 2006a; Kramer et al., 2006b) have suggested that 
AS160 activation is not restricted to the insulin-Akt pathway but can also be 
activated by the AMPK pathway. It is interesting to note that thrombin causes an 
increase in AS160 phosphorylation at Thr642 in the basal state which is in line with 
the increase in basal glucose uptake after thrombin treatment. 
The role of thrombin in inducing inflammation has been investigated. Thrombin 
can activate cellular signalling in many cell types and can stimulate the production 
of different pro-inflammatory mediators such as cytokines, chemokines and growth 
factors (Ma and Dorling, 2012). Thrombin has been shown to increase IL-6 
production in many tissues including fibroblasts (Chiu et al., 2008), adipocytes 
(Mihara et al., 2010), and bone cells (Tokuda et al., 2012). In reviewing the 
literature, no data was found showing the effects of thrombin treatment on skeletal 
muscle IL-6 release. The current study found that thrombin increased IL-6 
secretion compared to non-thrombin treated cells. A further study with more focus 
on whether AMPK is involved in IL-6 secretion is therefore suggested. 
In conclusion, very little is known about the metabolic effects of hypercoagulation 
(increased thrombin) on insulin signalling and glucose metabolism in human 
skeletal muscle. This is the first study to look at thrombin and insulin 
action/signalling in human skeletal muscle. Thrombin was shown to have multiple 
metabolic effects represented by a decrease in insulin stimulated IRS1 and Akt 
activation which was mediated through PKCα, but thrombin had no effect on the 
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parallel insulin-stimulated aPKC and AS160 pathway. Thrombin directly increased 
glucose uptake through an AMPK mediated mechanism.  
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CHAPTER 5 : EFFECTS OF THROMBIN AND EXERCISE ON 
HUMAN CULTURED SKELETAL MUSCLE MYOTUBES. 
 Introduction  5.1
Exercise and regular physical activity have favourable health benefits, and it is 
reported that regular exercise has an essential role in the prevention and 
treatment of metabolic disease, cardiovascular disease and mental health issues 
(Pedersen and Saltin, 2015). Exercise has both local and systemic benefits, the 
local benefits represented by skeletal muscle growth and positive metabolic 
adaptations whereas the systemic outcomes appear as improvements in 
cardiovascular function and decreased fat mass (Neufer et al., 2015). In an insulin 
resistant state such as T2D, exercise improves whole body glucose tolerance and 
insulin sensitivity (Rogers et al., 1988; Dela et al., 1995). In skeletal muscle cells, a 
single bout of exercise increases glucose uptake (Richter et al., 1989), and 
improves insulin sensitivity in the post-exercise period (Henriksen, 2002). 
For the last few decades, different in vitro models of exercise have been used to 
study the exact molecular mechanisms and the cellular responses as well as the 
therapeutic implications of the exercise. Details about the use of EPS models and 
implications were discussed previously in general introduction in section  1.22.3. 
As mentioned earlier in general introduction section  1.22.1, muscle contraction 
stimulates glucose uptake by increase GLUT4 translocation into the cell surface. 
The particular mechanisms that involve the increase in GLUT4 expression at the 
cell membrane in response to contraction are not fully clarified but it is generally 
believed that AMPK is involved. However, some studies on AMPK knockdown 
mice show a normal increase in GLUT4 expression level at cells membrane in 
response to contraction (Maarbjerg et al., 2009). 
Nedachi et al. (2008) subjected C2C12 myotubes to EPS and showed an increase 
in activation of AMPK and increased glucose transport. Human myotubes in 
culture have also been shown to respond to EPS in a metabolically similar way to 
that of skeletal muscle exercise in vivo. Examples of these metabolic adaptations 
include; activation of AMPK and improvement in glucose uptake and oxidation 
(Lambernd et al., 2012; Nikolić et al., 2012; Christensen et al., 2015; Evers-van 
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Gogh et al., 2015). Even for short-duration, the low frequency model of EPS 
increased AMPK activation compared to resting muscles (Goto-Inoue et al., 2016; 
Miyatake et al., 2016). 
Skeletal muscle myotubes become metabolically active during exercise. Variable 
metabolic activities have been reported in human myotubes in response to EPS 
Contraction-stimulated glucose uptake was markedly elevated in response to EPS 
compared to resting cells in cultured human myotubes (Nikolić et al., 2012; Brown 
et al., 2015a). Furthermore, glycogen metabolism in cultured myotubes is affected 
by EPS. Glycogen content in response to EPS decreased in myotubes (Manabe et 
al., 2012; Farmawati et al., 2013) and this observation is also described in in vivo 
exercise (Jensen and Richter, 2012). Feng et al. (2015) reported that insulin-
stimulated glycogen synthesis in human myotubes was increased after EPS. 
Glucose oxidation is another metabolic characteristic that is shown to increase in 
response to EPS in human myotubes (Nikolić et al., 2012; Feng et al., 2015).  
Currently, it is accepted that skeletal muscle is an endocrine organ that releases a 
variety of myokines. Muscle contraction during exercise is considered a key 
stimulus for both expression and release of myokines such as IL-6 (Steensberg et 
al., 2000) and IL-8 (Steensberg et al., 2007). The use of EPS models as an in vitro 
exercise protocol provides invaluable evidence that skeletal muscle cells per se 
are the definite source of specific myokines. Lambernd et al. (2012) showed that 
IL-6 secretion is significantly increased in response to EPS in cultured human 
muscle cells. Furthermore, Scheler et al. (2013) highlight the significance of 
skeletal muscle cells as an endocrine organ and showed that both IL-8 and IL-6 
are significantly increased in response to EPS both at gene and protein levels in 
cultured human muscle cells.  
Insulin and exercise are the most important metabolic stimuli in skeletal muscle 
cells. Treatment with thrombin was shown to cause multiple metabolic effects on 
insulin signalling and insulin induced glucose uptake in cultured human myotubes. 
Therefore, this study set out to investigate the effects of elevated thrombin and 
EPS on human cultured myotubes, exploring the effects of thrombin on the release 
of inflammatory cytokines (IL-6 and IL-8) in response to EPS. 
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Our hypothesis was that, hypercoagulation that is associated with T2D affects in 
the metabolic response to exercise in skeletal muscle cells.   
Aims of this chapter: 
1- Exploring the effects of thrombin on exercise signalling represented by 
AMPKThr172 in response to EPS. 
2- Examining the effects of thrombin and/or EPS on insulin stimulated glucose 
uptake. 
3- Examining the effects of thrombin and/or EPS on cytokines release from 
cultured skeletal muscle cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
126 
 
 Methods 5.2
5.2.1 Experimental design 
All experiments were performed on passage 6 myotubes on day seven of 
differentiation. Media was changed to serum reduced media (minimal essential 
media supplemented with 0.25 % (v/v) FBS), and the cells either treated with 
thrombin (5U/ml for 6 hours) according to previous optimisation of the dose and 
duration as discussed in sections  3.2.4,  3.2.5 and  3.2.6. After the 6 hour thrombin 
treatment, media was changed to fresh starvation media and 16 hours of EPS 
applied. For glucose uptake experiments, insulin was added at a concentration of 
100 nM for the last 10 minutes of the exercise protocol`.  
5.2.2 In vitro model of exercise (EPS) 
Electrical pulse stimulation (EPS) was performed using a C-Pace EP cell culture 
pacer (IonOptix, Dublin) using a two-step protocol (alternation between a period of 
high frequency and low frequency electrical pulses). Cells were plated in 35mm 
dishes, grown to confluence and differentiated for 7 days. At day 7 differentiation, 
cells were treated as described above before subjecting to EPS. Electrical pulse 
stimulation (EPS) was applied via carbon electrodes at 5 volts, 24 milliseconds, 2 
Hz for 1 hour followed immediately by 5 volts, 24 milliseconds, 0.2 Hz for 1 hour. 
This alternation in frequency was continued for 16 hours (period of exercise), the 
16 hours EPS period has chosen based on previous work in our lab on control 
cultured myotubes showing a maximal AMPK activation after 16 hours EPS 
(Brown et al., 2015a). The following Figure  5-1 shows the photographic picture of 
the C-Pace EP cell culture pacer that used in this experiment. 
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Figure ‎5-1: IonOptix C-PACE electrical stimulator (An in vitro model of exercise). 
(A): is an image of a culture dish electrode used for EPS which is suitable to 
hold 6 individual 35 mm dishes. (B): the C-Pace EP a multi-channel stimulator 
used for EPS of cells in culture. Images captured from (IonOptix, 2011). 
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5.2.3 Glucose uptake 
Seven days differentiated myotubes in 35 mm plates were set into Control and 
thrombin treated cells both were divided into two groups; with or without 16 hours 
EPS at 37 °C in serum reduced media. Subsequently, 2-deoxy-D-[2, 6-3H] glucose 
uptake was measured as described previously in general Materials and Methods 
chapter, section  2.9. 
5.2.4 Western blot 
After 16 hours incubation with or without EPS, western blot was performed as 
described previously in general Materials and Methods chapter, section  2.8. The 
non-specific sites on the nitrocellulose membranes were blocked by incubation in 
Tris buffered saline tween (TBST) containing 5% (w/v) milk as a blocking buffer for 
1 hour. Membranes were incubated with monoclonal primary antibody (1°Ab) 
diluted in 0.5% blocking buffer, overnight at 4 °C. Phospho AMPK antibodies were 
used at a 1:1000 dilution while native AMPK was 1:2000. 
5.2.5 Measurement of lactate dehydrogenase (LDH) release 
Lactate dehydrogenase levels were measured in the media from cells with or 
without thrombin and subjected to -/+ 16 hours exercise (EPS) and -/+ compound 
C using the colorimetric Lactate Dehydrogenase kit (PromoKine). Cells were 
incubated in serum reduced media then treated with or without thrombin for 6 
hours and with or without 40 μM compound C that was added for the last 30 
minutes of thrombin treatment. Media was then changed to fresh media to start the 
exercise protocol. After 16 hours of EPS, media was collected and LDH release 
into the media was determined colorimetrically at 450 nm according to the 
manufacturer’s instructions. LDH release was measured as described in general 
Materials and Methods chapter, section  2.12. 
5.2.6 ELISA 
Secretion of IL-6 and IL-8 was determined by enzyme-linked immunosorbent 
assay (ELISA) using the Single-Analyte ELISArray (Qiagen). After 7 days of 
differentiation, media was changed to serum-reduced MEM, and cells were treated 
or untreated with 5U/ml thrombin for 6 hours after which fresh media was put on 
cells. Cells were then either subjected to EPS or kept in the incubator for 16 hours. 
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After EPS, media was removed, centrifuged at 1000g for 10 minutes and assayed 
for secretion of IL-6 and IL-8 according to the manufacturer’s protocol that 
described in general Materials and Methods chapter, section  2.11. 
 
 Results 5.3
5.3.1 AMPK activation in response to 16 hours EPS 
AMP-activated protein kinase (AMPK) is key sensor of energy status in skeletal 
muscle and is activated during exercise. AMPK activation was measured by 
Western blot using phospho-specific antibodies against Thr172, phosphorylation of 
which is essential for the full activity of the kinase (Scott et al., 2002). Figure  5-2 
shows that, in non-thrombin treated cells, phosphorylation was increased 
significantly after 16 hours EPS (p<0.01). In contrast, thrombin treated myotubes 
subjected to the same EPS protocol showed no activation of AMPK over its basal 
activity. Thrombin was shown to significantly increase basal AMPK activation 
compared to control non-thrombin treated myotubes (p<0.001). However, there 
was no further activation of the thrombin treated cells in response to EPS, 
however,  AMPK activation in these cells was still significantly higher than resting 
control muscle (p<0.001).  
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Figure ‎5-2: Effects of EPS and thrombin on AMPK activation. (A) Shows the blots 
of AMPK activation at Thr172 for basal and 16 hours EPS with and without 
thrombin, cells were treated with thrombin (5 U/ml) for 6 hours then subjected to 
EPS or kept in incubator. (B) The results of densitometry analysis of P-
AMPK/total AMPK for both thrombin and non-thrombin treated cells with or 
without exercise (16 hours EPS). Values are expressed as mean ± SEM. n = 4, 
**p< 0.01, ***p< 0.001 comparing to the basal untreated myotubes. 
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5.3.2  Glucose uptake 
To examine the metabolic effects of the in vitro exercise protocol (16 hours EPS), 
radiolabelled glucose uptake was measured in both thrombin and non-thrombin 
treated myotubes.  
As shown in Figure  4-5 (A), in non-thrombin treated cells, insulin increased 
glucose uptake significantly (p< 0.05) over basal. Furthermore, 16 hours EPS also 
caused a significant increase in glucose uptake over basal (p< 0.05). Additionally, 
an additive effect was observed when cells were stimulated with both insulin and 
16 hours EPS with a significant increase observed over both basal (p<0.001) and 
insulin alone (p<0.05).  
In thrombin treated myotubes, there was an increase in basal glucose uptake 
compared to non-thrombin treated myotubes (p< 0.01). In addition, as we showed 
previously in chapter 3, insulin-stimulated glucose uptake did not increase over 
basal in thrombin-treated cells. In addition, 16 hours EPS failed to stimulate an 
increase in glucose uptake over basal to a significant level as observed in non-
thrombin treated cells. Thrombin treatment caused myotubes to lose the additive 
effects of insulin and 16 hours EPS observed in non-thrombin treated cells. There 
were no statistical differences comparing absolute levels of glucose uptake in 
response to insulin, 16 hours EPS and insulin plus 16 hours EPS between 
thrombin and non-thrombin treated myotubes.  
By calculating fold change (glucose uptake in response to stimulus over basal) 
Figure  5-3 (B) shows that there was a significant difference in fold change with 
insulin and EPS together in thrombin treated versus non-treated cells (p< 0.05). 
No such differences were observed in fold change for insulin or EPS alone. 
  
132 
 
 
Figure ‎5-3: Effects of EPS and thrombin on glucose uptake in myotubes. Both 
thrombin treated and control (non-thrombin treated) with or without 16 h EPS 
and with or without 100 nM insulin for 10 min. (A) Graph shows the absolute 
glucose uptake values in non-thrombin and thrombin treated myotubes in basal, 
insulin, 16 hours EPS and insulin plus EPS. (B) Graph representative of the fold 
ratio in glucose uptake with stimulus over the basal in both control and 
thrombin treated myotubes. Values are expressed as the mean ± SEM, n = 5, *p< 
0.05, **p< 0.01.
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5.3.3 Lactate dehydrogenase (LDH) release 
As described in Chapter 4, section  4.3.6, thrombin was shown to increase both 
AMPK and basal glucose uptake, while compound C partially reversed these 
effects.  For the current experiment, the design was similar to that described 
previously  4.2.1. Myotubes were treated with thrombin (5 U/ml for 6 hours) and for 
the last 30 minutes, 40μM compound C was added. Fresh starvation media was 
added to cells before 16 hours EPS. The results of 3 successive experiments 
showed cell death in dishes treated with combination of thrombin and compound C 
as noted morphologically (under microscopic examination) and by examining  LDH 
release as an indicator of cytotoxicity. LDH assay results showed that the 
combination of thrombin and compound C for the given time followed by EPS 
caused cell death as shown in Figure  5-4 (A). There was a pronounced difference 
between cells treated with a combination of thrombin and compound C together 
compared to that with or without thrombin whether they were subjected to EPS or 
not (p<0.05). Morphological changes were noted in cells treated with a 
combination of thrombin and compound C, cells looked unhealthy and adopted 
rounded shapes and eventually become suspended in the culture media, whereas, 
myotubes without compound C treatment remained healthy looking and attached 
to the bottom of the plates with an elongated spindle shape (Figure  5-4 B). 
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Figure ‎5-4: LDH cytotoxicity release in response to EPS and compound C 
treatment in cultured myotubes. LDH release from the cells into the media was 
used as a sign of cytotoxicity, cells were either control (non-thrombin treated) or 
treated‎with‎thrombin‎for‎6‎hrs‎and‎for‎the‎last‎30‎minutes,‎40μM‎compound‎c‎
was added then media changed to fresh starvation media before 16 hours EPS. 
(A) Graph of LDH release in arbitrary units with different treatments. Values are 
expressed as the mean ± SEM, n = 3, *p< 0.05. (B) Representative light 
microscope images of myotubes cultures after 16 hours EPS without or with 
thrombin ± compound C.  
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5.3.4 Cytokine release 
Skeletal muscle produces cytokines in response to contraction. The effect of EPS 
on IL-6 and IL-8 secretion is shown in Figure  5-5  and Figure  5-6. Basal IL-6 
release was significantly higher in thrombin-treated compared with non-thrombin 
treated cells (p<0.05). EPS increased IL-6 secretion in non-thrombin treated cells. 
Thrombin was shown to inhibit further increase of IL-6 secretion in response to 
EPS over basal levels. IL-8 showed a similar pattern to that noted for IL-6, when 
addition of thrombin caused a significant increase in basal IL-8 secretion into the 
media compared to non-thrombin treated cells (p<0.05). 16 hours EPS caused a 
significant increase in IL-8 secretion into the media only in control non-thrombin 
treated cells (p<0.05), while no further increase in cytokine release in thrombin-
treated cells subjected to EPS was observed.  
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Figure ‎5-5: IL-6 secretion in response to EPS and thrombin cultured 
myotubes.Fresh media was added to 4 controls and 4 thrombin treated cultures 
and subjected to EPS for 16 hours. Media was collected and assayed for IL-6 
secretion by ELISA. (A) Represents a standard curve of IL-6 prepared from 
provided standard IL-6 which was diluted by serial dilution. (B) Normalised IL-6 
secretion to total protein content of the cells. Results are expressed as mean ± 
SEM. n=4, * p<0.05. 
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Figure ‎5-6: IL-8 secretion in response to EPS and thrombin cultured myotubes. 
Fresh media was added to 4 controls and 4 thrombin treated cultures and 
subjected to EPS for 16 hours. Media was collected and assayed for IL-8 
secretion by ELISA. (A) Represents a standard curve of IL-8 prepared from 
provided standard IL-8 which was diluted by serial dilution. (B) Normalised IL-8 
secretion to total protein content of the cells. Results are expressed as mean ± 
SEM, n=4, *p<0.05, **p<0.01. 
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 Discussion 5.4
Thrombin is a serine protease enzyme that carries out a variety of biological 
processes, as well as its role in coagulation, such as cell division, cancer growth, 
and inflammation. T2D is regarded as a hypercoagulable state. An elevated 
thrombin level has been recognised in association with metabolic abnormalities of 
T2D like hyperglycaemia and hyperinsulinemia (Carr, 2001). In chapters 3 and 4, 
thrombin was shown to have effects on the insulin signalling pathway and glucose 
uptake in cultured human myotubes. The aims of this chapter were to assess the 
effects of thrombin on exercise related metabolic and signalling events. The most 
obvious findings to emerge from the study are that AMPK activation and glucose 
uptake increase in response to EPS in non-thrombin treated myotubes, and EPS 
enhanced the effect of insulin on glucose uptake. Treatment with thrombin 
increased basal AMPK activation, glucose uptake and cytokine release, and these 
effects were not significantly increased by EPS.  
EPS is an in vitro model system for exercising cultured muscle cells. The use of 
EPS gave the great opportunity to explore the intrinsic mechanisms of exercise in 
skeletal muscle cells, while excluding the systemic and serum factors that might 
have an impact on metabolism in response to physical activity. The low frequency-
long duration EPS used in this study is similar to that used in many other studies 
(Lambernd et al., 2012; Nikolić et al., 2012; Brown et al., 2015a) as in vitro model 
that can mimic some of the effects of exercise seen in whole body studies. 
AMPK is activated in response to contraction in skeletal muscle and mediates 
insulin independent glucose uptake (Mu et al., 2001). In the current study, 
stimulation of cultured human control myotubes by EPS leads to an increase in 
AMPKThr172 phosphorylation. These results are consistent with data obtained from 
other studies using the EPS system in both  mouse C2C12 myotubes (Nedachi et 
al., 2008; Manabe et al., 2012) and human cells (Lambernd et al., 2012; Brown et 
al., 2015b; Christensen et al., 2015). In thrombin treated cells, thrombin was 
shown to significantly increase basal AMPK activation, with no further activation 
after EPS. The possible explanations for this might be that AMPK activation with 
thrombin reached maximal activation and cannot rise beyond this point. 
Supporting this opinion is that AMPK phosphorylation with thrombin under basal 
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conditions was comparable to that seen in EPS subjected cells in the absence of 
thrombin (Figure  5-2). The other possible explanation is that, thrombin inhibits 
further activation of AMPK above basal activity. 
The early metabolic response of skeletal muscle cells to exercise is to increase 
glucose uptake. Previous studies on cultured muscle cells have shown that EPS 
boosts glucose uptake (Nikolić et al., 2012; Brown et al., 2015a). The results of 
this study in control non-thrombin treated cells are consistent with these previous 
reports, and the increase in glucose uptake in response to EPS is similar to that 
observed in response to in vivo exercise. EPS failed to stimulate glucose uptake to 
a significant level above basal in thrombin treated cells. It is interesting to note that 
basal glucose uptake in response to thrombin treatment was significantly higher 
than non-thrombin treated cells. It could be argued that the positive effect of EPS 
on glucose uptake is lost upon thrombin treatment, although no significant 
statistical differences in the response to EPS between thrombin treated and non-
treated cells was observed. These results are consistent with the AMPK data that 
also fails to increase with EPS in thrombin-treated cells.  
Exercise and insulin increase glucose uptake in skeletal muscle using two 
independent pathways. Both a single bout of exercise and exercise training are 
reported to enhance insulin action in human skeletal muscle (Howlett et al., 2002; 
Hawley and Lessard, 2008). In line with these observations, glucose uptake in 
non-thrombin treated myotubes increased in response to insulin or EPS and there 
was an additive effect of insulin plus EPS over insulin alone. These results are in 
agreement with those obtained by Brown et al. (2015a). 
In cells treated with thrombin, the ability of insulin or EPS to increase glucose 
uptake was lost. The insulin sensitising effect of EPS on glucose uptake was also 
absent. Thrombin appears to impair the beneficial effect of EPS (increasing 
glucose uptake) in skeletal muscle cells. 
Results in chapter 4 showed that compound C AMPK inhibitor can reverse the 
stimulatory effect of thrombin on AMPK activation and could also partially reduce 
the thrombin-mediated increase in basal glucose uptake. Studies in this chapter 
suggested that thrombin inhibited the effects of EPS in cultured skeletal muscle 
cells. Therefore, myotubes were treated with compound C to assess if AMPK 
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inhibition could reverse the thrombin inhibitory effects in response to EPS. The 
combination of thrombin and compound C treatment together with EPS was 
detrimental to cell health and caused cell death as confirmed by LDH enzyme 
release and microscopically.  
It is not surprising to know that compound C is cytotoxic and has been used in 
cancer research to inhibit cancer growth and induce cell death in different tumor 
cells (Jin et al., 2009; Yang et al., 2012). The inhibitory effects of compound C in 
chapter 4 without any signs of cell death could be due to the short duration of 
compound C application (30 minutes) followed by immediate assay. However, the 
use of compound C in this study was involved keeping cells for another 16 hours 
for EPS.  
Exercise is a positive regulator for many metabolic parameters, and currently, the 
role of skeletal muscle contraction in elevated serum cytokines during exercise is 
accepted. Skeletal muscle cells express and secrete different proteins (cytokines) 
during and shortly after muscle contraction which are known as myokines 
(Febbraio and Pedersen, 2005). Some of these cytokines could be involved as 
essential factors for mediating the health promoting effects of exercise (Pedersen 
and Febbraio, 2012).  
IL-6 and IL-8 secretion were chosen to be investigated in response to in vitro 
exercise for many reasons such as; both cytokines are shown to increase in 
response to exercise (Peake et al., 2015). The Gene sets of these 
proinflammatory cytokines are shown to be upregulated in diabetic myotubes 
compared to control (Brown et al., 2015b). Finally, both cytokines are involved in 
thrombin effects on different cell lines.  
The current study found that both IL-6 and IL-8 release from non-thrombin cultured 
cells are increased in response to EPS. These results are in accord with studies 
indicating that in vitro exercise causes an increase in IL-6 and IL-8 secretion from 
skeletal muscle (Lambernd et al., 2012; Scheler et al., 2013).  
Cytokine release in response to thrombin treatment is disturbed. Thrombin 
increases the release of IL-6 and IL-8 significantly, and the increase in cytokine 
release after EPS that is noted with non-thrombin treated cells is lost.  
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The increase of cytokine release with thrombin has been reported before with 
other cell types but, this could be the first study highlighting the increase in 
cytokine release after thrombin treatment in skeletal muscle cells. Thrombin has 
been shown to stimulate IL-6 production in different cell types including fibroblasts 
(Chiu et al., 2008) and adipocytes (Mihara et al., 2010). Additionally, IL-8 
production has been shown to rise in response to thrombin in human lung 
epithelial cells (Lin et al., 2015) and cultured human fetal astrocytes (Simmons et 
al., 2013). 
In conclusion, this is the first study looking at the effects of thrombin in cultured 
human skeletal muscle subjected to an in vitro exercise protocol. The metabolic 
changes with EPS were no longer apparent in the presence of thrombin. The 
increase in AMPK activity, elevation of glucose uptake and the rise in cytokine 
release (above basal values) in response to EPS that were noted with non-
thrombin treated muscle cells are lost upon thrombin treatment. Additionally, 
myotubes respond to thrombin by increasing basal activity of multiple metabolic, 
signalling and inflammatory pathways. Thus, hypercoagulation associated with 
diabetes could be involved in multiple metabolic effects in skeletal muscle 
including insulin signalling, exercise signalling, proinflammatory pathways, and 
glucose uptake.  
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CHAPTER 6 : EFFECTS OF IN VITRO ELECTRICAL PULSE 
STIMULATION (EPS) ON CULTURED DIABETIC HUMAN MUSCLE 
CELLS.  
 Introduction  6.1
T2D is a worldwide health problem that is rapidly growing (da Rocha Fernandes et 
al., 2016). Resistance to insulin action in addition to reduced insulin secretion are 
the cardinal features of T2D subjects. Skeletal muscle is the main organ that 
accounts for insulin resistance, as it is responsible for more than 80% of glucose 
disposal after meals in response to insulin secretion (DeFronzo et al., 1981; 
Thiebaud et al., 1982). The principal function of insulin in skeletal muscle of a 
normal glucose tolerant individual is the enhancement of glucose uptake and 
metabolism. In general, it is accepted that in T2D individuals, insulin loses its 
ability to facilitate glucose uptake into skeletal muscle in vivo (DeFronzo et al., 
1985; Hepburn et al., 1994). This defect in insulin action has also been reported in 
cultured diabetic skeletal muscle cells (Henry et al., 1995; McIntyre et al., 2004; 
Brown et al., 2015b).  
The phenotypic characteristics of the native skeletal muscle fibres are retained in 
multinucleated myotubes in culture (van der Ven et al., 1992), which attracted 
researchers to use muscle cell cultures from different pathological conditions as 
well as from healthy control subjects. These cultures are subjected to the same 
standardised conditions and excluding the possible interfering systemic and serum 
factors, the defects that emerged reflects the intrinsic phenotypic abnormalities. 
There is a growing body of literature comparing human myotubes from diabetic 
versus non-diabetic control subjects in terms of metabolic and signalling pathways 
(McIntyre et al., 2004; Chen et al., 2005; Brown et al., 2015b).  
High levels of regular physical activity are associated with a lower incidence of 
diseases such as T2D, cancer, obesity, hypertension, and depression. Physical 
exercise is demonstrated to reverse the metabolic abnormalities associated with 
insulin resistance and T2D, especially regular exercise training (Knowler et al., 
2002; Haskell et al., 2007). In skeletal muscle, exercise corrects the metabolic 
defects associated with diabetes via different pathways that include AMPK 
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activation and increased/decreased gene expression and/or protein synthesis 
leading to an enhancement in insulin sensitivity (Stallknecht et al., 2000; Hawley, 
2002; Park et al., 2002). Acute exercise and regular exercise training are regarded 
as a first line treatment in the prevention of obesity and/or T2D (Henriksen, 2002; 
Zanuso et al., 2010).  
For the last few decades, in vitro models of exercise have been performed using 
skeletal muscle fibres activated by nerve impulse and more recently by electrical 
pulse stimulation (EPS) of cultured myotubes. EPS provides researchers the 
opportunity to study the molecular mechanism of exercise under completely 
controlled conditions in both animal and human muscle cells (Fujita et al., 2007; 
Burch et al., 2010). 
The use of EPS in human myotubes has been reported to increase in glucose 
uptake and improve metabolic activity (Nikolić et al., 2012). AMPK has been 
reported to be activated in response to EPS in both mouse C2C12 myotubes and 
human myotubes (Nedachi et al., 2008; Lambernd et al., 2012). Feng et al. (2015) 
used the EPS system with diabetic myotubes to examine some metabolic process 
associated with insulin sensitivity like glycogen synthesis. Glycogen synthesis was 
shown to be unaffected by EPS in both control and T2D myotubes, whereas 
insulin-stimulated glycogen synthesis after EPS was increased in myotubes of 
T2D compared to control. Feng et al. (2015) didn’t explore whether these effects 
involved AMPK activation. No previous studies have examined the effects of EPS 
on AMPK activation in cultured human diabetic myotubes. 
The insulin sensitisation effect is a crucial health benefit of exercise. Exercise-
mediated enhancement of glucose uptake is preserved for 2–3 hours post-
exercise. Furthermore, after a single bout of exercise, enhanced insulin sensitivity 
at the level of both skeletal muscle and whole body is retained for up to 24-48 
hours (Cartee et al., 1989; Cartee and Holloszy, 1990; Arias et al., 2007). In 
skeletal muscle cells the enhancement of insulin sensitivity can be demonstrated 
in two forms; the first is the preservation of the increased insulin mediated glucose 
uptake, and the second is the increased phosphorylation and activation of kinases 
that mediate insulin action after exercise. Studies on isolated muscles show that 
the enhancement in insulin sensitivity is independent of increased blood flow or 
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other systemic influences (Gulve et al., 1990; Hamada et al., 2006), and the same 
was observed in cultured muscles subjected to EPS which show increased insulin 
stimulated glucose uptake (Brown et al., 2015a) and increased insulin stimulated 
glycogen synthesis (Feng et al., 2015).  
The exact molecular mechanisms by which the beneficial effects of exercise are 
mediated in skeletal muscle are still not clearly defined. The enzyme AMPK plays 
an essential role in the cellular response to exercise, where AMPK is activated in 
the cellular state in which the cell is in need of energy as observed in exercise ( 
decreased  ATP and increased AMP/ADP) (Hardie and Sakamoto, 2006). The 
exact status of AMPK activity and expression in skeletal muscle of diabetic and 
insulin resistant subjects is still controversial. Therefore, an in vitro exercise 
protocol using human skeletal myotubes from T2D and control subjects was 
established in order to examine clearly the activation of AMPK, and the increase in 
cellular glucose uptake and cytokine levels, and most importantly the insulin 
sensitising effects in response to exercise. Under these highly regulated conditions 
the effects of other factors such as serum factors that could change in response to 
exercise in an in vivo exercise protocol could be excluded.  
Our hypothesis was that, contraction mediated metabolic responses is preserved 
in cultured human skeletal muscle cells obtained from T2D individuals using EPS 
as an in vitro model to exercise cultured cells.  
Aims of this chapter: 
1- Exploring the activity of AMPK in diabetic versus control at basal and in 
response to EPS. 
2- Examining the effects of EPS and/or insulin on glucose uptake in diabetic 
versus control cultured skeletal muscle cells. 
3-Examining the effects of EPS and/or insulin on distal insulin signalling pathway 
(AS160 activation) in diabetic versus control cultured skeletal muscle cells. 
4- Examining the effects of EPS on cytokines release diabetic versus control 
cultured skeletal muscle cells.  
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 Materials and methods 6.2
6.2.1 Study subjects  
Muscle biopsies were taken from T2D subjects with strong clinical evidence of 
insulin resistance. To specify, all patients were taking >100 U insulin/day and had 
at least one first-degree relative with T2D. After diagnosis, patients had been 
treated with diet and oral hypoglycaemic drug for more than 3 years before starting 
insulin. All enrolled patients had a body mass index (BMI) < 32 kg/m2 to exclude 
the effects of marked obesity. Skeletal muscle biopsies were also taken from six, 
age and BMI-matched nondiabetic control subjects with no family history of T2D. 
Metabolic and anthropometric features of recruited subjects have been 
documented before (McIntyre et al., 2004; Brown et al., 2015b). The following 
Table  6-1 shows the clinical characteristics of subjects from which muscle cells 
were taken. 
Table ‎6-1: Metabolic and anthropometric characteristics of subjects of study. 
   
 Data are presented as means ± SE; T2D vs. control. T2D subjects had 
significantly higher Hb A1c, waist/hip ratio, and triglycerides. Controls had 
significantly higher total cholesterol. **P< 0.01; *P< 0.05.  
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6.2.2 Cell culture 
Muscle biopsies were obtained from the vastus lateralis muscle of diabetic 
subjects by needle biopsy under local anesthesia while control muscle was 
obtained from the vastus lateralis muscle at the time of hip surgery under general 
anesthesia and the cells isolated and purified as mentioned in sections  2.5 
and  2.5. All experiments were performed on cells at passages 6 and 7 on day 7 
differentiated myotubes. 
6.2.3 In vitro model of exercise (EPS) 
Electrical pulse stimulation (EPS) was performed using a C-Pace EP cell culture 
pacer (IonOptix, Dublin) using a two-step protocol (alternation between a period of 
high frequency and low frequency electrical pulses). Cells were plated on 35mm 
dishes, grown to confluence and differentiated by changing the media to 
differentiation media. At day 7 of differentiation, media was changed to starvation 
media and electrical pulse stimulation (EPS) applied via carbon electrodes at 
5volts, 24ms, 2 Hz for 1 hour followed immediately by 5V, 24ms, 0.2Hz for 1h. 
This alternation in frequency was continued for 16 hours (period of exercise). 
6.2.4 Glucose uptake 
Measurement of 2-deoxy-D-[2, 6-3H] glucose uptake was carried out as described 
in Materials and Methods chapter section  2.9, and was performed on day 7 
differentiated cells in 35 mm plates. Cells were divided into two groups for 
treatment; with or without 16 hours EPS at 37 °C. 
6.2.5 Western blot 
After 16 hours incubation with or without EPS, protein was extracted and western 
blotting was carried out as mentioned in Materials and Methods, section  2.8, with 
the following differences. Non-specific sites on the nitrocellulose membranes were 
blocked by incubation in Tris buffered saline tween (TBST) containing 5% (w/v) 
milk as a blocking buffer for 1 hour for AMPK and 3% (w/v) BSA for AS160 at 
room temperature. Membranes were incubated with monoclonal primary antibody 
(1°Ab) diluted in 0.5% blocking buffer TBST/0.5% (w/v) milk or BSA, overnight at 4 
°C. After washing, membranes were incubated with a horseradish peroxidase 
(HRP) conjugated secondary antibody IgG, diluted in 0.5% blocking buffer. 
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Detection took place using enhanced chemiluminescence and densitometry 
measurements performed using the Bio-RAD Molecular Imager GS-800 calibrated 
densitometer and Quantity One software. Phospho-AMPK, native AMPK and 
native AS160 antibodies were used at a 1:1000 dilution and phospho-AS160 was 
used at a 1:500 dilution. 
6.2.6 ELISA 
Secretion of IL-6 and IL-8 were determined by enzyme-linked immunosorbent 
assay (ELISA) using the Single-Analyte ELISArray (Qiagen). Media was changed 
to starvation media and the day 7 differentiated cells were either subjected to EPS 
or kept in the incubator for 16 hours. After 16 hours EPS, media was removed, 
centrifuged at 1000g for 10 minutes and assayed for secretion of IL-6 and IL-8 
according to the manufacturer’s protocol and described in detail in Materials and 
Methods section  2.11.  
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  Results 6.3
6.3.1 Effects of EPS on glucose uptake in control and T2D myotubes  
To examine the metabolic effects of the in vitro exercise protocol (16 hours EPS), 
radiolabelled glucose uptake was measured in both diabetic and non-diabetic 
(control) myotubes.  
As shown Figure  6-1 (A), in non-diabetic myotubes, there was a statistically 
significant increase in glucose uptake in response to insulin from 539.8±42.1 to 
744.3±59.3 pmol/min/mg (p< 0.05). Furthermore, 16 hours EPS had the same 
effect in these cells when it caused an increase in glucose uptake to significant 
level 782.9±68.1 pmol/min/mg over basal uptake (p< 0.05). There is an additive 
effect of combining insulin and 16 hours EPS on glucose uptake to a highly 
significant level 931±58.7 pmol/min/mg over basal (p< 0.001) and to a significant 
level as well over insulin stimulated glucose uptake (p< 0.05). 
In diabetic myotubes Figure  6-1(A), the level of glucose uptake in response to 16 
hours EPS was 736.5±59.3 pmol/min/mg which is comparable to that of the control 
cells. However, unlike the control cells, the increase in glucose uptake in response 
to 16 hours EPS against basal uptake, which was 644.7±51.6 pmol/min/mg, did 
not reach to significance level due to the higher basal glucose uptake in diabetic 
myotubes. In addition, insulin failed to stimulate an increase in glucose uptake 
(670.5±45.7 pmol/min/mg) over basal glucose uptake. EPS in combination with 
insulin did not increased glucose uptake in comparison to insulin alone. Due to an 
increase in basal glucose uptake in diabetic cells, the expression of fold changes 
of stimulus (insulin, 16 hours EPS and insulin plus 16 hours EPS) over basal 
glucose uptake were examined.  
In Figure  6-1(B) the fold changes of insulin over basal glucose uptake in control 
cells was 1.4 fold which is significantly higher than that 1.1 fold observed in 
diabetic (p< 0.01). The same was observed for insulin plus 16 hours EPS; the 1.5 
fold increase was significantly higher (p< 0.01) in control compared to1.1 fold 
increase observed in the diabetic myotubes.  
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Figure ‎6-1: Glucose uptake in both control and diabetic myotubes with or without 
16 hours EPS and with or without 100 nM insulin for 10 minutes. (A) Graph 
shows the glucose uptake in control and diabetic myotubes at basal levels, after 
insulin stimulation, 16 hours EPS and insulin plus 16 hours EPS. (B) Graph 
representative of the fold changes in glucose uptake with stimulus over basal in 
both control and diabetic. Values are expressed as the mean ± SEM, n=6 for 
each group, *p< 0.05, **p< 0.01, ***p< 0.001. 
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6.3.2 AMPK activation in control and diabetic myotubes after EPS 
AMP-activated protein kinase (AMPK) is a key sensor of energy status in skeletal 
muscle. AMPK activation was measured by western blot using phospho-specific 
antibodies against threonine residue (Thr172), and activation is essential for the full 
activation of the kinase activity (Scott et al., 2002).  
As shown in Figure  6-2, in control myotubes cultures, phosphorylation of 
AMPKThr172 was shown to increase significantly with 16 hours EPS (p<0.01). In 
contrast, diabetic myotubes subjected to the same EPS protocol showed no 
activation of AMPK over basal. There was a significant increase in AMPK 
activation in the basal state in the diabetic versus control cultures (p<0.01). 
However, there was no further activation of AMPK in the diabetic cells in response 
to exercise. However, AMPK activation in diabetic cells was still significantly higher 
than in resting control muscle (p<0.05).  
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Figure ‎6-2: AMPK activation in response to 16 hours EPS in cultured myotubes.    
(A) Shows the blots of AMPK activation at Thr172 for basal state after 16 hours 
EPS for both control and diabetic. (B) Graph represents the densitometric 
analysis results of phospho/total AMPK for both control and diabetes with and 
without 16 hours EPS. Values are expressed as the mean ± SEM, n=6 for each 
group, *p< 0.05, **p< 0.01. 
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6.3.3 Effects of EPS on AS160Thr642 phosphorylation in control and T2D 
myotubes  
AS160 is the direct downstream signalling molecule of Akt, activated by insulin 
and responsible for an increase in glucose uptake. The effect of 100 nM insulin, 16 
hours EPS and a combination of both insulin and EPS on AS160 activation were 
investigated by Western blot measuring Thr642 phosphorylation. Thr642 is one of 
the most important phosphorylation sites activated by Akt. 
Figure  6-3 shows that in control myotubes, insulin significantly increased AS160 
activation by increasing Thr642 phosphorylation compared to the basal state 
(p<0.01). In addition, there was an additive effect of insulin and EPS together over 
insulin alone (p<0.05). In diabetic cells, insulin increased AS160 phosphorylation 
to a significant level (p< 0.01) compared to basal, but there was no additive effect 
of the combination of insulin and exercise on Thr642 phosphorylation. Furthermore, 
there was a significant difference between control and diabetic myotubes after 
stimulation with a combination of both insulin and EPS with increased activation of 
AS160 in control compared to diabetic myotubes (p< 0.01). 
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Figure ‎6-3: AS160Thr642 activation in cultured myotubes. (A) Shows the blots of 
AS160 activation (phosphorylation) on AS160Thr642 for cells subjected to the 
following conditions; rest (basal), 100 nM insulin for 10 minutes, 16 hours EPS, 
and a combination of 16 hours EPS and 10 minutes insulin at the end of EPS for 
both control and diabetic myotubes. (B) Graph represents the densitometric 
analysis results of phospho Thr642/native AS160 for both control and diabetes 
for the same conditions. Values are expressed as the mean ± SEM, n=6 for each 
group, **p< 0.01, ***p< 0.001.  
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6.3.5 Effects of EPS on AS160Ser588 phosphorylation in control and T2D 
myotubes: 
AS160Ser588 is the other direct downstream target site of Akt, activated by insulin 
and responsible for an increase in glucose uptake. The effect of 100 nM insulin, 16 
hours EPS and the combination of EPS and insulin on AS160Ser588 activation was 
investigated by Western blot measuring Ser588 phosphorylation in both control and 
diabetic myotubes.  
As can be observed in Figure  6-4, insulin significantly increased AS160Ser588 
phosphorylation above basal in control cells but not in diabetic myotubes, and 
there was a significant difference (p<0.05) between control and diabetic cells in 
response to insulin stimulation. Furthermore, in control myotubes 16 hours EPS 
significantly increased AS160 activation by increasing Ser588 phosphorylation 
compared to basal (p< 0.05), but there was no additive effect observed by 
combining EPS and insulin. In diabetic cells, EPS alone did not increase 
AS160Ser588 phosphorylation, and did not enhance insulin stimulated S588 
phosphorylation. 
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Figure ‎6-4: AS160Ser588 activation in cultured myotubes. (A) Shows the blots of 
AS160 activation (phosphorylation) of AS160 Ser588 for cells subjected to the 
following conditions; rest (basal), 100 nM insulin for 10 minutes, 16 hours EPS, 
and a combination of 16 hours EPS followed by 10min insulin treatment for both 
control and diabetic myotubes. (B) Graph represents the densitometric analysis 
results of phospho S 588 /native AS160 for both control and diabetes for the 
same conditions. Values are expressed as the mean ± SEM, n=6 for each group, 
*p< 0.05.  
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6.3.7 Effects of EPS on Cytokines release in control and T2D myotubes 
Skeletal muscle produces cytokines in response to contraction. The effect of EPS 
on IL-6 and IL-8 secretion is shown in Figure  6-5 and Figure  6-6. IL-6 secretion 
was significantly increased from both control and diabetic myotubes after 16 hours 
EPS (p<0.05). There was no difference in IL-6 secretion levels between control 
and diabetic myotubes. The same pattern was observed with IL-8 secretion, the 
increase in IL-8 secretion observed from the control and diabetic myotubes after 
16 hours EPS compared to basal resting corresponding cultures was statistically 
significant (p<0.05). The values of both IL-6 and IL-8 secretion were normalised to 
total protein concentration.  
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Figure ‎6-5: Effects of EPS on IL-6 secretion in control and diabetic  cell cultures. 
Fresh reduced serum media was added to 6 controls and 6 diabetic cultures and 
subjected to EPS for 16 hours. Media was collected and assayed for IL-6 
secretion by ELISA. The graph represents the IL-6 secretion into the media in 
response to contraction normalised to the total protein concentration of the 
cells. Results are expressed as mean ± SEM. * p<0.05.  
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Figure ‎6-6: Effects of EPS on IL-8 secretion in control and diabetic cell cultures. 
Fresh reduced serum media was added to 6 controls and 6 diabetic cultures and 
subjected to EPS for 16 hours. Media was collected and assayed for IL-8 
secretion by ELISA. The graph represents the IL-8 secretion into the media in 
response to contraction normalised to the total protein concentration of the 
cells. Results are expressed as mean ± SEM. * p<0.05. 
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 Discussion 6.4
Glucose uptake in skeletal muscle is achieved by distinct ways; insulin signalling 
and contraction, or exercise-related pathways are involved. In T2D, skeletal 
muscle is characterized by decreased insulin sensitivity which is associated with a 
decrease in glucose uptake in response to insulin (Zierath et al., 1996; Bennett et 
al., 2000; Brown et al., 2015b). The contraction mediated or exercise mimetic-
mediated (AICAR) glucose uptake in these cells has been reported to be 
preserved (Lee et al., 1995; Lund et al., 1995; McIntyre et al., 2004).  
To date, there are few studies that have investigated the effects of EPS in human 
cultured diabetic myotubes. To our knowledge, this is the first study that measured 
AMPK activation in cultured diabetic myotubes using an in vitro system of exercise 
(EPS). The most interesting findings of this study are; there is an intrinsic 
molecular defect in diabetic myotubes represented by defective AMPK and 
glucose uptake in response to EPS. AMPK activation and glucose uptake 
increased in response to EPS in control myotubes, and EPS enhanced the effect 
of insulin. Conversely, EPS did not increase AMPK activation and glucose uptake, 
nor enhanced the action of insulin in cultured diabetic muscle cells. 
Activation of AMPK by exercise draws the attention to its ability to improve glucose 
control and the possibility of therapeutic use in T2D patients through its effects on 
glucose and lipid metabolism (Hardie, 2013). A thorough examination of related 
literatures reveals that whole body insulin sensitivity and/or glucose uptake are 
improved in insulin resistant subjects in response to exercise or exercise mimetics. 
Table  6-2 shows details of the studies related to AMPK and the metabolic effects 
of exercise in insulin resistant skeletal muscle compared to insulin sensitive 
controls. It is recognised that the AMPK level and activity vary among different 
studies. Studies can be divided into three categories, the first with normal basal 
AMPK activity and a normal response (increase) in response to stimulation 
(studies 1-6 in Table  6-2). The second group are those with abnormally elevated 
resting AMPK levels in insulin resistant muscle and failure to increase further with 
stimulation (studies 7 and 8). Finally, the third group represents studies that show 
an abnormal low level of AMPK in insulin resistant muscle compared to insulin 
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sensitive muscle that returns to normal with exercise or other stimulation (studies 
9-11).  
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Table ‎6-2: A review of literatures about AMPK level and activation in response to exercise or other stimulus in insulin resistant versus 
insulin sensitive skeletal muscle cells.  
  studies AMPK activity 
In  insulin resistant 
Measurement method Exercise 
type 
Subject and 
Muscle tissue  
obesity Insulin 
sensitivity in 
type 2 DM 
 Basal stimulation      
1- (Musi et al., 
2001) 
  
 
 
Activity by 
immunoprecipitation  & 
immunoblotting  
45 minutes 
cycling 
Diabetes versus control 
before and after exercise 
Non-obese  
Improved 
( decrease plasma 
glucose and insulin  
2- (Højlund et al., 
2004) 
 
No stimulation 
Only basal 
measured 
immunoprecipitation  & α 
Thr
172 
phosphorylation 
immunoblotting 
No exercise Diabetes versus control  obese  Not measured 
3- (Wojtaszewski 
et al., 2005) 
  
 
 
immunoblotting  
α Thr
172  
phosphorylation 
6-week 
training 
 
Diabetes versus control 
Muscle trained and 
resting side (after 6 
weeks) 
Diabetic 
obese Vs 
lean control 
Improve insulin action 
(glucose removal rate)  
4- (Chen et al., 
2005) 
 
 
        
      
 
immunoblotting α Thr
172  
phosphorylation 
2 mM 
AICAR 
muscle biopsy taken 
during surgery 
(muscle culture)  
Lean Vs 
Obese Vs 
Obese 
diabetic 
Not measured 
5- (Kjobsted et al., 
2016) 
 
 
  
                
  
immunoprecipitation 
60 minutes 
cycling 
3 muscle biopsies,  
before , immediately 
after and 3hours after 
exercise 
Obese 
control Vs  
Obese 
diabetic 
decreasing insulin 
level compared with 
pre-exercise 
6- (Koistinen et al., 
2003) 
  
 
α Thr
172 
phosphorylation by 
immunoblotting 
1 mM 
AICAR 
Skeletal muscle strips 
Diabetes versus control  
Non-obese 
 
Improved insulin 
action by increased 
glucose uptake 
(additive effect) 
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7- (Sriwijitkamol 
et al., 2007) 
 
 
    NO 
   
 
Immunoprecipitation 
And 
immunoblotting 
40 minutes 
cycling  
 
4 muscle biopsies 
0, 10, 40, and 90 
minutes after exercise 
 
Lean Vs 
Obese Vs 
Obese 
diabetic 
Improved insulin 
action by decreasing 
plasma glucose 
concentrations 
8- (Christopher et 
al., 2003) 
Animal study 
 
 
    NO  
Immunoprecipitation. 30 minutes 
Muscle biopsy before 
and after exercise on 2 
occasions before and 
after induction of DM 
Weight 
matched 
animal  
Not measured 
 
9- 
(Bandyopadhyay 
et al., 2006) 
    
 
 
 
 
 
Immunoprecipitation 
and  
immunoblotting 
Rosiglitazone 
treatment 
3 month 
biopsy before and after 3 
month rosiglitazone 
therapy  
Lean Vs 
Obese Vs 
Obese 
diabetic 
Improved insulin 
action   
10- (Cao et al., 
2012) 
Animal study 
 
 
 
 
 
 
Western Blotting 
2 groups  
Acute 90 
minutes 
& chronic   
Swimming 
Biopsy after exercise 
protocols compared to 
controls 
Control lean 
Vs   
Obese HFD 
Vs 
HFD diabetic 
Improve insulin action 
11- (Lessard et al., 
2006) 
 Animal study 
 
 
 
 
Immunoprecipitation 
and  
immunoblotting 
rosiglitazone 
treatment 
6 weeks 
obese Zucker and age-
matched lean rats 
Lean Vs 
obese Vs 
obese with 
treat 
Improved metabolic 
parameters associated 
with increased AMPK  
12-(Barnes et al., 
2002)  
Animal study 
 
 
NO 
AMPKα1 
but increase 
AMPKα2 
 
Immunoprecipitation 
 
In vitro 
contraction  
Epitrochlearis Muscle 
from Female obese  
male Zucker and age-
matched lean rats 
Lean Vs 
obese  
Improved insulin 
action   
Vs.: Versus , HFD: high fat diet                
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6.4.1 Control non-diabetic myotubes 
In the present study, in control non-diabetic myotubes the main findings were as 
follow; AMPK activation increased with EPS. Glucose uptake was increased in 
response to insulin and EPS each one separately. Furthermore, combined 
stimulation (EPS+insulin) caused additive effects to the action of insulin on 
glucose uptake and distal insulin signalling pathway. 
Previous studies reported that an in vivo single bout of exercise increases AMPK 
activation in healthy non-diabetic muscle cells (Musi et al., 2001; Wojtaszewski et 
al., 2005; Kjobsted et al., 2016). Furthermore, in vitro EPS was shown to increase 
AMPK activity in control myotubes (Nikolić et al., 2012; Brown et al., 2015a) which 
are consistent with the results obtained in the control myotubes used in In the 
present study. 
Glucose uptake into skeletal muscle is achieved by two principal independent 
mechanisms. These are either insulin dependent or insulin independent pathways. 
Exercise (muscle contraction) represents the main insulin independent 
mechanism. A single bout of in vivo exercise raises glucose uptake into skeletal 
muscle (Richter et al., 1989), and improves insulin sensitivity in the post-exercise 
period (Henriksen, 2002). Previous studies on cultured human muscle cells have 
shown that EPS stimulates glucose uptake (Lambernd et al., 2012; Nikolić et al., 
2012; Brown et al., 2015a). In line with these observations, in this study glucose 
uptake in non-diabetic skeletal muscle myotubes increased in response to insulin, 
EPS and there was an additive effect of combining insulin plus EPS.  
Exercise or physical activity increases peripheral insulin sensitivity. The ability of 
insulin to stimulate glucose uptake in skeletal muscle in response to a prior bout of 
exercise is increased several hours thereafter (Richter et al., 1982; Frøsig et al., 
2009). During exercise and shortly after, the increased insulin-mediated glucose 
uptake depends on systemic and local cellular factors. The cellular processes that 
are involved in insulin sensitisation are mediated by an increase in GLUT4 
translocation and availability at the cell membrane (Hansen et al., 1998). The 
enhanced insulin sensitivity in both cultured muscle cells and isolated muscle 
fibres in response to EPS or AICAR is an important observation. This confirms that 
the sensitisation effect is not entirely dependent upon systemic influences such as 
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enhanced blood flow, and that it is an intrinsic characteristic of the muscle cells 
(Hamada et al., 2006; Brown et al., 2015a).  
Upon insulin stimulation, a series of signalling events occur ending with GLUT4 
translocation. The increased GLUT4 translocation is mediated by activation of both 
insulin dependent and independent signalling pathways. The increased insulin-
stimulated glucose uptake is not associated with enhancement of the proximal 
insulin signalling pathway. Studies show that prior exercise does not increases IR 
tyrosine kinase activity, IRS1 tyrosine phosphorylation, PI3K, Akt Ser473 and Thr 
308 phosphorylation (Wojtaszewski et al., 1997; Wojtaszewski et al., 2000; Frøsig 
et al., 2007). On the other hand, several studies have reported that insulin 
stimulated AS160 phosphorylation and glucose uptake are both enhanced after 
exercise (Arias et al., 2007; Treebak et al., 2009; Schweitzer et al., 2012; Cartee, 
2015).  
AS160 is a family of kinases that are directly activated by Akt upon insulin or 
exercise stimulation. TBC1 domain family member 1 (TBC1D1) and 4 (TBC1D4) 
are members of this family and act as GTPase activating proteins that serve to 
control GLUT4 translocation. It is suggested that these proteins act as a 
convergence points for both insulin dependent and independent signalling 
pathways (Cartee and Wojtaszewski, 2007). Insulin and exercise significantly 
increase AS160 phosphorylation (otherwise known as TBC1D4) in human skeletal 
muscle (Mîinea et al., 2005; Howlett et al., 2008). Phosphorylation of AS160 was 
shown to increase in response to exercise in both rat (Funai et al., 2009) and 
human skeletal muscle cells (Treebak et al., 2009) and was associated with 
enhanced insulin stimulated glucose uptake several hours after exercise. 
Multiple phosphorylation sites of AS160 have been reported to be activated by 
distinct upstream kinases including Akt and AMPK (Geraghty et al., 2007; Howlett 
et al., 2008). Activation of these sites on AS160 leads to inhibition of the GTPase-
activating protein, eliminating their inhibition on GLUT4 translocation process and 
increasing glucose uptake. Thr642 and Ser588 are key residues regulating insulin 
mediated GLUT4 translocation (Sano et al., 2003). Studies showed that mutations 
of AS160 on Thr642 and Ser588 reduce insulin stimulated GLUT4 translocation 
(Sano et al., 2003; Mîinea et al., 2005). Thus, reasonably these sites were 
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investigated to study the effects of exercise-induced insulin sensitisation and the 
responses of cultured myotubes to insulin, EPS and both. 
In the current study, AS160 phosphorylation at Thr642 was increased in response to 
insulin in control myotubes, and EPS causes an enhancement in insulin stimulated 
AS160 phosphorylation in these cells, and was associated with enhanced glucose 
uptake (additive effect). These results are in agreement with that obtained by 
various studies in both human and animal models that showed a sustained post 
exercise activation in distal insulin signalling molecules in skeletal muscles (Arias 
et al., 2007; Treebak et al., 2014; Kjøbsted et al., 2015). The following Table  6-3 
summarises the effects of different models of exercise on different AS160 
phosphorylation sites in skeletal muscle cells.  
Furthermore, in this study AS160Ser588 phosphorylation was increased in control 
myotubes in response to both insulin and exercise but no additive effect has been 
observed for the co-activation of insulin and EPS.  
Schweitzer et al (2012) and Castorena et al. (2014), both using control rat skeletal 
muscles, similarly showed that insulin and exercise stimulate AS160Ser588 
phosphorylation. Both fore mentioned studies showed an additive effect for the co-
activation of insulin and exercise as measured with insulin stimulation after 3 hours 
post exercise. The differences from the results of the current study could be 
attributed to the differences in exercise protocol (in vivo vs. in vitro). In a human In 
vivo study, Treebak et al. (2009) showed that AS160Ser588 activation was increased 
in response to exercise and physiological insulin (after food) which is similar to the 
results of the control myotubes in the current study.  
In summary, insulin and EPS alone increased glucose uptake, and EPS enhanced 
the effect of insulin on glucose uptake so mimicking the key changes observed in 
vivo. EPS caused an increase AMPK phosphorylation at Thr172. Interestingly; I 
found that insulin increased AS160Thr642 phosphorylation, and that this was 
enhanced by EPS. This raises the intriguing possibility that the enhanced effect of 
exercise on insulin action during the post-exercise period involves AS160Thr642 
phosphorylation. Both insulin and EPS individually increased phosphorylation at 
AS160Ser588, but there was no additive effect of EPS and insulin.  
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Table ‎6-3: A review of literatures about AS160 activation in response to exercise and/or insulin in different models of exercise. 
Study 
Animal/ 
human 
Tissue/cell 
culture 
Exercise type/ 
duration 
Insulin 
AS160 
phospho 
sites 
activated 
by insulin 
 
 
AMPK 
activatio
n after 
exercise 
Additive effects of AS160 
activation in response to 
combined (Ex+Ins) 
1- (Castorena 
et al., 2014) 
Animal 
(rats) 
Isolated 
muscle fibers 
In vivo swimming 
4 bouts (30-min)  
100 
µU/mL 
Thr642          
and        
Ser588 
Controls increased 
Additive effects of both Thr642 and 
Ser588 
insulin-
resistant 
increased 
No Additive effects of both Thr642 and 
Ser588 
2-(Funai et al., 
2009) 
Animal  
(rats) 
Isolated 
muscle fibers 
In vivo swimming 
4 bouts (30-min) 
50   
µU/mL 
Thr642 
Controls 
Not 
measured 
Additive effects in Thr642 
No diabetes   
3-(Schweitzer 
et al., 2012) 
Animal 
(rats) 
Isolated 
muscle fibers 
In vivo swimming 
4 bouts (30-min) 
50   
µU/mL 
Thr642      
and    
Ser588 
Controls 
Not 
measured 
Additive effects of both Thr642 and 
Ser588 
No diabetes   
4-(Kjøbsted et 
al., 2016) 
Animal  
mice 
Isolated 
muscle fibers 
In vitro In Situ 
Contraction  10 
min 
100 
µU/mL 
Thr649  
Ser711  
Ser324  
Ser595 
Controls 
WT 
Highly 
increased 
Additive effects in Thr642and Ser711 
AMPK 
KO/KD 
Not 
increased 
No Additive effects in any residues 
5-(Kjøbsted et 
al., 2015) 
Animal 
mice 
Isolated 
muscle fibers 
AICAR 
4-6 hours 
100 
µU/mL 
Thr649  
Ser711  
Ser324 
Ser595 
Controls 
WT 
Highly 
increased 
Additive effects in Thr642 and Ser711 
AMPK 
KO/KD 
Not 
increased 
No Additive effects in any residues 
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6-(Arias et al., 
2007) 
Animal 
(rats) 
Isolated 
muscle fibers 
In vivo swimming 
4 bouts (30-min) 
50 µU/ml PAS-AS160 
Controls increased Additive effects in PAS-AS160 
No diabetes   
7-(Treebak et 
al., 2009) human 
Isolated 
muscle fibers 
In vivo         one-
legged knee 
extensor for 60 
min 
100min 
euglycae
mic–
hyperinsul
inemic 
clamp 
Ser318 
Ser341  
Ser751  
Thr642  
Ser588 
Controls 
Not 
measured 
Additive effects of Ser341, Ser751 
and Ser588 
No diabetes   
8-(Kjobsted et 
al., 2016) human 
Isolated 
muscle fibers 
In vivo        cycle 
ergometer for 60 
min 
4h 
euglycae
mic-
hyperinsul
inemic 
clamp 
Ser318      
Ser341      
Thr642      
Ser588 
Controls increased No Additive effects in any residues 
diabetes increased No Additive effects in any residues 
9-(Treebak et 
al., 2014) human 
Isolated 
muscle fibers 
In vivo         one-
legged knee 
extensor for 60 
min 
Physiologi
cal  insulin 
after food 
Ser318     
Ser341 
Ser704 
Thr642 
Controls 
fasted 
increased 
Ser588 and Ser751 only activated by 
contraction and not activated by 
Physiological  insulin(fed state) 
Controls fed increased 
Additive effects of Ser341, Ser704 
and Thr642 
 
 In animal studies; Thr649 corresponds to Thr642, Ser595 corresponds to Ser588, Ser711 corresponds to Ser704, and Ser324 corresponds to 
Ser318. 
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6.4.2 Diabetic myotubes 
In the present study, one of the most important findings was that the basal activity 
of AMPK in diabetic cultured skeletal muscle was higher than that of control. 
Furthermore, the elevated AMPK activity at rest failed to further increase with 
exercise. This result is consistent with other studies in human (Sriwijitkamol et al., 
2007; Green et al., 2011) and in diabetic dog skeletal muscle (Christopher et al., 
2003). In these studies, the elevated basal AMPK activity in diabetes was 
attributed to the metabolic decompensation that associates with diabetes 
(Christopher et al., 2003). High basal AMPK activity was attributed as well to 
serum factors that are well known to be elevated in the diabetic state like IL-6 and 
leptin (Sriwijitkamol et al., 2007). Previous work confirmed that AMPK in skeletal 
muscle is activated by IL-6 (MacDonald et al., 2003; Kelly et al., 2004) or in 
response to leptin (Minokoshi et al., 2002). The elevated level of these proteins in 
T2D individuals could have a role in an elevated basal AMPK.  
In the current study, it could not be confirmed or refuted that leptin or IL-6 levels (in 
subjects from whom the muscle cells were taken) were responsible. However, it is 
possible that insulin resistance and/or the diabetic state cause epigenetic changes 
in skeletal muscle cells that may be responsible for the elevated basal AMPK 
level. These changes could be a compensation for the metabolic events 
associated with diabetes. Furthermore, this elevated basal AMPK activity in 
diabetic myotubes is associated with a slight increase in basal glucose uptake; 
however, the increased basal glucose uptake in T2D myotubes was statistically 
not significant. This is in agreement with our previous work on control myotubes in 
which a stimulus (thrombin) causes increased basal AMPK activity associated with 
an increase in basal glucose uptake (Al-Bayati et al., 2016). 
In diabetic myotubes, EPS did not increase AMPK activation above its resting 
activity which was already high. This failure to activate AMPK in response to EPS 
in diabetic myotubes may partly be explained by the possibility of reaching highest 
activation limits. In other words, AMPK activation in diabetic muscle cell cultures at 
rest reached the maximum activation capacity and could not rise beyond this point. 
Another possible explanation might be that, the long standing insulin resistance in 
the diabetic subject from whom the samples were taken could be accompanied by 
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metabolic abnormalities that inhibit AMPK further activation in response to EPS. In 
previous work on these cells, McIntyre et al.(2004) found that glucose uptake was 
increased in response to AICAR in both control and diabetic cells. They supposed 
that the increased in glucose uptake is related to AICAR-activated phosphorylation 
of AMPK. However, they did not measure AMPK activation in their work. In this 
study, EPS was shown to increase AMPK activation in control but not in diabetic 
myotubes and the increased AMPK activation in control myotubes was associated 
with a concomitant increase in glucose uptake. 
In addition, hyperglycaemia and abnormal glycogen content in diabetic skeletal 
muscle are metabolic disturbances that accompany diabetes and have been 
shown to have an effect on AMPK levels and activation in response to exercise. 
The results of increased basal AMPK activity and failure to stimulate by EPS 
match those observed in earlier in vivo exercise studies. For example, Christopher 
et al. (2003) who examined AMPK activation in response to in vivo exercise 
diabetic dogs and Sriwijitkamol et al. (2007) in diabetic human skeletal muscle 
cells.  
In the present study, it is interesting to observe that glucose uptake in diabetic 
myotubes failed to increase significantly in response to insulin which confirms that 
the diabetic phenotype has been preserved in cultured myotubes. These results 
are in agreement with those obtained in previous studies using diabetic cell 
cultures (Thompson et al., 1996; McIntyre et al., 2004). In addition, EPS failed to 
stimulate glucose uptake in diabetic myotubes and no additive effect of glucose 
uptake was observed by stimulation with both EPS and insulin. In agreement with 
these results, Stephens and Sparks (2014) claimed in their review that some 
subjects, including some T2D and severely insulin resistant individuals, tend to be 
more “exercise resistant” compared to insulin sensitive persons. Those individuals 
seem to have a diminished metabolic response to exercise due to different genetic 
and epigenetic causes. 
In the current study, AS160 phosphorylation at Thr642 was increased in response to 
insulin in both control and diabetic myotubes. In other words, the diabetic 
phenotype has no effect on insulin stimulated AS160Thr642 phosphorylation. These 
results match those observed in earlier studies that compared enzyme activity in 
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control with that of T2D individuals and their insulin resistant relatives (Karlsson et 
al., 2006; Vind et al., 2011).  
No enhancement in the AS160Thr642 phosphorylation was observed in response to 
combined insulin and EPS in diabetic myotubes. This is consistent with that 
obtained from an animal in vivo exercise protocol performed by Castorena et al. 
(2014) who showed that impaired AS160Thr642 phosphorylation in high-fat diet rats 
( insulin-resistant) compared to low-fat diet rats (normal insulin sensitivity) 3 hours 
post exercise. Furthermore, EPS alone did not cause activation of AS160Thr642 in 
both diabetic and control which is consistent with the results of Chen et al. (2011).  
In the later study, they suggest that AS160Thr642 is more important for insulin than 
contraction-stimulated glucose uptake.  
Another important finding was that, there is reduced insulin stimulated AS160Ser588 
phosphorylation in skeletal muscle of patients with T2D compared to control. This 
could help to explain the failure of diabetic myotubes to increase glucose uptake 
above basal after insulin or EPS stimulation. These results are in line with those of 
a previous study carried out comparing the effects of insulin stimulation in human 
muscle cells in obese T2D, compared with matched controls. The insulin 
stimulated AS160Ser588 was lower in T2D than in control individuals (Vind et al., 
2011). 
Kjobsted et al.(2016) showed that, there are no differences between obese T2D 
and BMI matched control skeletal muscle AMPK activation and insulin 
sensitisation in the both examined phosphorylation sites, AS160Thr642 and  
AS160Ser588, in response to in vivo exercise bout. Three main differences have 
been observed in Kjobsted et al.(2016) from the current study that could be 
attributed; first is the duration of T2D which was (3.5 ± 1.2) years which is shorter 
than that of the current study. Furthermore, type of exercise (in vivo) versus EPS 
(in vitro) in ours. Finally, the type of treatment used for T2D which was diet and/or 
metformin. Whereas high doses of insulin 131.2± 9.6 units/ day were used for T2D 
subjects of the current study which reflect the severity of insulin resistance. The 
differences in activation in response to combined EPS and insulin between 
diabetic and control are in agreement with the glucose uptake data that showed 
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increased insulin mediated glucose uptake after EPS in control but not in diabetic 
myotubes.  
In summary, basal AMPK activation was significantly increased in diabetic versus 
control muscle cell cultures, and both basal glucose uptake and AS160Ser588 
phosphorylation tended to be higher in the diabetic muscle cells. EPS failed to 
increase AMPK activation above baseline, and neither insulin nor EPS alone 
increased glucose uptake and AS160Ser588 phosphorylation in the diabetic muscle 
cells. Insulin alone did increase phosphorylation at AS160Thr642, suggesting that 
this is not implicated in the decreased effect of insulin on glucose uptake in the 
diabetic muscle cells. However, the effect of EPS to enhance the action of insulin 
on glucose uptake and AS160Thr642 phosphorylation observed in the control 
muscle cells was not evident in the diabetic cultures.  
The long standing insulin resistant state in T2D subjects of the current study could 
be the cause of the inability of the diabetic cells to respond to EPS and/or insulin 
and can be attributed to the abnormal signalling. 
Regular exercise is a key regulator for many metabolic processes, and plays a 
crucial role in prevention and treatment of many diseases. Many cellular and 
molecular regulators have been suggested to mediate exercise function at the 
level of skeletal muscle. Skeletal muscle cells express and secrete a range of 
biologically active peptides and proteins during and shortly after muscle 
contraction, known as myokines which have both local and systemic functions 
(Febbraio and Pedersen, 2005). The health promoting effects of exercise are 
largely attributed to some of these peptides (Pedersen and Febbraio, 2012).  
IL-6 and IL-8 are important cytokines implicated in the exercise process in skeletal 
muscle cells. Contracting skeletal muscle has been shown to increase expression 
and secretion of these cytokines in response to exercise (Peake et al., 2015). In 
addition, IL-6 and IL-8 gene expression has been shown to be upregulated in 
insulin resistant cells (Brown et al., 2015b). In the current study, skeletal muscle 
cells from diabetes conserved their ability to increase cytokine release in response 
to exercise, and no differences were observed between diabetic and control 
skeletal muscle cells after 16 hours EPS. This is in keeping with the observation 
that IL-6 secretion from skeletal muscle in response to contraction was mediated 
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in part through an AMPK independent mechanism (Lauritzen et al., 2013). These 
results are consistent with data obtained from previous in vitro exercise studies 
performed on control human muscle cells that showed an increased IL-6 and IL-8 
secretion with EPS (Lambernd et al., 2012; Scheler et al., 2013). For the diabetic 
cells this is the first study that has examined cytokine secretion after in vitro 
exercise and currently, there are no available data with which to compare our 
results.  
Earlier studies reported a difference in gene expression of IL-6 and IL-8 between 
diabetes and control in response to exercise. Tantiwong et al.(2010) and Feng et 
al. (2015) showed that both IL-6 and IL-8 gene expression are increase in 
response to an in vivo or EPS respectively in control but not in T2D skeletal 
muscle. Furthermore, gene expression of both of these cytokines is shown to 
increase in diabetes skeletal muscle in the basal state (Brown et al., 2015b). The 
differences between cytokine gene expression and protein release in response to 
EPS highlights to an important remark. There are defects in diabetic muscle cells 
that make them resistant to exercise, but some metabolic processes such as 
cytokine release could be preserved. Future further efforts are needed focusing on 
the secretory function of skeletal muscle cells in response to exercise and the 
effect of these cytokines on metabolic processes.  
In conclusion, control and diabetic myotubes respond in a different way to insulin, 
EPS and insulin plus EPS. In controls glucose uptake was significantly increased 
after insulin, 16 hours EPS and a combination of insulin and EPS. In contrast, 
diabetic muscle cell cultures failed to increased glucose uptake above basal in 
response to these stimuli. There are intrinsic defects that prevent diabetic 
myotubes from responding normally to EPS and/or insulin. The main differences 
are the basal increase in AMPK that failed to further increase with EPS. 
Furthermore, in control myotubes, AS160 activation at Thr642 increased in 
response to insulin and the combined stimulation (EPS+insulin) further increased 
Thr642 phosphorylation. However, some responses to exercise were preserved 
such as cytokine release after EPS stimulation that showed no differences 
between diabetic and control myotubes. 
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CHAPTER 7 : GENERAL DISCUSSION 
 
T2D is a major global health problem, characterised by chronic hyperglycemia and 
peripheral insulin resistance. Resistance to the effects of insulin in insulin sensitive 
tissues is an early manifestation of T2D. Skeletal muscle represents the major 
insulin sensitive tissue in the human body, and insulin resistance in skeletal 
muscle is a core defect in T2D (Wu and Ballantyne, 2017).  
Diabetic individuals have shown to be hypercoagulative. An association has been 
suggested between hyperglycaemia and high thrombin production (Rao et al., 
1999), and decreased insulin sensitivity correlates with elevated thrombin levels 
(Romano et al., 2003). Key inflammatory cytokines such as IL-6, TNF-α and others 
that are linked to insulin resistance are reported to be increased in response to 
thrombin (Strande and Phillips, 2009). Inhibition of thrombin action in insulin 
resistant animals results in increased whole body glucose clearance, reversal of 
the suppression in the insulin signalling molecules IRS1 and Akt, and 
normalisation of elevated inflammatory markers (Mihara et al., 2010).  
Genetically, high heritability indices were reported in a cohort of Mexican 
Americans for a number of coagulation cascade's factors, including prothrombin 
which was strongly associated with T2D (Almasy et al., 2005). A common genetic 
origin of both T2D and vascular disease, the ‘‘common soil’’ hypothesis has been 
proposed as well. Finally, the IRS1 gene and some variants of the TCF7L2 gene 
have been linked to both increased coagulopathy and insulin resistance as 
discovered by new genetic studies (Delgado-Lista et al., 2011; Zhang et al., 2016).  
The studies in chapters 3, 4, set out with the aim of answering our first research 
question that was; 
Does thrombin affect insulin action in human skeletal muscle cells and contribute 
directly to the insulin resistant state?  
The main findings were; thrombin causes a reduction in insulin signalling 
characterised by decreased insulin-stimulated IRS1Y612 and AktSer473 
phosphorylation. In addition, thrombin directly increased glucose uptake with 
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evidence that this is facilitated through an insulin independent pathway (AMPK 
mediated). The following, Figure  7-1 summarises the action of thrombin on 
glucose uptake in cultured human myotubes. 
 
 
Figure ‎7-1: Summary of thrombin action on cultured human skeletal muscle, 
shaded arrows shows the effects of thrombin on activation of AMPK and insulin 
signalling molecules and glucose uptake.  
 
The effect of thrombin on insulin signalling and glucose metabolism led as to ask 
our second research question which was: 
Does thrombin affect the metabolic response to exercise in human skeletal muscle 
cells? 
By using (EPS) as an in vitro system to exercise skeletal muscle cells in culture, 
main results were as follows; in control non-thrombin treated myotubes, 16 hours 
EPS causes a significant increase in both AMPKThr172 phosphorylation and glucose 
uptake and the EPS facilitates an additive effect on insulin stimulated glucose 
uptake. IL-6 and IL-8 release into media were shown to increase in response to 
EPS. Whereas, thrombin treated cultures lose the metabolic and signalling 
responses to EPS that are seen in non-thrombin treated myotubes. 
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The nice response to EPS that were observed in control myotubes in thrombin 
work and the fact that primary skeletal muscle cell cultures from a diabetic person 
retain the key metabolic and genetic features of T2D, encourage as to ask third 
research question which was: 
Is the contraction stimulated glucose uptake preserved in cultured muscle cells 
from T2D patients assessed using EPS? 
The main findings were that; 
In control myotubes, AMPK increased in response to EPS, glucose uptake 
increased after insulin and EPS. Furthermore, exercise enhanced the effect of 
insulin. In contrast, no significant increase in glucose uptake in diabetic myotubes 
was observed after insulin or EPS and EPS did not enhance the effect of insulin. 
In diabetic myotubes, AMPK activity was shown to be increased at rest with no 
further increase following EPS. The insulin enhancement after exercise was 
shown to be due to the distal insulin signalling pathway, AS160Thr642 
phosphorylation was similar in both diabetes and control in response to insulin, but 
differs in that in control myotubes there was an additive effect of EPS on insulin 
stimulated AS160Thr642 phosphorylation that was not evident in the diabetic 
myotubes. 
  Clinical implications 7.1
Thrombin has multiple metabolic effects on insulin signalling and glucose 
metabolism. Pulling all these effects together, thrombin inhibited the classical 
insulin signalling pathway. In terms of glucose metabolism, this inhibition is by-
passed through an AMPK mediated pathway. However, it is evident that insulin 
exerts many actions beyond glucose uptake and metabolism, and it may well be 
that the inhibitory effect of thrombin on the classical insulin signalling pathway 
decreases the action of insulin on these other non-glucose functions. 
Based on our results of thrombin effects on exercise signalling, the possible 
clinical consequences would be a normalisation of the hypercoagulable state in 
T2D patients could improve the metabolic responses to exercise. 
  
178 
 
A new study by Kopec et al. (2017) showed that, a mutant mouse model of 
elevated thrombin procoagulant activity was significantly more prone to develop 
insulin resistance in response to high fat diet compared with wild type mice. 
Furthermore, treatment of these mice with a direct thrombin inhibitor, Dabigatran, 
reduced the high fat diet induced obesity and suppression of metabolic 
consequences of insulin resistance.  
Inhibition of thrombin action using a chemically selective thrombin inhibitor in an 
insulin resistance animal model like that used by Mihara et al. (2010) and Kopec et 
al. (2017) could be considered as well. In the aforementioned studies, they treated 
an insulin resistant mouse model with a selective thrombin inhibitor (Argatroban 
and Dabigatran) and found that treated animals showed improved whole body 
glucose clearance and an enhancement in insulin signalling in fat cells compared 
with untreated animals. A similar approach might be conducted to examine both 
insulin signalling in skeletal muscle of such model and even the response to in 
vivo exercise protocol. 
The safety of these chemically selective thrombin inhibitors should be considered 
and examined whether they can be used in human subjects with different 
hypercoagulable states including T2D. 
To our knowledge, no previous studies on human have been performed to 
examine the effects of the different antithrombin and anticoagulants therapies that 
are used for treatment of variable hypercoagulable states on insulin sensitivity 
and/or exercise response and metabolism. Thus, it seems worthy to conduct such 
studies comparing whether targeting thrombin may be a beneficial therapeutic 
approach and could improve exercise performance and insulin sensitivity.  
 
Primary skeletal muscle cell cultures from diabetic individuals retain the key 
metabolic and genetic features of T2D. Under highly controlled conditions of the 
cell culture system and excluding of all serum and systemic factors that can 
encounter. The use of EPS for comparing the metabolic response to contraction 
between diabetic versus control myotubes would be of great value. Our 
observations not only help to delineate the nature and location of the retained 
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molecular defects in diabetic muscle, but also help to identify normal metabolic 
responses that might be used therapeutically to by-pass these defects. Although 
our study revealed a presence of metabolic and signalling abnormalities in diabetic 
cells, some responses to exercise like cytokines release was preserved. Thus, 
even individual with severe diabetes and insulin resistance can gain some benefits 
from exercise.  
 
 Studies advantages 7.2
1. This is the first work to investigate the metabolic effects of thrombin on 
skeletal muscle cells using 2D cultures of myotubes. The work could 
emphasise the link between hypercoagulability and insulin resistance in T2D 
as we showed that increased coagulability in T2D could result in multiple 
metabolic effects beyond increased thrombogencity, and includes direct 
effects on insulin signalling and glucose metabolism.  
 
2. The use of electrical pulse stimulation as an in vitro system of exercise 
enables pre-clinical examination and allows understanding and dissecting the 
molecular mechanisms of the exercise in insulin resistance and other 
pathology. This is the first study that use EPS in thrombin treated cultured 
myotubes as a model of hypercoagulation. The results of this study revealed 
that hypercoagulability associated with T2D might interfere with the metabolic 
response to contraction and exercise and could be translated clinically.  
 
3. This work is one of the earliest studies using in vitro exercise system (EPS) in 
human cultured diabetic muscle cells. For the first time, the activity of AMPK 
and glucose uptake in response to EPS has been examined, excluding the 
effects of systemic and serum factors. EPS system showed that there are 
metabolic abnormalities that prevent skeletal muscle of severe insulin 
resistant subjects to respond to exercise in the same manner as the control. 
The work done so far can be extended further to examine cultures from 
diabetic subjects with different durations and type of therapy and has set a 
solid basis to examine different therapeutic approaches. 
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 Studies limitations 7.3
Although the research reaches its aims, there were some unavoidable limitations: 
First. Cells were taken from control individuals who were not diabetic with no 
family history of T2D (thrombin work), and there are always inter-individual 
variations that might increase variability of the results of signalling and 
metabolic parameters. We tried to overcome this by dividing each cell lines 
(cultures taken from one subject) into control and treated so that only the 
effects of the treatment were encountered. For better results and to reduce 
this variability muscle biopsy to be taken from age, sex, level of activity and 
BMI matched individuals. 
 
Second. The experiments were conducted on cultured cells and the limitations of 
cell culture systems are well known and discussed thoroughly in chapter 
1 section  1.25. The lack of cell to cell contact and the interaction with 
other cell types via direct contact and bioactive molecules represents one 
of the major differences between cell culture and in vivo study, but the 
use of co-cultures with adipocytes might solve this limitation. 
 
Third. Third, there is a lack of knowledge of the exact physiological level of 
thrombin in serum in vivo. Most studies have determined thrombin 
activity rather than thrombin level. Thus, it is difficult to compare the dose 
used in cell culture with physiological levels. In our work, we depended 
on dose response and viability to determine the suitable dose that exerts 
effects without causing cell death. Further efforts and studies needed to 
determine what the physiological level is and try to use this level. 
 
Fourth. Thrombin was used only for a short period (6 hours) while the elevated 
thrombin during the insulin resistant state is a chronic phenomenon. 
Therefore, chronic treatment of thrombin is suggested to be examined in 
order to explore the effects of chronic hypercoagulation on insulin 
sensitivity. 
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Fifth. The fact that contraction of skeletal myotubes in culture is non-neural 
mediated and so lacks the input of neurotransmitters. Moreover, EPS-
induced contraction of control skeletal muscle cell cultures has been 
imaged as video as shown in the following link, but not in diabetic cultures 
yet. https://doi.org/10.1371/journal.pone.0122982.s002  
However, the results related to cytokines release in response to EPS showed 
similar results in both controls and diabetes. 
  
Sixth. In cultured diabetic versus control skeletal muscle cells, an issue that was 
not addressed in this study was whether the long duration of T2D and type 
of therapy could be the causative factors of failure to respond to EPS as 
control cultures, the solution will be discussed in future research 
recommendations. 
  Future research recommendations  7.4
Thrombin treatment was carried out for only 6 hours. It would be interesting to 
explore thrombin impact after a longer treatment time, and then investigating the 
effects of chronic thrombin treatment on insulin sensitivity. This can be achieved 
by different ways including either animal studies or in cell culture. The insulin 
resistance animal model like that used by Mihara et al. (2010) could be 
considered. However, longer duration of thrombin treatment with dose used in our 
work is shown to cause cell death. For example, cultures can be treated with low 
doses of thrombin from the day one differentiation for every day until day seven 
where the cell become fully differentiated to perform the experiments. 
Effect of thrombin on glucose uptake was shown to be mediated via AMPK and we 
used a chemical inhibitor of AMPK (compound C) to explore the pathway. 
Compound C can affect other untargeted proteins; therefore, it would be 
interesting to specifically knock down AMPK expression using techniques such as 
siRNA as a clean way of inhibiting AMPK activity. This could help to investigate 
whether the observed high AMPK activity in response to thrombin treatment could 
be the cause of decreased metabolic response to EPS.  
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Furthermore, it would be worth exploring the effects of thrombin on muscle cells 
obtained from insulin resistant individuals. This will help to show the effects of 
hypercoagulation on individuals who were already T2D and if thrombin causes 
further resistance to the effects of insulin or further impairment of the response to 
EPS. 
The response to EPS in cultured diabetic versus control skeletal muscle cells 
could be extended in different ways. To explore the steps proximal to AMPK such 
as upstream kinases like LKB1, CaMKKs and Calcium ions availability or the other 
causes of the basal elevation of AMPK.  
Cytokine release in response to EPS was shown to be preserved even with the 
presence of the observed signalling defects. This could be utilised for further 
research that the pathway by which the diabetic cells preserved its ability to 
secrete cytokines and the metabolic benefits after these cytokines secretion.  
Moreover, more research is required to determine the effects of duration of T2D 
and type of therapy. This can be achieved by examining cultures from diabetic and 
insulin resistant subjects of variable duration and different therapy and then 
analysing the metabolic and signalling processes that were examined in this study. 
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Conclusions 
This is the first study that looked at thrombin and insulin action/signalling in human 
skeletal muscle. We found that thrombin activation results in multiple metabolic 
effects beyond increased thrombogenicity but does not include a decrease in 
insulin sensitivity (glucose uptake) in cultured human skeletal muscle cells. 
Furthermore, thrombin treated cultures lose the metabolic and signalling 
responses to EPS compared to untreated cultures. Thus, hypercoagulation 
associated with T2D could be involved in metabolic responses of skeletal muscle 
to exercise affecting both signalling, proinflammatory pathways, and glucose 
uptake. Additionally, metabolic abnormalities were observed in skeletal muscle of 
severe insulin resistant subjects. These defects prevent the diabetic muscle cells 
to respond to exercise in the same manner as that of the control muscle cells. 
However, some of the effects of exercise are preserved in diabetic myotubes 
represented by the inflammatory cytokines secretion in response to EPS.  
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APPENDIX 1: Definition criteria of diagnosis of metabolic syndrome as considered by different associations. Adapted from (O'Neill 
and O'Driscoll, 2015).  
WHO; World Health Organization; EGIR, European Group for the Study of Insulin Resistance; NCEP: ATPIII, National Cholesterol Education Program – 
Third Adult Treatment Panel; AACE: American Association of Clinical Endocrinology; IDF: International Diabetes Federation. WC: west circumference. 
BMI: body mass index *: the AACE definition means being of high risk of insulin resistant existence of at least one of the followings: being diagnosed 
as hypertensive or have cardiovascular‎diseases;‎family‎history‎of‎T2D‎or‎history‎of‎gestational‎diabetes‎or‎glucose‎intolerance;‎BMI > 25‎kg/m2‎or‎
WC > 94‎cm‎(men),‎>80‎cm‎(women);‎age‎>40‎years. 
 
WHO EGIR NCEP:ATPIII AACE IDF 
High insulin level 
  + 
Two of the following: 
1. Abdominal obesity                                             
WC > 37″,                     
 BMI > 30 kg/ m2 
2. Triglycerides >150 mg/ 
dL, HDL Cholesterol        
(male <35 mg/ dL)            
(female <39 mg/ dL)  
 
3. BP ≥  140/90 mm Hg 
4. Microalbuminuria                                 
>30  mg/ g 
High fasting insulin 
concentrations         
(insulin resistance) 
+
Two of the following:   
1. WC ≥ 94 cm (male),                                                                                           
≥80 cm (female)           
 2. Triglycerides 
>2mol/L,  
HDL Cholesterol  
<1.0 mmol/L or treated 
for dyslipidaemia                
3. BP ≥ 140/90 mmHg 
hypertensive medication                 
4. Fasting glucose ≥6.1 
mmol/ L 
Any three of the following: 
 
1. WC > 40″ (male)        
>35″ (female) 
 
2. Triglycerides ≥150 mg/
dL,  HDL Cholesterol  ,             
<40 mg/ dL (male),        
<50 mg/ dL (female) 
 
3.  BP ≥  130/85 mm Hg 
4. Fasting plasma glucose 
≥110 mg/ dL 
high risk of being insulin 
resistant * 
+ 
Two of the following: 
1. Triglycerides  
≥150 mg/ dL     
                                 2.  
HDL Cholesterol      
 <40 mg/ dL (male),       
<50 mg/ dL (female) 
 
3. BP ≥ 130/85 mm Hg     
4. Fasting glucose ≥6.1 
mmol/ L or IGT  
Central obesity (ethnicity 
and gender specific) 
+ 
Two of the following: 
1. Triglycerides  
≥150 mg/ dL                                
HDL Cholesterol           
 <40 mg/ dL (male)          
<50 mg/dL(female) 
 
2. BP ≥  130/85 mm Hg 
 
3. Fasting plasma glucose  
≥5.6 mmol/ L or treatment 
of T2D 
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